🔗 Share

Patent application title:

CRISPR CASCADE ASSAY

Publication number:

US20230167487A2

Publication date:

2023-06-01

Application number:

17/861,209

Filed date:

2022-07-09

Abstract:

The present disclosure describes a CRISPR nuclease cascade assay that can detect one or more target nucleic acids of interest of interest at attamolar (aM) (or lower) limits in about 10 minutes or less without the need for amplifying the target nucleic acids of interest. The CRISPR cascade assays utilize signal amplification mechanisms comprising various components including CRISPR nucleases, guide RNAs (gRNAs), blocked nucleic acid molecules, blocked primer molecules, and reporter moieties.

Inventors:

Anurup Ganguli 30 🇺🇸 San Diego, CA, United States
Ariana Mostafa 21 🇺🇸 San Diego, CA, United States
Jacob Berger 21 🇺🇸 San Diego, CA, United States
Ashish Pandey 21 🇺🇸 San Diego, CA, United States

Rashid Bashir 9 🇺🇸 Urbana, IL, United States

Interested in similar patents?

Get notified when new applications in this technology area are published.

Create Free Alert

Classification:

C12N2310/20 » CPC further

Structure or type of the nucleic acid; Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

C12Q1/6823 » CPC main

Measuring or testing processes involving enzymes, nucleic acids or microorganisms ; Compositions therefor; Processes of preparing such compositions involving nucleic acids; Hybridisation assays characterised by the detection means Release of bound markers

C12N9/22 » CPC further

Enzymes; Proenzymes; Compositions thereof ; Processes for preparing, activating, inhibiting, separating or purifying enzymes; Hydrolases (3) acting on ester bonds (3.1) Ribonucleases RNAses, DNAses

C12Q1/682 » CPC further

Description

RELATED APPLICATIONS

This application claims priority to U.S. Ser. No. 63/220,987, filed 12 Jul. 2021, and U.S. Ser. No. 63/289,112, filed 13 Dec. 2021.

FIELD OF THE INVENTION

The present disclosure relates to methods, compositions of matter and assay systems used to detect one or more target nucleic acids of interest in a sample. The assay systems provide signal amplification upon detection of a target nucleic acids of interest without amplification of the target nucleic acids.

BACKGROUND OF THE INVENTION

In the following discussion certain articles and methods will be described for background and introductory purposes. Nothing contained herein is to be construed as an “admission” of prior art. Applicant expressly reserves the right to demonstrate, where appropriate, that the articles and methods referenced herein do not constitute prior art under the applicable statutory provisions.

Rapid and accurate identification of infectious agents is important in order to select correct treatment and prevent further spreading of viral infections and pandemic diseases. For example, viral pathogens, such as SARS-CoV-2, and the associated COVID-19 disease require immediate detection and response to decrease mortality, morbidity and transmission.

Classic nucleic acid-guided nuclease or CRISPR (clustered regularly interspaced short palindromic repeats) detection methods usually rely on pre-amplification of target nucleic acids of interest to enhance detection sensitivity. However, amplification increases time to detection and may cause changes to the relative proportion of nucleic acids in samples that, in turn, lead to artifacts or inaccurate results. Improved technologies that allow very rapid and accurate detection of pathogens are therefore needed for timely diagnosis, prevention and treatment of disease, as well as in other applications.

SUMMARY OF THE INVENTION

This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter. Other features, details, utilities, and advantages of the claimed subject matter will be apparent from the following written Detailed Description including those aspects illustrated in the accompanying drawings and defined in the appended claims. Further, all of the functionalities described in connection with one embodiment of the compositions and methods described herein are intended to be applicable to the additional embodiments of the compositions and methods described herein except where expressly stated or where the feature or function is incompatible with the additional embodiments. For example, where a given feature or function is expressly described in connection with one embodiment but not expressly mentioned in connection with an alternative embodiment, it should be understood that the feature or function may be deployed, utilized, or implemented in connection with the alternative embodiment unless the feature or function is incompatible with the alternative embodiment.

The present disclosure provides compositions of matter, methods, and cascade assays to detect target nucleic acids of interest. The cascade assays described herein comprise two different ribonucleoprotein complexes and either blocked nucleic acid molecules or blocked primer molecules. The blocked nucleic acid molecules or blocked primer molecules keep one of the ribonucleoprotein complexes “locked” unless and until a target nucleic acid of interest activates the other ribonucleoprotein complex. The present nucleic acid-guided nuclease cascade assay can detect one or more target nucleic acids of interest (e.g., DNA, RNA and/or cDNA) at attamolar (aM) (or lower) limits in about 10 minutes or less without the need for amplifying the target nucleic acid(s) of interest, thereby avoiding the drawbacks of multiplex amplification, such as primer-dimerization. A particularly advantageous feature of the cascade assay is that, with the exception of the gRNA in RNP1, the cascade assay components stay the same no matter what target nucleic acid(s) of interest are being detected. In this sense, the cascade assay is modular.

There is provided herein in one embodiment of the disclosure a reaction mixture comprising: (i) a first ribonucleoprotein (RNP) complex (RNP1) comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the first nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; (ii) a second ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; wherein the second nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; and (iii) a plurality of blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the blocked nucleic acid molecules cannot activate the RNP1 or the RNP2.

There is provided in a second embodiment of the disclosure, a reaction mixture comprising: (i) a first complex comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the first nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; (ii) a second complex comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; wherein the second nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; and (iii) a plurality of blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the blocked nucleic acid molecule cannot activate the first or second complex.

Provided in a third embodiment is a reaction mixture comprising: (i) a first ribonucleoprotein (RNP) (RNP1) complex comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the first nucleic acid-guided nuclease exhibits both sequence-specific activity and non-sequence-specific activity; (ii) a second ribonucleoprotein (RNP2) complex comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; wherein the second nucleic acid-guided nuclease exhibits both sequence-specific activity and non-sequence-specific activity; and (iii) a plurality of blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the blocked nucleic acid molecules do not bind to the RNP1 complex or the RNP2 complex. In yet another fourth embodiment of the disclosure there is provided a reaction mixture comprising: (i) a first complex comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the first nucleic acid-guided nuclease exhibits both sequence-specific activity and non-sequence-specific activity; (ii) a second complex comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; wherein the second nucleic acid-guided nuclease exhibits both sequence-specific activity and non-sequence-specific activity; and (iii) a plurality of blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the blocked nucleic acid molecules are not recognized by the RNP1s or RNP2s.

A fifth embodiment provides a cascade assay method for detecting a target nucleic acid of interest in a sample comprising the steps of: (a) providing a reaction mixture comprising: (i) a first ribonucleoprotein (RNP) complex (RNP1) comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the first nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; (ii) a second ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; wherein the second nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; and (iii) a plurality of blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the blocked nucleic acid molecules cannot activate the RNP1 or the RNP2; (b) contacting the reaction mixture with the sample under conditions that allow the target nucleic acid of interest in the sample to bind to RNP1; wherein upon binding of the target nucleic acid of interest RNP1 becomes active initiating trans-cleavage of at least one of the blocked nucleic acid molecules thereby producing at least one unblocked nucleic acid molecule and the at least one unblocked nucleic acid molecule binds to RNP2 initiating cleavage of at least one further blocked nucleic acid molecule; and (c) detecting products of the cleavage, thereby detecting the target nucleic acid of interest in the sample.

In a sixth embodiment there is provided a kit for detecting a target nucleic acid of interest in a sample comprising: (i) a first ribonucleoprotein (RNP1) complex (RNP1) comprising a first nucleic acid-guided nuclease and a first gRNA, wherein the first gRNA comprises a sequence complementary to the target nucleic acid of interest; and wherein binding of the RNP1 complex to the target nucleic acid of interest activates cis-cleavage and trans-cleavage activity of the first nucleic acid-guided nuclease; (ii) a second ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; a (iii) plurality of blocked nucleic acid molecules comprising a sequence corresponding to the second gRNA, wherein trans-cleavage activity of the blocked nucleic acid molecules results in at least one unblocked nucleic acid molecule; and wherein the unblocked nucleic acid molecule activates trans-cleavage activity of the second nucleic acid-guided nuclease in at least one RNP2 initiating cleavage of more blocked nucleic acid molecules; and (iv) a reporter moiety, wherein the reporter molecule comprises a nucleic acid molecule and/or is operably linked to the blocked nucleic acid molecule and produces a detectable signal upon trans-cleavage activity by the RNP1 or the RNP2, to identify the presence of the target nucleic acid of interest in the sample.

In some aspects of any one of the aforementioned embodiments, the first and/or second nucleic acid-guided nuclease is a Cas3, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14, Cas12h, Cas12i, Cas12j, Cas13a, Cas13b nuclease; in some aspects, the first nucleic acid-guided nuclease can is a different nucleic acid-guided nuclease than the second nucleic acid-guided nuclease; in some aspects, the first and/or second nucleic acid-guided nuclease is a Type V nucleic acid-guided nuclease or a Type VI nucleic acid-guided nuclease and/or in some aspects, the first and/or second nucleic acid-guided nuclease comprises a RuvC nuclease domain or a RuvC-like nuclease domain and lacks an HNH nuclease domain.

In some aspects of any one of the aforementioned embodiments, the blocked nucleic acid molecules comprise a structure represented by any one of Formulas I-IV, wherein Formulas I-IV comprise in the 5′-to-3′ direction:

(a)A-(B-L)_J-C-M-T-D (Formula I);

- wherein A is 0-15 nucleotides in length;
- B is 4-12 nucleotides in length;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10;
- C is 4-15 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)_J-C and T-D are separate nucleic acid strands;
- T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; and
- D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A;

(b)D-T-T′-C-(L-B)_J-A (Formula II);

- wherein D is 0-10 nucleotides in length;
- T-T′ is 17-135 nucleotides in length;
- T′ is 1-10 nucleotides in length and does not hybridize with T;
- C is 4-15 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length and does not hybridize with T;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- J is an integer between 1 and 10;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;

(c)T-D-M-A-(B-L)_J-C (Formula III);

- wherein T is 17-135 nucleotides in length;
- D is 0-10 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L)_J-C are separate nucleic acid strands;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10; and
- C is 4-15 nucleotides in length; or

(d)T-D-M-A-L_p-C (Formula IV);

- wherein T is 17-31 nucleotides in length (e.g., 17-100, 17-50, or 17-25);
- D is 0-15 nucleotides in length;
- M is 1-25 nucleotides in length;
- A is 0-15 nucleotides in length and comprises a sequence complementary to D; and
- L is 3-25 nucleotides in length;
- p is 0 or 1;
- C is 4-15 nucleotides in length and comprises a sequence complementary to T.

And in Some Aspects,

- (a) T of Formula I comprises at least 80% sequence complementarity to B and C;
- (b) D of Formula I comprises at least 80% sequence complementarity to A;
- (c) C of Formula II comprises at least 80% sequence complementarity to T;
- (d) B of Formula II comprises at least 80% sequence complementarity to T;
- (e) A of Formula II comprises at least 80% sequence complementarity to D;
- (f) A of Formula III comprises at least 80% sequence complementarity to D;
- (g) B of Formula III comprises at least 80% sequence complementarity to T;
- (h) A of Formula IV comprises at least 80% sequence complementarity to D; and/or
- (i) C of Formula IV comprises at least 80% sequence complementarity to T.

In some aspects of the aforementioned embodiments, the blocked nucleic acid molecules comprise a first sequence complementary to the second gRNA and a second sequence not complementary to the second gRNA, wherein the second sequence at least partially hybridizes to the first sequence resulting in at least one loop.

In some aspects of the aforementioned embodiments, the reaction mixture comprises about 1 fM to about 10 μM of the RNP1 and in some aspects the reaction mixture comprises about 1 fM to about 1 mM of the RNP2.

In some aspects of the aforementioned embodiments, the reaction mixture comprises at least two different RNP1s, wherein different RNP1s comprise different gRNA sequences, and in some aspects the reaction mixture comprises 2 to 10000 different RNP1s, or 2 to 1000 different RNP1s, or 2 to 100 different RNP1s, or 2 to 10 different RNP1s.

In some aspects of the aforementioned embodiments, the blocked nucleic acid molecules include the sequence of any one of SEQ ID NOs: 14-1421.

In some aspects of the aforementioned embodiments, the blocked nucleic acid molecules are circular, and in some aspects the blocked nucleic acid molecules are linear.

In some aspects the K_dof the blocked nucleic acid molecules to the RNP2 is about 10⁵-fold greater, 10⁶-fold greater, 10⁷-fold greater, 10⁸-fold greater, 10⁹-fold greater, 10¹⁰-fold greater or more than the K_dof unblocked nucleic acid molecules.

In some aspects of the aforementioned embodiments, the target nucleic acid of interest is of bacterial, viral, fungal, mammalian or plant origin, and in some aspects, the sample may include peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, and umbilical cord blood; food; agricultural products; pharmaceuticals; cosmetics, nutraceuticals; personal care products; environmental substances such as soil, water, or air; industrial sites and products; or manufactured or natural chemicals and compounds.

In some aspects of the aforementioned embodiments, the reaction mixture further comprises a reporter moiety: wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule that is operably linked to the blocked nucleic acid molecule and produces a detectable signal upon cleavage by RNP1 and/or RNP2; or wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule and is not operably linked to the blocked nucleic acid molecule and produces a detectable signal upon cleavage by RNP1 and/or RNP2. In some aspects, the detectable signal is produced within about 1-10 minutes upon binding of the target nucleic acid of interest to RNP1; in some aspects, the detectable signal is a fluorescent, chemiluminescent, radioactive, colorimetric or optical signal; and/or in some aspects, the reporter moiety comprises a modified nucleoside or nucleotide including but not limited to locked nucleic acids (LNAs), peptide nucleic acids (PNAs), 2′-O-methyl (2′-O-Me) modified nucleosides, 2′-fluoro (2′-F) modified nucleoside, and/or a phosphorothioate (PS) bonds.

In some aspects of the aforementioned embodiments, the blocked nucleic acid molecules do not comprise a PAM sequence, yet in other aspects, the blocked nucleic acid molecules comprise a PAM sequence, and in some aspects the PAM sequence is disposed between the first and second sequences, wherein the first sequence is 5′ to the PAM sequence.

In some aspects of the aforementioned embodiments, the blocked nucleic acid molecule is a blocked primer molecule.

In a seventh embodiment of the disclosure, there is provided a blocked nucleic acid molecule comprising: a first region recognized by a ribonucleoprotein (RNP) complex; one or more second regions not complementary to the first region; and one or more third regions complementary and hybridized to the first region, wherein cleavage of the one or more second regions results in dehybridization of the third region from the first region, resulting in an unblocked nucleic acid molecule.

An eighth embodiment provides a method of unblocking a blocked nucleic acid comprising: (a) providing a blocked nucleic acid molecule comprising: a first region recognized by a ribonucleoprotein (RNP) complex; one or more second regions not complementary to the first region; and one or more third regions complementary and hybridized to the first region, wherein cleavage of the one or more second regions results in dehybridization of the third region from the first region, resulting in an unblocked nucleic acid molecule; and (b) initiating cleavage of the one or more second regions, wherein the blocked nucleic acid molecule becomes an unblocked nucleic acid molecule.

A ninth embodiment provides a composition of matter comprising: a first region recognized by a ribonucleoprotein (RNP) complex; one or more second regions of not complementary to the first region; and one or more third regions complementary and hybridized to the first region, wherein cleavage of the one or more second regions results in dehybridization of the third region from the first region, resulting in an unblocked nucleic acid molecule; and the RNP complex comprising a gRNA that is complementary to the first region and a nucleic acid-guided nuclease, wherein the nucleic acid-guided nuclease exhibits both sequence-specific and non-sequence-specific nuclease activity.

Additionally, a tenth embodiment of the disclosure provides a cascade assay method of detecting a target nucleic acid of interest in a sample comprising the steps of: (a) providing a reaction mixture comprising: (i) a first ribonucleoprotein (RNP) complex (RNP1) comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the first nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; (ii) a second ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; wherein the second nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; and (iii) a plurality of linear blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the linear blocked nucleic acid molecules cannot activate the RNP1 or the RNP2; (b) contacting the reaction mixture with the sample under conditions that allow the target nucleic acid of interest in the sample to bind to RNP1; wherein upon binding of the target nucleic acid of interest RNP1 becomes active initiating trans-cleavage of at least one of the linear blocked nucleic acid molecules thereby producing at least one linear unblocked nucleic acid molecule and the at least one linear unblocked nucleic acid molecule to RNP2 initiating cleavage of at least one further linear blocked nucleic acid molecule; and (c) detecting the cleavage products, thereby detecting the target nucleic acid of interest in the sample.

In some aspects, the blocked nucleic acid molecule comprises a structure represented by any one of Formulas I-IV, wherein Formulas I-IV are in the 5′-to-3′ direction:

(a)A-(B-L)_J-C-M-T-D (Formula I);

- wherein A is 0-15 nucleotides in length;
- B is 4-12 nucleotides in length;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10;
- C is 4-15 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)_J-C and T-D are separate nucleic acid strands;
- T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; and
- D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A;

(b)D-T-T′-C-(L-B)_J-A (Formula II);

- wherein D is 0-10 nucleotides in length;
- T-T′ is 17-135 nucleotides in length;
- T′ is 1-10 nucleotides in length and does not hybridize with T;
- C is 4-15 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length and does not hybridize with T;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- J is an integer between 1 and 10;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;

(c)T-D-M-A-(B-L)_J-C (Formula III);

- wherein T is 17-135 nucleotides in length;
- D is 0-10 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L)_J-C are separate nucleic acid strands;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10; and
- C is 4-15 nucleotides in length; or

(d)T-D-M-A-L_p-C (Formula IV);

- wherein T is 17-31 nucleotides in length (e.g., 17-100, 17-50, or 17-25);
- D is 0-15 nucleotides in length;
- M is 1-25 nucleotides in length;
- A is 0-15 nucleotides in length and comprises a sequence complementary to D; and
- L is 3-25 nucleotides in length;
- p is 0 or 1;
- C is 4-15 nucleotides in length and comprises a sequence complementary to T.

Further

- (a) T of Formula I comprises at least 80% sequence complementarity to B and C;
- (b) D of Formula I comprises at least 80% sequence complementarity to A;
- (c) C of Formula II comprises at least 80% sequence complementarity to T;
- (d) B of Formula II comprises at least 80% sequence complementarity to T;
- (e) A of Formula II comprises at least 80% sequence complementarity to D;
- (f) A of Formula III comprises at least 80% sequence complementarity to D;
- (g) B of Formula III comprises at least 80% sequence complementarity to T;
- (h) A of Formula IV comprises at least 80% sequence complementarity to D; and/or
- (i) C of Formula IV comprises at least 80% sequence complementarity to T.

In some aspects of the aforementioned embodiments, the blocked nucleic acid molecule comprises a modified nucleoside or nucleotide, including but not limited to a locked nucleic acid (LNA), peptide nucleic acid (PNA), 2′-O-methyl (2′-O-Me) modified nucleoside, 2′-fluoro (2′-F) modified nucleoside, and/or a phosphorothioate (PS) bond. In some aspects, the blocked nucleic acid molecule includes the sequence of any one of SEQ ID NOs: 14-1421; the blocked nucleic acid molecule is a blocked primer molecule; the blocked nucleic acid molecule does not comprise a PAM sequence; and/or in some aspects the blocked nucleic acid molecule comprises a PAM sequence, and the PAM sequence is disposed between the first and second sequences, wherein the first sequence is 5′ to the PAM sequence.

In some aspects, the K_dof the blocked nucleic acid molecules to the RNP2 is about 10⁵-fold greater, 10⁶-fold greater, 10⁷-fold greater, 10⁸-fold greater, 10⁹-fold greater, 10¹⁰-fold greater or more than the K_dof unblocked nucleic acid molecules.

In an eleventh embodiment, there is provided composition of matter comprising a ribonucleoprotein (RNP) complex and a blocked nucleic acid molecule, wherein the blocked nucleic acid molecule is represented by any one of Formula I-IV, wherein Formulas I-IV comprise in the 5′-to-3′ direction comprises:

(a)A-(B-L)_J-C-M-T-D (Formula I);

- wherein A is 0-15 nucleotides in length;
- B is 4-12 nucleotides in length;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10;
- C is 4-15 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)_J-C and T-D are separate nucleic acid strands;
- T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; and
- D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A;

(b)D-T-T′-C-(L-B)_J-A (Formula II);

- wherein D is 0-10 nucleotides in length;
- T-T′ is 17-135 nucleotides in length;
- T′ is 1-10 nucleotides in length and does not hybridize with T;
- C is 4-15 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length and does not hybridize with T;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- J is an integer between 1 and 10;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;

(c)T-D-M-A-(B-L)_J-C (Formula III);

- wherein T is 17-135 nucleotides in length;
- D is 0-10 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and
- A-(B-L)_J-C are separate nucleic acid strands;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10; and
- C is 4-15 nucleotides in length; or

(d)T-D-M-A-L_p-C (Formula IV);

- wherein T is 17-31 nucleotides in length (e.g., 17-100, 17-50, or 17-25);
- D is 0-15 nucleotides in length;
- M is 1-25 nucleotides in length;
- A is 0-15 nucleotides in length and comprises a sequence complementary to D; and
- L is 3-25 nucleotides in length;
- p is 0 or 1;
- C is 4-15 nucleotides in length and comprises a sequence complementary to T.

In Some Aspects of this Embodiment,

T of Formula I comprises at least 80% sequence complementarity to B and C;

- (a) D of Formula I comprises at least 80% sequence complementarity to A;
- (b) C of Formula II comprises at least 80% sequence complementarity to T;
- (c) B of Formula II comprises at least 80% sequence complementarity to T;
- (d) A of Formula II comprises at least 80% sequence complementarity to D;
- (e) A of Formula III comprises at least 80% sequence complementarity to D;
- (f) B of Formula III comprises at least 80% sequence complementarity to T;
- (g) A of Formula IV comprises at least 80% sequence complementarity to D; and/or
- (h) C of Formula IV comprises at least 80% sequence complementarity to T.

In some aspects of the aforementioned embodiment, the blocked primer molecules include the sequence of any one of SEQ ID NOs: 14-1421.

In some aspects of the aforementioned embodiment, the RNP complex comprises a Cas3, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14, Cas12h, Cas12i, Cas12j, Cas13a, Cas13b nuclease; in some aspects, the RNP complex comprises a Type V nucleic acid-guided nuclease or a Type VI nucleic acid-guided nuclease and/or in some aspects, the RNP complex comprises a RuvC nuclease domain or a RuvC-like nuclease domain and lacks an HNH nuclease domain.

In some aspects of the aforementioned embodiment, the blocked nucleic acid molecule comprises a modified nucleoside or nucleotide comprises a locked nucleic acid (LNA), peptide nucleic acid (PNA), 2′-O-methyl (2′-O-Me) modified nucleoside, 2′-fluoro (2′-F) modified nucleoside, and/or a phosphorothioate (PS) bond.

In some aspects, the blocked nucleic acid molecule does not comprise a PAM sequence, and in other aspects, the blocked nucleic acid molecule comprises a PAM sequence where the PAM sequence is disposed between the first and second sequences, wherein the first sequence is 5′ to the PAM sequence. In some aspects, the blocked nucleic acid molecule is a blocked primer molecule.

In some aspects of the aforementioned embodiment(s), the composition of matter further comprises a reporter moiety: wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule that is operably linked to the blocked nucleic acid molecule and produces a detectable signal upon cleavage by RNP1 and/or RNP2; or wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule and is not operably linked to the blocked nucleic acid molecule and produces a detectable signal upon cleavage by RNP1 and/or RNP2. In some aspects, the detectable signal is produced within about 1-10 minutes upon binding of the target nucleic acid of interest to RNP1; in some aspects, the detectable signal is a fluorescent, chemiluminescent, radioactive, colorimetric or optical signal; and/or in some aspects, the reporter moiety comprises a modified nucleoside or nucleotide including but not limited to locked nucleic acids (LNAs), peptide nucleic acids (PNAs), 2′-O-methyl (2′-O-Me) modified nucleosides, 2′-fluoro (2′-F) modified nucleoside, and/or a phosphorothioate (PS) bonds.

Yet another embodiment provides a reaction mixture comprising: (i) a first ribonucleoprotein (RNP) complex (RNP1) comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the first nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; (ii) a second ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; wherein the second nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; (iii) a plurality of template molecules comprising a sequence corresponding to the second gRNA; (iv) a plurality of blocked primer molecules comprising a sequence complementary to the template molecules, wherein the blocked nucleic acid molecules cannot be extended by a polymerase; and (v) a polymerase and a plurality of nucleotides.

Another embodiment provides a cascade assay method for detecting a target nucleic acid of interest in a sample comprising: (a) providing a reaction mixture comprising: (i) a first ribonucleoprotein (RNP) complex (RNP1) comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the first nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; (ii) a second ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; wherein the second nucleic acid-guided nuclease exhibits both cis-cleavage activity and trans-cleavage activity; (iii) a plurality of template molecules comprising a sequence corresponding to the second gRNA; (iv) a plurality of blocked primer molecules comprising a sequence complementary to the template molecules, wherein the blocked nucleic acid molecules cannot be extended by a polymerase; and (v) a polymerase and a plurality of nucleotides; (b) contacting the reaction mixture with the sample under conditions that allow target nucleic acids of interest in the sample to bind to the first gRNA, wherein: upon binding of the target nucleic acid of interest, the RNP1 active cleaving at least one of the blocked primer molecules, thereby producing at least one unblocked primer molecule that can be extended by the polymerase; at least one unblocked primer molecule binds to one of the template molecules and is extended by the polymerase and nucleotides to form at least one synthesized activating molecule having a sequence complementary to the second gRNA; at least one synthesized activating molecule binds to the second gRNA, and RNP2 becomes active cleaving at least one further blocked primer molecule; and detecting the cleavage products of step (b), thereby detecting the target nucleic acid of interest in the sample.

A further embodiment provides a kit for detecting a target nucleic acid of interest in a sample comprising: (i) a first ribonucleoprotein complex (RNP1) comprising a first nucleic acid-guided nuclease and a first gRNA, wherein the first gRNA comprises a sequence complementary to the target nucleic acid of interest; and wherein binding of the RNP1 complex to the target nucleic acid of interest activates cis-cleavage and trans-cleavage activity of the first nucleic acid-guided nuclease; (ii) a second ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; (iii) a plurality of template molecules comprising a non-target sequence to the second gRNA; (iv) a polymerase and nucleotides; (v) a plurality of blocked primer molecules comprising a sequence complementary to the template molecules, wherein the blocked primer molecule cannot be extended by the polymerase, trans-cleavage of the blocked primer molecules results in at least one unblocked primer molecule; and wherein the unblocked primer molecule can bind to at least one the template molecule and be extended by the polymerase to form a synthesized activating molecule; and (vi) a reporter moiety, wherein the reporter moiety comprises a nucleic acid molecule and/or is operably linked to the blocked primer molecule and produces a detectable signal upon trans-cleavage activity of the blocked primer molecule by the RNP1 or the RNP2, to identify the presence of the target nucleic acid of interest in the sample.

In any of these embodiments, the first and/or second nucleic acid-guided nuclease in the reaction mixture is a Cas3, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14, Cas12h, Cas12i, Cas12j, Cas13a, Cas13b nuclease; in some aspects, the first nucleic acid-guided nuclease is a different nucleic acid-guided nuclease than the second nucleic acid-guided nuclease; in some aspects the first and/or second nucleic acid-guided nuclease is a Type V nucleic acid-guided nuclease or a Type VI nucleic acid-guided nuclease; and in some aspects, the first and/or second nucleic acid-guided nuclease comprises a RuvC nuclease domain or a RuvC-like nuclease domain and lacks an HNH nuclease domain.

In some aspects the blocked primer molecules comprise a first sequence complementary to the second gRNA and a second sequence not complementary to the second gRNA, wherein the second sequence at least partially hybridizes to the first sequence resulting in at least one loop; and in some aspects, the blocked primer molecules comprise a structure represented by any one of Formulas I-IV, wherein Formulas I-IV are in the 5′-to-3′ direction:

(a)A-(B-L)_J-C-M-T-D (Formula I);

- wherein A is 0-15 nucleotides in length;
- B is 4-12 nucleotides in length;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10;
- C is 4-15 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)_J-C and T-D are separate nucleic acid strands;
- T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; and
- D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A;

(b)D-T-T′-C-(L-B)_J-A (Formula II);

- wherein D is 0-10 nucleotides in length;
- T-T′ is 17-135 nucleotides in length;
- T′ is 1-10 nucleotides in length and does not hybridize with T;
- C is 4-15 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length and does not hybridize with T;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- J is an integer between 1 and 10;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;

(c)T-D-M-A-(B-L)_J-C (Formula III);

- wherein T is 17-135 nucleotides in length;
- D is 0-10 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L)_J-C are separate nucleic acid strands;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10; and
- C is 4-15 nucleotides in length; or

(d)T-D-M-A-L_p-C (Formula IV);

- wherein T is 17-31 nucleotides in length (e.g., 17-100, 17-50, or 17-25);
- D is 0-15 nucleotides in length;
- M is 1-25 nucleotides in length;
- A is 0-15 nucleotides in length and comprises a sequence complementary to D; and
- L is 3-25 nucleotides in length;
- p is 0 or 1;
- C is 4-15 nucleotides in length and comprises a sequence complementary to T.

In Some Aspects,

- (a) T of Formula I comprises at least 80% sequence complementarity to B and C;
- (b) D of Formula I comprises at least 80% sequence complementarity to A;
- (c) C of Formula II comprises at least 80% sequence complementarity to T;
- (d) B of Formula II comprises at least 80% sequence complementarity to T;
- (e) A of Formula II comprises at least 80% sequence complementarity to D;
- (f) A of Formula III comprises at least 80% sequence complementarity to D;
- (g) B of Formula III comprises at least 80% sequence complementarity to T;
- (h) A of Formula IV comprises at least 80% sequence complementarity to D; and/or
- (i) C of Formula IV comprises at least 80% sequence complementarity to T.

In some aspects the reaction mixture comprises about 1 fM to about 10 μM of the RNP1, and in some aspects, the reaction mixture of claim 1, wherein the reaction mixture comprises about 1 fM to about 1 mM of the RNP2.

In some aspects of these embodiments, the reaction mixture comprises at least two different RNP1s, wherein different RNP1s comprise different gRNA sequences, and in some aspects, the reaction mixture comprises 2 to 10000 different RNP1s, 2 to 1000 different RNP1s, 2 to 100 different RNP1s, or 2 to 10 different RNP1s.

In some aspects the blocked primer molecules include the sequence of any one of SEQ ID NOs: 14-1421. In some aspects the K_dof the blocked primer molecules to the RNP2 is about 10⁵-fold greater, 10⁶-fold greater, 10⁷-fold greater, 10⁸-fold greater, 10⁹-fold greater, 10¹⁰-fold greater or more than the K_dof unblocked primer molecules.

In some aspects of the aforementioned embodiments, the template molecules do not comprise a complement of a PAM sequence, and in some aspects, the template molecules comprise a complement of a PAM sequence. In some aspects, the template molecules are single-stranded. In some aspects, the template molecules are linear; in yet other aspects the template molecules are circularized. In some aspects comprising circular blocked nucleic acid molecules, at least one of the plurality of circular high Kd blocked nucleic acid molecules comprises a first region comprising a sequence specific to the second guide RNA and a second region comprising a nuclease-cleavable sequence; where at least one circular high Kd blocked nucleic acid molecule comprises a nuclease-resistant DNA sequence in the first region and a nuclease-cleavable DNA sequence in the second region; at least one circular high Kd blocked nucleic acid molecule comprises a nuclease-resistant RNA sequence in the first region and a nuclease-cleavable DNA and RNA sequence in the second region; at least one circular high Kd blocked nucleic acid molecule comprises a nuclease-resistant DNA sequence in the first region and a nuclease-cleavable DNA and RNA sequence in the second region; or at least one circular high Kd blocked nucleic acid molecule comprises a nuclease-resistant RNA sequence in the first region and a nuclease-cleavable RNA sequence in the second region.

In some aspects the polymerase comprises strand displacement activity and/or 3′-to-5′ exonuclease activity, and in some aspects, the polymerase is Phi29 polymerase.

Yet another embodiment provides a composition of matter comprising a circular high Kd blocked nucleic acid molecule comprising: a region recognized by a gRNA in an RNP complex; a region comprising a sequence cleavable by a nucleic acid-guided nuclease in the RNP complex; and wherein the circular high Kd blocked nucleic acid molecule cannot activate the RNP complex, and wherein the circular high Kd blocked nucleic molecules are high Kd in relation to binding to the RNP complex.

A further embodiment provides a method of unblocking a circular high Kd blocked nucleic acid molecule comprising the steps of: (a) providing a circular high Kd blocked nucleic acid molecule comprising: a first region recognized by a gRNA in an RNP complex; a second region comprising a sequence cleavable by a nucleic acid-guided nuclease in the RNP complex, wherein the circular high Kd blocked nucleic acid molecule cannot substantially activate the RNP complex; and (b) initiating cleavage of the second region by the nucleic acid-guided nuclease in the RNP complex, wherein the circular high Kd blocked nucleic acid molecule becomes a linear low Kd unblocked nucleic acid molecule, and wherein the circular high Kd blocked nucleic acid molecules are high Kd and linear low K_dunblocked nucleic acid molecules are high K_dand low K_din relation to binding the RNP complex.

Also provided as an embodiment is a cascade assay method of detecting a target nucleic acid of interest in a sample comprising the steps of: (a) providing a reaction mixture comprising: (i) a first ribonucleoprotein (RNP) complex (RNP1) comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest; (ii) a second ribonucleoprotein (RNP2) complex comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid molecule; and (iii) a plurality of circular blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the circular blocked nucleic acid molecules cannot activate the RNP1 complex or the RNP2 complex; (b) contacting the reaction mixture with the sample under conditions that allow the target nucleic acid of interest in the sample to bind to RNP1; wherein upon binding of the target nucleic acid of interest, RNP1 becomes active initiating trans-cleavage of at least one of the circular blocked nucleic acid molecules thereby producing at least one linear unblocked nucleic acid molecule; the at least one linear unblocked nucleic acid molecule binds to RNP2 initiating cleavage of at least one further circular blocked nucleic acid molecule; and (c) detecting the cleavage products, thereby detecting the target nucleic acid of interest in the sample.

In some aspects, the RNP complex (either RNP1 or RNP2) comprises a nucleic acid-guided nuclease selected from Cas3, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14, Cas12h, Cas12i, Cas12j, Cas13a, or Cas13b, and in some aspects, the RNP complex comprises a nucleic acid-guided nuclease that is a Type V nucleic acid-guided nuclease or a Type VI nucleic acid-guided nuclease; the RNP complex comprises a nucleic acid-guided nuclease that exhibits both cis-cleavage and trans-cleavage activity; and/or the RNP complex comprises a nucleic acid-guided nuclease comprising a RuvC nuclease domain or a RuvC-like nuclease domain but lacks an HNH nuclease domain.

In some aspects of any embodiments comprising circular high K_dblocked nucleic acid molecules, the circular high K_dblocked nucleic acid molecule comprises a nuclease-resistant DNA sequence in the first region and a nuclease-cleavable DNA sequence in the second region; the circular high K_dblocked nucleic acid molecule comprises a nuclease-resistant RNA sequence in the first region and a nuclease-cleavable DNA and RNA sequence in the second region; the circular high K_dblocked nucleic acid molecule comprises a nuclease-resistant DNA sequence in the first region and a nuclease-cleavable DNA and RNA sequence in the second region; or the circular high K_dblocked nucleic acid molecule comprises a nuclease-resistant RNA sequence in the first region and a nuclease-cleavable RNA sequence in the second region.

In some aspects of these embodiments, the circular high K_dblocked nucleic acid molecule comprises 5′ and 3′ ends hybridized to each other and DNA, RNA, LNA or PNA bases having a high T_m; and in some aspects, the K_dof the circular high K_dblocked nucleic acid molecules to the RNP complex or RNP2 is about 10⁵-fold greater, 10⁶-fold greater, 10⁷-fold greater, 10⁸-fold greater, 10⁹-fold greater, 10¹⁰-fold greater or more than the K_dof unblocked circular high K_dblocked nucleic acid molecules.

In some aspects the circular high K_dblocked nucleic acid molecule comprises a modified nucleoside or nucleotide, including but not limited to a locked nucleic acid (LNA), a peptide nucleic acid (PNA), a 2′-O-methyl (2′-O-Me) modified nucleoside, a 2′-fluoro (2′-F) modified nucleoside, and/or a phosphorothioate (PS) bond.

In some aspects the circular high K_dblocked nucleic acid molecule is a single-stranded, double-stranded, or partially double-stranded molecule comprising one or more different combinations of DNA-DNA, DNA-RNA or RNA-RNA hybrid molecules. In some aspects the circular high K_dblocked nucleic acid molecule is a circular high K_dprimer molecule. In some aspects the circular high K_dblocked nucleic acid molecule does not comprise a PAM sequence or the circular high K_dblocked nucleic acid molecule comprises a PAM sequence.

In some aspects of the aforementioned embodiments, the compositions of matter or reaction further comprises a reporter moiety wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule that is operably linked to the blocked nucleic acid molecule and produces a detectable signal upon cleavage by RNP1 and/or RNP2; or wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule and is not operably linked to the blocked nucleic acid molecule and produces a detectable signal upon cleavage by RNP1 and/or RNP2. In some aspects, the detectable signal is produced within about 1-10 minutes upon binding of the target nucleic acid of interest to RNP1; in some aspects, the detectable signal is a fluorescent, chemiluminescent, radioactive, colorimetric or optical signal; and/or in some aspects, the reporter moiety comprises a modified nucleoside or nucleotide including but not limited to locked nucleic acids (LNAs), peptide nucleic acids (PNAs), 2′-O-methyl (2′-O-Me) modified nucleosides, 2′-fluoro (2′-F) modified nucleoside, and/or a phosphorothioate (PS) bonds.

Yet another embodiment provides a composition of matter comprising: (a) a first preassembled ribonucleoprotein complex (RNP1) comprising a first nucleic acid-guided nuclease and a first guide RNA that is specific to a target nucleic acid of interest, wherein the first nucleic acid-guided nuclease exhibits cis-cleavage activity and trans-cleavage activity; (b) a second preassembled ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second guide RNA, wherein the second nucleic acid-guided nuclease exhibits cis-cleavage activity and trans-cleavage activity; and (c) a plurality of circular high K_dblocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the circular high K_dblocked nucleic acid molecules are not recognized by the RNP1 or RNP2, and wherein the circular high K_dblocked nucleic acid molecules are high K_din relation to binding to RNP2.

Another embodiment provides a composition of matter comprising: (a) a first preassembled ribonucleoprotein complex (RNP1) comprising a first nucleic acid-guided nuclease and a first guide RNA that is specific to a target nucleic acid of interest, wherein the first nucleic acid-guided nuclease exhibits cis-cleavage activity and trans-cleavage activity; (b) a second preassembled ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second guide RNA, wherein the second nucleic acid-guided nuclease exhibits cis-cleavage activity and trans-cleavage activity; and (c) a plurality of engineered linear high K_dblocked nucleic acid molecules comprising a first sequence complementary to the second gRNA, wherein the linear high K_dblocked nucleic acid molecules are not recognized by the RNP1 and RNP2, and wherein the linear high K_dblocked nucleic acid molecules are high K_din relation to binding to the RNP2.

Yet another embodiment provides a composition of matter comprising: (a) a first preassembled ribonucleoprotein complex (RNP1) comprising a first nucleic acid-guided nuclease and a first guide RNA that is specific to a target nucleic acid of interest, wherein the first nucleic acid-guided nuclease exhibits cis-cleavage activity and trans-cleavage activity; (b) a second preassembled ribonucleoprotein complex (RNP2) comprising a second nucleic acid-guided nuclease and a second guide RNA, wherein the second nucleic acid-guided nuclease exhibits cis-cleavage activity and trans-cleavage activity; and (c) a plurality of engineered high K_dblocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the high K_dblocked nucleic acid molecules are not recognized by the RNP1 and RNP2, and wherein the high K_dblocked nucleic acid molecules are high K_din relation to binding to the RNP complex.

In aspects of any one of the foregoing embodiments, the high K_dblocked nucleic acid molecule comprises DNA, RNA, LNA or PNA bases having a high Tm; the 5′ and 3′ ends of the high K_dblocked nucleic acid molecule comprise phosphorothioate bonds (PS); high K_dblocked nucleic acid molecule comprises one or more different combinations of DNA-DNA, DNA-RNA or RNA-RNA hybrid molecules; and/or the high K_dblocked nucleic acid molecule comprises a nucleic acid region comprising nanoparticles attached thereto, wherein the nanoparticles provide steric hindrance to internalization in RNP2 and block RNP2 activation until cleavage and removal of the nucleic acid region comprising the nanoparticles.

In other aspects, the first and/or second nucleic acid-guided nuclease is a Cas3, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14, Cas12h, Cas12i, Cas12j, Cas13a, Cas13b nuclease; in some aspects, the first nucleic acid-guided nuclease can is a different nucleic acid-guided nuclease than the second nucleic acid-guided nuclease; in some aspects, the first and/or second nucleic acid-guided nuclease is a Type V nucleic acid-guided nuclease or a Type VI nucleic acid-guided nuclease and/or in some aspects, the first and/or second nucleic acid-guided nuclease comprises a RuvC nuclease domain or a RuvC-like nuclease domain and lacks an HNH nuclease domain.

Aspects also include the composition of matter comprises about 1 fM to about 10 μM of the RNP1; and/or the composition of matter comprises about 1 fM to about 1 mM of the RNP2.

In some aspects the composition of matter comprises at least two different RNP1 complex species, wherein different RNP1s comprise different gRNA sequences; and in some aspects the composition comprises 2 to 10000 different RNP1s, 2 to 1000 different RNP1s, 2 to 100 different RNP1s, or 2 to 10 different RNP1s.

In some aspects the RNP2 recognizes a PAM sequence, and in other aspects the RNP2 complex does not recognize a PAM sequence.

In some aspects of the aforementioned embodiments, the composition of matter further comprises a reporter moiety, wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule that is operably linked to the blocked nucleic acid molecule and produces a detectable signal upon cleavage by RNP1 and/or RNP2; or wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule and is not operably linked to the blocked nucleic acid molecule and produces a detectable signal upon cleavage by RNP1 and/or RNP2. In some aspects, the detectable signal is produced within about 1-10 minutes upon binding of the target nucleic acid of interest to RNP1; in some aspects, the detectable signal is a fluorescent, chemiluminescent, radioactive, colorimetric or optical signal; and/or in some aspects, the reporter moiety comprises a modified nucleoside or nucleotide including but not limited to locked nucleic acids (LNAs), peptide nucleic acids (PNAs), 2′-O-methyl (2′-O-Me) modified nucleosides, 2′-fluoro (2′-F) modified nucleoside, and/or a phosphorothioate (PS) bonds.

In some aspects the high Kd blocked nucleic acid molecule is a high Kd blocked primer molecule.

In some aspects the linear high K_dblocked nucleic acid molecule is converted to a linear low K_dblocked nucleic acid molecule upon trans-cleavage by RNP1 and/or RNP2. In some aspects the K_dof the blocked nucleic acid molecules to the RNP2 is about 10⁵-fold greater, 10⁶-fold greater, 10⁷-fold greater, 10⁸-fold greater, 10⁹-fold greater, 10¹⁰-fold greater or more than the K_dof unblocked nucleic acid molecules.

In some aspects of the compositions of matter comprising circular blocked nucleic acid molecules, at least one of the plurality of circular high Kd blocked nucleic acid molecules comprises a first region comprising a sequence specific to the second guide RNA and a second region comprising a nuclease-cleavable sequence; where at least one circular high Kd blocked nucleic acid molecule comprises a nuclease-resistant DNA sequence in the first region and a nuclease-cleavable DNA sequence in the second region; at least one circular high Kd blocked nucleic acid molecule comprises a nuclease-resistant RNA sequence in the first region and a nuclease-cleavable DNA and RNA sequence in the second region; at least one circular high Kd blocked nucleic acid molecule comprises a nuclease-resistant DNA sequence in the first region and a nuclease-cleavable DNA and RNA sequence in the second region; or at least one circular high Kd blocked nucleic acid molecule comprises a nuclease-resistant RNA sequence in the first region and a nuclease-cleavable RNA sequence in the second region.

In some aspects of the compositions of matter comprising linear blocked nucleic acid molecules, the linear high K_dnucleic acid molecules comprise a structure represented by any one of Formulas I-IV, where Formulas I-IV comprise in the 5′-to-3′ direction:

(a)A-(B-L)_J-C-M-T-D (Formula I);

- wherein A is 0-15 nucleotides in length;
- B is 4-12 nucleotides in length;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10;
- C is 4-15 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)_J-C and T-D are separate nucleic acid strands;
- T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; and
- D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A;

(b)D-T-T′-C-(L-B)_J-A (Formula II);

- wherein D is 0-10 nucleotides in length;
- T-T′ is 17-135 nucleotides in length;
- T′ is 1-10 nucleotides in length and does not hybridize with T;
- C is 4-15 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length and does not hybridize with T;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- J is an integer between 1 and 10;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;

(c)T-D-M-A-(B-L)_J-C (Formula III);

- wherein T is 17-135 nucleotides in length;
- D is 0-10 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L)_J-C are separate nucleic acid strands;
- A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;
- B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10; and
- C is 4-15 nucleotides in length; or

(d)T-D-M-A-L_p-C (Formula IV);

- wherein T is 17-31 nucleotides in length (e.g., 17-100, 17-50, or 17-25);
- D is 0-15 nucleotides in length;
- M is 1-25 nucleotides in length;
- A is 0-15 nucleotides in length and comprises a sequence complementary to D; and
- L is 3-25 nucleotides in length;
- p is 0 or 1;
- C is 4-15 nucleotides in length and comprises a sequence complementary to T.

And in Some Aspects,

- (a) T of Formula I comprises at least 80% sequence complementarity to B and C;
- (b) D of Formula I comprises at least 80% sequence complementarity to A;
- (c) C of Formula II comprises at least 80% sequence complementarity to T;
- (d) B of Formula II comprises at least 80% sequence complementarity to T;
- (e) A of Formula II comprises at least 80% sequence complementarity to D;
- (f) A of Formula III comprises at least 80% sequence complementarity to D;
- (g) B of Formula III comprises at least 80% sequence complementarity to T;
- (h) A of Formula IV comprises at least 80% sequence complementarity to D; and/or
- (i) C of Formula IV comprises at least 80% sequence complementarity to T.

In some aspects, at least one of the linear blocked nucleic acid molecules include the sequence of any one of SEQ ID NOs: 14-1421.

In another embodiment, there is provided a method for syndromic testing comprising: (a) providing a reaction mixture comprising: (i) a plurality of first ribonucleoprotein complexes (RNP1s), each RNP1 comprising a nucleic acid-guided nuclease exhibiting both cis-cleavage and trans-cleavage activity and a first guide RNA (gRNA), wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the reaction mixture comprises at least two different RNP1s, wherein different RNP1s comprise different first gRNAs; (ii) a second ribonucleoprotein complex (RNP2), wherein the RNP2 comprises a second nucleic acid-guided nuclease and a second gRNA that does not recognize any of the target nucleic acids of interest; and (iii) a plurality of blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the blocked nucleic acid molecule cannot substantially activate the plurality of RNP1s or the RNP2; (b) contacting the reaction mixture with a sample under conditions that allow target nucleic acids of interest in the sample to bind to the RNP1s, wherein: upon binding of any one of the target nucleic acids of interest, the RNP1 becomes active, cleaving at least one of the blocked nucleic acid molecules, thereby producing at least one unblocked nucleic acid molecule; and at least one unblocked nucleic acid molecule binds to the second gRNA thereby activating RNP2 and initiating trans-cleavage of at least one further blocked nucleic acid molecule; and (c) detecting products of the cleavage of step (b), thus identifying at least one target nucleic acid of interest in the sample.

In some aspects of this embodiment, the first and/or second nucleic acid-guided nuclease is a Cas3, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14, Cas12h, Cas12i, Cas12j, Cas13a, Cas13b nuclease; in some aspects, the first nucleic acid-guided nuclease can is a different nucleic acid-guided nuclease than the second nucleic acid-guided nuclease; in some aspects, the first and/or second nucleic acid-guided nuclease is a Type V nucleic acid-guided nuclease or a Type VI nucleic acid-guided nuclease and/or in some aspects, the first and/or second nucleic acid-guided nuclease comprises a RuvC nuclease domain or a RuvC-like nuclease domain and lacks an HNH nuclease domain.

Aspects also include the reaction mixture comprises about 1 fM to about 10 μM of the RNP1; and/or the reaction mixture comprises about 1 fM to about 1 mM of the RNP2. In some aspects the reaction mixture comprises at least two different RNP1 complex species, wherein different RNP1s comprise different gRNA sequences; and in some aspects the composition comprises 2 to 10000 different RNP1s, 2 to 1000 different RNP1s, 2 to 100 different RNP1s, or 2 to 10 different RNP1s.

In some aspects the K_dof the plurality of blocked nucleic acid molecules to the RNP2 is about 10⁵-fold greater, 10⁶-fold greater, 10⁷-fold greater, 10⁸-fold greater, 10⁹-fold greater, 10¹⁰-fold greater or more than the K_dof unblocked nucleic acid molecules.

In some aspects of the aforementioned embodiment, the target nucleic acid of interest is of bacterial, viral, fungal, or mammalian origin, and in some aspects, the sample may include peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, and/or umbilical cord blood.

In some aspects the blocked nucleic acid molecules comprise a PAM sequence and in other aspects, the blocked nucleic acid molecules do not comprise a PAM sequence. In some aspects the blocked nucleic acid molecules are linear and in some aspects, the blocked nucleic acids are circular and in yet other aspects, the blocked nucleic acid molecules are a mixture of circular and linear blocked nucleic acid molecules.

In some aspects the blocked nucleic acid molecules are blocked primer molecules and wherein the reaction mixture further comprises a polymerase and nucleotides.

In some aspects, the syndromic testing is for any two or more of common flu (e.g., influenza A, influenza A/H1, influenza A/H3, influenza A/H1-2009, and influenza B); one of the multiple strains of respiratory syncytial virus (RSV), such as RSV-A and RSV-B; at least one variant of SARS-CoV-2 (e.g., B.1.1.7, B.1.351, P.1, B.1.617.2, BA.1, BA.2, BA.2.12.1, BA.4, and BA.5); and at least one of other pathogens of interest (e.g., parainfluenza virus 1-4, human metapneumovirus, human rhinovirus, human enterovirus, adenovirus, coronavirus HKU1, coronavirus NL63, coronavirus 229E, coronavirus OC43, MERS).

Yet other embodiments provide: a method of detecting a target nucleic acid of interest in a sample comprising the steps of: providing a reaction mixture comprising a first RNP complex comprising a first nucleic acid-guided nuclease and a first guide RNA (gRNA), wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest; and a second RNP complex comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; and contacting the reaction mixture with the sample under conditions that allow the target nucleic acid of interest in the sample to bind to the first gRNA, wherein upon binding of the target nucleic acid of interest, the first RNP complex becomes active which catalyzes activation of the second RNP complex via one or more blocked nucleic acids to produce a detectable signal from a reporter moiety.

A further embodiment provides a modular cascade assay comprising: a first nucleic acid-guided nuclease, wherein the first nucleic acid-guided nuclease will form a first ribonucleoprotein complex with a first gRNA that is complementary to a target nucleic acid of interest; a second RNP2 complex comprising a second nucleic acid-guided nuclease and a second gRNA that is not complementary to a target nucleic acid of interest; and a plurality of blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the blocked nucleic acid molecules cannot activate the RNP1 complex or the RNP2 complex; wherein by changing the sequence of the first gRNA, the modular cascade assay is changed to detect different target nucleic acids of interest.

These aspects and other features and advantages of the invention are described below in more detail.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other features and advantages of the present invention will be more fully understood from the following detailed description of illustrative embodiments taken in conjunction with the accompanying drawings in which:

FIG. 1A is an overview of a prior art assay where target nucleic acids of interest from a sample must be amplified before performing a detection assay.

FIG. 1B is an overview of the general principles underlying the nucleic acid-guided nuclease cascade assay described in detail herein where target nucleic acids of interest from a sample do not need to be amplified before detection.

FIG. 2A is a diagram showing the sequence of steps in an exemplary cascade assay utilizing blocked nucleic acids.

FIG. 2B is a diagram showing an exemplary blocked nucleic acid molecule and a method for unblocking the blocked nucleic acid molecules of the disclosure.

FIG. 2C shows schematics of several exemplary blocked nucleic acid molecules containing the structure of Formula I, as described herein.

FIG. 2D shows schematics of several exemplary blocked nucleic acid molecules containing the structure of Formula II, as described herein.

FIG. 2E shows schematics of several exemplary blocked nucleic acid molecules containing the structure of Formula III, as described herein.

FIG. 2F shows schematics of several exemplary blocked nucleic acid molecules containing the structure of Formula IV, as described herein.

FIG. 2G shows an exemplary single-stranded blocked nucleic acid molecule with a design able to block R-loop formation with an RNP complex, thereby blocking activation of the trans-nuclease activity of an RNP complex (i.e., RNP2).

FIG. 2H shows schematics of exemplary circularized blocked nucleic acid molecules.

FIG. 3A is a diagram showing the sequence of steps in an exemplary cascade assay involving circular blocked primer molecules and linear template molecules.

FIG. 3B is a diagram showing the sequence of steps in an exemplary cascade assay involving circular blocked primer molecules and circular template molecules.

FIG. 4 illustrates three embodiments of reporter moieties.

FIG. 5A shows a lateral flow assay that can be used to detect the cleavage and separation of a signal from a reporter moiety.

FIG. 5B shows a schematic of a lateral flow assay device illustrating the results of an exemplary syndromic test.

FIG. 6 shows a titered quantification of a synthesized nucleocapsid gene (N-gene) using the nucleic acid detection methods described herein. As described in Example VI, a cascade assay was initiated using the detection methods described in Examples II-V above.

FIG. 7 shows titered quantification of an inactivated SARS-CoV-2 virus using the nucleic acid detection methods described in Examples II-V above.

FIG. 8 shows titered quantification of DNA from Methicillin-resistant Staphylococcus (MRSA) using the nucleic acid detection methods described in Examples II-V.

FIG. 9 shows titered quantification of DNA from Methicillin-resistant Staphylococcus (MRSA) using the nucleic acid detection methods described in Examples II-V.

FIG. 10 shows the detection of 3 copies of a molecule of DNA from Methicillin-resistant Staphylococcus (MRSA) using Molecule C5 as the blocked nucleic acid molecule.

FIG. 11 shows the detection of 3 copies of a molecule of DNA from Methicillin-resistant Staphylococcus (MRSA) using Molecule C6 as the blocked nucleic acid molecule.

FIG. 12 shows the detection of 3 copies of a molecule of DNA from Methicillin-resistant Staphylococcus (MRSA) using Molecule C7 as the blocked nucleic acid molecule.

FIG. 13 shows the detection of 3 copies of a molecule of DNA from Methicillin-resistant Staphylococcus (MRSA) using Molecule C8 as the blocked nucleic acid molecule.

FIG. 14 shows the detection of 3 copies of a molecule of DNA from Methicillin-resistant Staphylococcus (MRSA) using Molecule C9 as the blocked nucleic acid molecule.

It should be understood that the drawings are not necessarily to scale, and that like reference numbers refer to like features.

Definitions

All of the functionalities described in connection with one embodiment of the compositions and methods described herein are intended to be applicable to the additional embodiments of the compositions and methods described herein except where expressly stated or where the feature or function is incompatible with the additional embodiments. For example, where a given feature or function is expressly described in connection with one embodiment but not expressly mentioned in connection with an alternative embodiment, it should be understood that the feature or function may be deployed, utilized, or implemented in connection with the alternative embodiment unless the feature or function is incompatible with the alternative embodiment.

Note that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a cell” refers to one or more cells, and reference to “a system” includes reference to equivalent steps, methods and devices known to those skilled in the art, and so forth. Additionally, it is to be understood that terms such as “left,” “right,” “top,” “bottom,” “front,” “rear,” “side,” “height,” “length,” “width,” “upper,” “lower,” “interior,” “exterior,” “inner,” “outer” that may be used herein merely describe points of reference and do not necessarily limit embodiments of the present disclosure to any particular orientation or configuration. Furthermore, terms such as “first,” “second,” “third,” etc., merely identify one of a number of portions, components, steps, operations, functions, and/or points of reference as disclosed herein, and likewise do not necessarily limit embodiments of the present disclosure to any particular configuration or orientation.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing devices, formulations and methodologies that may be used in connection with the presently described invention. Conventional methods are used for the procedures described herein, such as those provided in the art, and demonstrated in the Examples and various general references. Unless otherwise stated, nucleic acid sequences described herein are given, when read from left to right, in the 5′ to 3′ direction. Nucleic acid sequences may be provided as DNA, as RNA, or a combination of DNA and RNA (e.g., a chimeric nucleic acid).

Where a range of values is provided, it is understood that each intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

The term “and/or” where used herein is to be taken as specific disclosure of each of the multiple specified features or components with or without another. Thus, the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

In the following description, numerous specific details are set forth to provide a more thorough understanding of the present invention. However, it will be apparent to one of skill in the art that the present invention may be practiced without one or more of these specific details. In other instances, features and procedures well known to those skilled in the art have not been described in order to avoid obscuring the invention. The terms used herein are intended to have the plain and ordinary meaning as understood by those of ordinary skill in the art.

As used herein, the term “about,” as applied to one or more values of interest, refers to a value that falls within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of a stated reference value, unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

As used herein, the terms “binding affinity” or “dissociation constant” or “K_d” refer to the tendency of a molecule to bind (covalently or non-covalently) to a different molecule. A high K_d(which in the context of the present disclosure refers to blocked nucleic acid molecules or blocked primer molecules binding to RNP2) indicates the presence of more unbound molecules, and a low K_d(which in the context of the present disclosure refers to unblocked nucleic acid molecules or unblocked primer molecules binding to RNP2) indicates the presence of more bound molecules. In the context of the present disclosure and the binding of blocked or unblocked nucleic acid molecules or blocked or unblocked primer molecules to RNP2, aow K_dvalues are in a range from about 100 fM to about 1 aM or lower (e.g., 100 zM) and high K_dvalues are in the range of 100 nM-100 μM (10 mM) and thus are about 10⁵- to 10¹⁰-fold or higher as compared to low K_dvalues.

As used herein, the terms “binding domain” or “binding site” refer to a region on a protein, DNA, or RNA, to which specific molecules and/or ions (ligands) may form a covalent or non-covalent bond. By way of example, a polynucleotide sequence present on a nucleic acid molecule (e.g., a primer binding domain) may serve as a binding domain for a different nucleic acid molecule (e.g., an unblocked primer nucleic acid molecule). Characteristics of binding sites are chemical specificity, a measure of the types of ligands that will bond, and affinity, which is a measure of the strength of the chemical bond.

As used herein, the term “blocked nucleic acid molecule” refers to nucleic acid molecules that cannot bind to the first or second RNP complex to activate cis- or trans-cleavage. “Unblocked nucleic acid molecule” refers to a formerly blocked nucleic acid molecule that can bind to the second RNP complex (RNP2) to activate trans-cleavage of additional blocked nucleic acid molecules.

The terms “Cas RNA-guided endonuclease” or “CRISPR nuclease” or “nucleic acid-guided nuclease” refer to a CRISPR-associated protein that is an RNA-guided endonuclease suitable for assembly with a sequence-specific gRNA to form a ribonucleoprotein (RNP) complex.

As used herein, the terms “cis-cleavage”, “cis-endonuclease activity”, “cis-mediated endonuclease activity”, “cis-nuclease activity”, “cis-mediated nuclease activity”, and variations thereof refer to sequence-specific cleavage of a target nucleic acid of interest, including an unblocked nucleic acid molecule or synthesized activating molecule, by a nucleic acid-guided nuclease in an RNP complex. Cis-cleavage is a single turn-over cleavage event in that only one substrate molecule is cleaved per event.

The term “complementary” as used herein refers to Watson-Crick base pairing between nucleotides and specifically refers to nucleotides hydrogen-bonded to one another with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine and guanine residues linked by three hydrogen bonds. In general, a nucleic acid includes a nucleotide sequence described as having a “percent complementarity” or “percent homology” to a specified second nucleotide sequence. For example, a nucleotide sequence may have 80%, 90%, or 100% complementarity to a specified second nucleotide sequence, indicating that 8 of 10, 9 of 10, or 10 of 10 nucleotides of a sequence are complementary to the specified second nucleotide sequence. For instance, the nucleotide sequence 3′-TCGA-5′ is 100% complementary to the nucleotide sequence 5′-AGCT-3′; and the nucleotide sequence 3′-TCGATCGATCGA-5′ [SEQ ID NO: 1] is 100% complementary to a region of the nucleotide sequence 5′-GCTAGCTAGC-3′ [SEQ ID NO: 2].

As used herein, the term “contacting” refers to placement of two moieties in direct physical association, including in solid or liquid form. Contacting can occur in vitro with isolated cells (for example in a tissue culture dish or other vessel) or in vivo by administering an agent to a subject.

A “control” is a reference standard of a known value or range of values.

The terms “guide nucleic acid” or “guide RNA” or “gRNA” refer to a polynucleotide comprising 1) a crRNA region or guide sequence capable of hybridizing to the target strand of a target nucleic acid of interest, and 2) a scaffold sequence capable of interacting or complexing with a nucleic acid-guided nuclease. The crRNA region of the gRNA is a customizable component that enables specificity in every nucleic acid-guided nuclease reaction. A gRNA can include any polynucleotide sequence having sufficient complementarity with a target nucleic acid of interest to hybridize with the target nucleic acid of interest and to direct sequence-specific binding of a ribonucleoprotein (RNP) complex containing the gRNA and nucleic acid-guided nuclease to the target nucleic acid. Target nucleic acids of interest may include a protospacer adjacent motif (PAM), and, following gRNA binding, the nucleic acid-guided nuclease induces a double-stranded break either inside or outside the protospacer region on the target nucleic acid of interest, including on an unblocked nucleic acid molecule or synthesized activating molecule. A gRNA may contain a spacer sequence including a plurality of bases complementary to a protospacer sequence in the target nucleic acid. For example, a spacer can contain about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, or more bases. The gRNA spacer may be 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 98%, 99%, or more complementary to its corresponding target nucleic acid of interest. Optimal alignment may be determined with the use of any suitable algorithm for aligning sequences. A guide RNA may be from about 20 nucleotides to about 300 nucleotides long. Guide RNAs may be produced synthetically or generated from a DNA template.

“Modified” refers to a changed state or structure of a molecule. Molecules may be modified in many ways including chemically, structurally, and functionally. In one embodiment, a nucleic acid molecule (for example, a blocked nucleic acid molecule) may be modified by the introduction of non-natural nucleosides, nucleotides, and/or internucleoside linkages. In another embodiment, a modified protein (e.g., a nucleic acid-guided nuclease) may refer to any polypeptide sequence alteration which is different from the wildtype.

The terms “percent sequence identity”, “percent identity”, or “sequence identity” refer to percent (%) sequence identity with respect to a reference polynucleotide or polypeptide sequence following alignment by standard techniques. Alignment for purposes of determining percent sequence identity can be achieved in various ways that are within the capabilities of one of skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, PSI-BLAST, or Megalign software. In some embodiments, the software is MUSCLE (Edgar, Nucleic Acids Res., 32(5):1792-1797 (2004)). Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For example, in embodiments, percent sequence identity values are generated using the sequence comparison computer program BLAST (Altschul et al., J. Mol. Biol., 215:403-410 (1990)).

As used herein, the terms “preassembled ribonucleoprotein complex”, “ribonucleoprotein complex”, “RNP complex”, or “RNP” refer to a complex containing a guide RNA (gRNA) and a nucleic acid-guided nuclease, where the gRNA is integrated with the nucleic acid-guided nuclease. The gRNA, which includes a sequence complementary to a target nucleic acid of interest, guides the RNP to the target nucleic acid of interest and hybridizes to it. The hybridized target nucleic acid-gRNA units are cleaved by the nucleic acid-guided nuclease. In the cascade assays described herein, a first ribonucleoprotein complex (RNP1) includes a first guide RNA (gRNA) specific to a nucleic acid target nucleic acid of interest, and a first nucleic acid-guided nuclease, such as, for example, cas12a or cas14a for a DNA target nucleic acid, or cas13a for an RNA target nucleic acid. A second ribonucleoprotein complex (RNP2) for signal amplification includes a second guide RNA specific to an unblocked nucleic acid or synthesized activating molecule, and a second nucleic acid-guided nuclease, which may be different from or the same as the first nucleic acid-guided nuclease.

As used herein, the terms “protein” and “polypeptide” are used interchangeably. Proteins may or may not be made up entirely of amino acids.

As used herein, the term “sample” refers to tissues; cells or component parts; body fluids, including but not limited to peripheral blood, serum, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, sweat, fecal matter, hair, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, and umbilical cord blood; food; agricultural products; pharmaceuticals; cosmetics, nutriceuticals; personal care products; environmental substances such as soil, water, or air; industrial sites and products; and chemicals and compounds. A sample further may include a homogenate, lysate or extract. A sample further refers to a medium, such as a nutrient broth or gel, which may contain cellular components, such as proteins or nucleic acid molecules.

The terms “target DNA sequence”, “target sequence”, “target nucleic acid of interest”, “target molecule of interest”, “target nucleic acid”, or “target of interest” refer to any locus that is recognized by a gRNA sequence in vitro or in vivo. The “target strand” of a target nucleic acid of interest is the strand of the double-stranded target nucleic acid that is complementary to a gRNA. The spacer sequence of a gRNA may be 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 98%, 99% or more complementary to the target nucleic acid of interest. Optimal alignment can be determined with the use of any suitable algorithm for aligning sequences. Full complementarity is not necessarily required provided there is sufficient complementarity to cause hybridization and trans-cleavage activation of an RNP complex. A target nucleic acid of interest can include any polynucleotide, such as DNA (ssDNA or dsDNA) or RNA polynucleotides. A target nucleic acid of interest may be located in the nucleus or cytoplasm of a cell such as, for example, within an organelle of a eukaryotic cell, such as a mitochondrion or a chloroplast, or it can be exogenous to a host cell, such as a eukaryotic cell or a prokaryotic cell. The target nucleic acid of interest may be present in a sample, such as a biological or environmental sample, and it can be a viral nucleic acid molecule, a bacterial nucleic acid molecule, a fungal nucleic acid molecule, or a polynucleotide of another organism, such as a coding or a non-coding sequence, and it may include single-stranded or double-stranded DNA molecules, such as a cDNA or genomic DNA, or RNA molecules, such as mRNA, tRNA, and rRNA. The target nucleic acid may be associated with a protospacer adjacent motif (PAM) sequence, which may include a 2-5 base pair sequence adjacent to the protospacer. In some embodiments 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more target nucleic acids can be detected by the disclosed method.

As used herein, the terms “trans-cleavage”, “trans-endonuclease activity”, “trans-mediated endonuclease activity”, “trans-nuclease activity”, “trans-mediated nuclease activity”, and variations thereof, refer to indiscriminate, non-sequence-specific cleavage of a nucleic acid molecule by an endonuclease (such as by a Cas12, Cas13, and Cas14) which is triggered by cis-(sequence-specific) cleavage. Trans-cleavage is a “multiple turn-over” event, in that more than one substrate molecule is cleaved after initiation by a single turn-over cis-cleavage event.

Type V CRISPR/Cas nucleic acid-guided nucleases are a subtype of Class 2 CRISPR/Cas effector nucleases such as, but not limited to, engineered Cas12a, Cas12b, Cas12c, C2c4, C2c8, C2c5, C2c10, C2c9, CasX (Cas12e), CasY (Cas12d), Cas 13a nucleases or naturally-occurring proteins, such as a Cas12a isolated from, for example, Francisella tularensis subsp. novicida (Gene ID: 60806594), Candidatus Methanoplasma termitum (Gene ID: 24818655), Candidatus Methanomethylophilus alvus (Gene ID: 15139718), and [Eubacterium] eligens ATCC 27750 (Gene ID: 41356122), and an artificial polypeptide, such as a chimeric protein.

The term “variant” refers to a polypeptide or polynucleotide that differs from a reference polypeptide or polynucleotide but retains essential properties. A typical variant of a polypeptide differs in amino acid sequence from another reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many if not most regions, identical. A variant and reference polypeptide may differ in amino acid sequence by one or more modifications (e.g., substitutions, additions, and/or deletions). A variant of a polypeptide may be a conservatively modified variant. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code (e.g., a non-natural amino acid). A variant of a polypeptide may be naturally occurring, such as an allelic variant, or it may be a variant that is not known to occur naturally. Variants include modifications-including chemical modifications—to one or more amino acids that do not involve amino acid substitutions, additions or deletions.

A “vector” is any of a variety of nucleic acids that comprise a desired sequence or sequences to be delivered to and/or expressed in a cell. Vectors are typically composed of DNA, although RNA vectors are also available. Vectors include, but are not limited to, plasmids, fosmids, phagemids, virus genomes, synthetic chromosomes, and the like.

DETAILED DESCRIPTION

The present disclosure provides compositions of matter, methods, and cascade assays for detecting nucleic acids. The cascade assays described herein comprise first and second ribonucleoprotein complexes and either blocked nucleic acid molecules or blocked primer molecules. The blocked nucleic acid molecules or blocked primer molecules keep the second ribonucleoprotein complexes “locked” unless and until a target nucleic acid of interest activates the first ribonucleoprotein complex. The methods comprise the steps of providing cascade assay components, contacting the cascade assay components with a sample, and detecting a signal that is generated only when a target nucleic acid of interest is present in the sample ids.

Early and accurate detection and determination of infections and diseases is crucial for appropriate prevention strategies, accurate testing, confirmation, and further diagnosis and treatment. Nucleic acid-guided nucleases, such as the Cas12a endonuclease, can be utilized as diagnostic tools for the detection of target nucleic acids of interest associated with diseases. However, currently available state-of-the-art CRISPR Cas12a-based nucleic acid detection relies on DNA amplification before using Cas12a enzymes, which significantly hinders the ability to perform rapid point-of-care testing. The lack of rapidity is due to the fact that target-specific activation of Cas12a enzymes, referred herein as cis-cleavage, is a single turnover event in which the number of activated enzyme complexes is, at most, equal to the number of copies of the target nucleic acids of interest in the sample. Once a ribonucleoprotein (RNP) complex is activated after completion of cis-cleavage, the RNP complex initiates rapid non-specific trans-endonuclease activity, which is a multi-turnover event. Some currently available methods use trans-cleavage to cleave fluorescent reporters that are initially quenched to generate a signal, thereby indicating the presence of a cis-cleavage event—the target nucleic acid. However, the K_catof activated Cas12a complex is 17/sec and 3/sec for dsDNA and ssDNA targets, respectively. Therefore, for less than 10,000 target copies, the number of reporters cleaved is not sufficient to generate a signal in less than 60 minutes. Hence, all current technologies rely on DNA amplification to first generate billions of target copies to activate a proportional number of ribonucleoprotein complexes to generate a detectable signal in 30-60 minutes.

The present disclosure describes a nucleic acid-guided nuclease cascade assay that can detect one or more target nucleic acids of interest (e.g., DNA, RNA and/or cDNA) at attamolar (aM) (or lower) limits in about 10 minutes or less without the need for amplifying the target nucleic acid(s) of interest, thereby avoiding the drawbacks of multiplex amplification, such as primer-dimerization. As described in detail below, the nucleic acid-guided nuclease cascade assays utilize signal amplification mechanisms comprising various components including nucleic acid-guided nucleases, guide RNAs (gRNAs), blocked nucleic acid molecules or blocked primer molecules, reporter moieties, and, in some embodiments, polymerases. A particularly advantageous feature of the cascade assay is that, with the exception of the gRNA (gRNA1) in RNP1, the cascade assay components stay the same no matter what target nucleic acid(s) of interest are being detected. In this sense, the cascade assay is modular.

FIG. 1A provides a simplified diagram demonstrating a prior art method (1) of a nucleic acid-guided nuclease detection assay where target nucleic acids of interest from a sample must be amplified in order to be detected. First, assuming the presence of a target nucleic acid of interest in a sample, the target nucleic acid of interest (2) is amplified to produce many copies of the target nucleic acid of interest (4). The detection assay is initiated (step 2) when the target nucleic acid of interest (4) is combined with and binds to a pre-assembled ribonucleoprotein complex (6), which is part of a reaction mix. The ribonucleoprotein complex (6) comprises a guide RNA (gRNA) and a nucleic acid-guided nuclease, where the gRNA is integrated with the nucleic acid-guided nuclease. The gRNA, which includes a sequence complementary to the target nucleic acid of interest, guides the RNP complex to the target nucleic acid of interest and hybridizes to it thereby activating the ribonucleoprotein complex (6). The nucleic acid-guided nuclease exhibits (i.e., possesses) both cis- and trans-cleavage activity, where trans-cleavage activity is initiated by cis-cleavage activity. Cis-cleavage activity occurs as the target nucleic acid of interest binds to the gRNA and is cleaved by the nucleic acid guided nuclease (i.e., activation). Once cis-cleavage of the target nucleic acid of interest is initiated, trans-cleavage activity is triggered, where trans-cleavage activity is indiscriminate, non-sequence-specific cleavage of nucleic acid molecules in the sample and is a multi-turnover event.

In step 3, the trans-cleavage activity triggers activation of reporter moieties (12) that are present in the reaction mix. The reporter moieties (12) may be a synthetic molecule linked or conjugated to a quencher (14) and a fluorophore (16) such as, for example, a probe with a dye label (e.g., FAM or FITC) on the 5′ end and a quencher on the 3′ end. The quencher (14) and fluorophore (16) typically are about 20-30 bases apart or less for effective quenching via fluorescence resonance energy transfer (FRET). Reporter moieties (12) are described in greater detail below. As more activated ribonucleoprotein complexes (6) are activated (6→8), more trans-cleavage activity of the nucleic acid-guided nuclease in the ribonucleoprotein complex is activated and more reporter moieties are activated (where here, “activated” means unquenched); thus, the binding of the target nucleic acid of interest (4).

As noted above, the downside to the prior art, currently available state-of-the-art nucleic acid-guided nuclease detection assays is that these detection assays rely on DNA amplification, which, in addition to issues with multiplexing, significantly hinders the ability to perform rapid point-of-care testing. The lack of rapidity is due to cis-cleavage of a target nucleic acid of interest being a single turnover event in which the number of activated enzyme complexes is, at most, equal to the number of copies of the target nucleic acids of interest in the sample. Once the ribonucleoprotein complex is activated after completion of cis-cleavage, trans-cleavage activity of the reporter moieties that are initially quenched is generated. However, the K_catof, e.g., activated Cas12a complex is 17/sec and 3/sec for dsDNA and ssDNA targets, respectively. Therefore, for less than 10,000 target copies, the number of reporters cleaved is not sufficient to generate a signal in less than 30-60 minutes.

FIG. 1B provides a simplified diagram demonstrating a method (100) of a nucleic acid-guided nuclease cascade assay. The cascade assay is initiated when the target nucleic acid of interest (104) binds to and activates a first pre-assembled ribonucleoprotein complex (RNP1) (102). A ribonucleoprotein complex comprises a guide RNA (gRNA) and a nucleic acid-guided nuclease, where the gRNA is integrated with the nucleic acid-guided nuclease. The gRNA, which includes a sequence complementary to the target nucleic acid of interest, guides an RNP complex to the target nucleic acid of interest and hybridizes to it. Typically, preassembled RNP complexes are employed in the reaction mix—as opposed to separate nucleic acid-guided nucleases and gRNAs—to facilitate rapid detection of the target nucleic acid(s) of interest.

“Activation” of RNP1 refers to activating trans-cleavage activity of the nucleic acid-guided nuclease in RNP1 (106) by first initiating cis-cleavage where the target nucleic acid of interest is cut by the nucleic acid-guided nuclease. The cis-cleavage activity initiates trans-cleavage activity (i.e., multi-turnover activity) of the nucleic acid-guided nuclease, where trans-cleavage is indiscriminate, non-sequence-specific cutting of nucleic acid molecules by the nucleic acid-guided nuclease of RNP1 (102). This trans-cleavage activity triggers activation of blocked ribonucleoprotein complexes (RNP2s) (108) in various ways, which are described in detail below. Each newly activated RNP2 (110) activates more RNP2 (108→110), which in turn cleave reporter moieties (112). The reporter moieties (112) may be a synthetic molecule linked or conjugated to a quencher (114) and a fluorophore (116) such as, for example, a probe with a dye label (e.g., FAM or FITC) on the 5′ end and a quencher on the 3′ end. The quencher (114) and fluorophore (116) can be about 20-30 bases apart or less for effective quenching via fluorescence resonance energy transfer (FRET). Reporter moieties also are described in greater detail below. As more RNP2s are activated (108→110), more trans-cleavage activity is activated and more reporter moieties are activated (where here, “activated” means unquenched); thus, the binding of the target nucleic acid of interest (104) to RNP1 (102) initiates what becomes a cascade of signal production (120), which increases exponentially. The cascade assay thus comprises a single turnover event that triggers a multi-turnover event that then triggers another multi-turnover event. As described below in relation to FIG. 4, the reporter moieties (112) may be provided as molecules that are separate from the other components of the nucleic acid-guided nuclease cascade assay, or the reporter moieties may be covalently or non-covalently linked to the blocked nucleic acid molecules or synthesized activating molecules (i.e., the target molecules for the RNP2). The various components common to the embodiments of the cascade assay and methods described herein are described below.

Target Nucleic Acids of Interest

The target nucleic acid of interest may be a DNA, RNA, or cDNA molecule. Target nucleic acids of interest may be isolated from a sample or organism by standard laboratory techniques or may be synthesized by standard laboratory techniques (e.g., RT-PCR). In some embodiments, the target nucleic acids of interest are identified in a sample, such as a biological sample from a subject or an environmental sample (e.g., water or soil). Non-limiting examples of biological samples include blood, serum, plasma, saliva, mucus, a nasal swab, a buccal swab, a cell, a cell culture, and tissue. The source of the sample could be any mammal, such as, but not limited to, a human, primate, monkey, cat, dog, mouse, pig, cow, horse, sheep, and bat. Samples may also be obtained from any other source, such as air, water, soil, surfaces, food, beverages, nutraceuticals, clinical sites or products, industrial sites and products, cosmetics, personal care products, pharmaceuticals, medical devices, agricultural equipment and sites, and commercial samples.

In some embodiments, the target nucleic acid of interest is from an infectious agent (e.g., a bacteria, protozoan, insect, worm, virus, or fungus). As a non-limiting example, the target nucleic acid of interest could be one or more nucleic acid molecules from bacteria, such as Bordetella parapertussis, Bordetella pertussis, Chlamydia pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, Acinetobacter calcoaceticus-baumannii complex, Bacteroides fragilis, Enterobacter cloacae complex, Escherichia coli, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae group, Moraxella catarrhalis, Proteus spp., Salmonella enterica, Serratia marcescens, Haemophilus influenzae, Neisseria meningitidis, Pseudomonas aeruginosa, Stenotrophomonas maltophilia, Enterococcus faecalis, Enterococcus faecium, Listeria monocytogenes, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Chlamydia tracomatis, Neisseria gonorrhoeae, Syphilis (Treponema pallidum), Ureaplasma urealyticum, Mycoplasma genitalium, and/or Gardnerella vaginalis. As a non-limiting example, the target nucleic acid of interest could be one or more nucleic acid molecules from a virus, such as adenovirus, coronavirus HKU1, coronavirus NL63, coronavirus 229E, coronavirus OC43, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human metapneumovirus, human rhinovirus, enterovirus, influenza A, influenza A/H1, influenza A/H3, influenza A/H1-2009, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, respiratory syncytial virus, herpes simplex virus 1, herpes simplex virus 2, human immunodeficiency virus (HIV), human papillomavirus, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), and/or human parvovirus B19 (B19V). Also, as a non-limiting example, the target nucleic acid of interest could be one or more nucleic acid molecules from a fungus, such as Candida albicans, Candida auris, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis, Cryptococcus neoformans, and/or Cryptococcus gattii. As another non-limiting example, the target nucleic acid of interest could be one or more nucleic acid molecules from a protozoan, such as Trichomonas vaginalis. In some embodiments, other target nucleic acids of interest may be for non-infectious conditions, e.g., to be used for genotyping. Other target nucleic acids of interest and samples are described herein.

The cascade assays described herein are particularly well-suited for syndromic testing. Syndromic testing allows simultaneous testing for multiple causative agents that cause similar symptoms. Syndromic testing allows rapid triage of patients, such as those needing emergency care, those amenable to treatment with pharmaceutical agents, those needing to be quarantined, etc. In syndrome testing, multiple target nucleic acids of interest are pooled into a single reaction, and this process may be repeated in multiple, separate reactions. A positive result in one of the reactions indicates that one of the target nucleic acids of interest in that pool is present. Pools of two to 10,000 target nucleic acids of interest may be employed, e.g., 2-1000, 2-100, 2-50, or 2-10. Further testing may be used to identify the specific member of the pool, if warranted. Syndromic testing allows the rapid triage of patients with the ability to focus further care rapidly.

While the methods described herein do not require the target nucleic acid of interest to be DNA (and in fact it is specifically contemplated that the target nucleic acid of interest may be RNA), it is understood by those in the field that a reverse transcription step to convert target RNA to cDNA may be performed prior to or while contacting the biological sample with the composition.

Nucleic Acid-Guided Nucleases

The cascade assays comprise nucleic acid-guided nucleases in the reaction mix, either provided as a protein, a coding sequence for the protein, or in a ribonucleoprotein (RNP) complex. In some embodiments, the one or more nucleic acid-guided nucleases in the reaction mix may be, for example, a Cas endonuclease. Any nucleic acid-guided nuclease having both cis- and trans-endonuclease activity may be employed, and the same nucleic acid-guided nuclease may be used for both RNPs or different nucleic acid-guided nucleases may be used in RNP1 and RNP2. Note that trans-cleavage activity is not triggered unless and until cis-cleavage activity (i.e., sequence specific activity) is initiated. Nucleic acid-guided nucleases include Type V and Type VI nucleic acid-guided nucleases, as well as nucleic acid-guided nucleases that comprise a RuvC nuclease domain or a RuvC-like nuclease domain but lack an HNH nuclease domain. Nucleic acid-guided nucleases with these properties are reviewed in Makarova and Koonin, Methods Mol. Biol., 1311:47-75 (2015) and Koonin, et al., Current Opinion in Microbiology, 37:67-78 (2020) and updated databases of nucleic acid-guided nucleases and nuclease systems that include newly-discovered systems include BioGRID ORCS (orcs:thebiogrid.org); GenomeCRISPR (genomecrispr.org); Plant Genome Editing Database (plantcrispr.org) and CRISPRCasFinder (crispercas.i2bc.paris-saclay.fr).

The type of nucleic acid-guided nuclease utilized in the method of detection depends on the type of target nucleic acid of interest to be detected. For example, a DNA nucleic acid-guided nuclease (e.g., a Cas12a, Cas14a, or Cas3) should be utilized if the target nucleic acid of interest is a DNA molecule, and an RNA nucleic acid-guided nuclease (e.g., Cas13a or Cas12g) should be utilized if the target nucleic acid of interest is an RNA molecule. Exemplary nucleic acid-guided nucleases include, but are not limited to, Cas RNA-guided DNA endonucleases, such as Cas3, Cas12a (e.g., AsCas12a, LbCas12a), Cas12b, Cas12c, Cas12d, Cas12e, Cas14, Cas12h, Cas12i, and Cas12j; Cas RNA-guided RNA endonucleases, such as Cas13a (LbaCas13, LbuCas13, LwaCas13), Cas13b (e.g., CccaCas13b, PsmCas13b), and Cas12g; and any other nucleic acid (DNA, RNA, or cDNA) targeting nucleic acid-guided nuclease with cis-cleavage activity and collateral trans-cleavage activity. In some embodiments, the nucleic acid-guided nuclease is a Type V CRISPR-Cas nuclease, such as a Cas12a, Cas13a, or Cas14a. In some embodiments, the nucleic acid-guided nuclease is a Type I CRISPR-Cas nuclease, such as Cas3. Type II and Type VI nucleic acid-guided nucleases may also be employed.

Guide RNA (gRNA)

The present disclosure detects a target nucleic acid of interest via a reaction mixture containing at least two gRNAs. Suitable guide RNAs include at least one crRNA region to enable specificity in every reaction. The gRNA of RNP1 is specific to a target nucleic acid of interest, and the gRNA of RNP2 is specific to an unblocked nucleic acid or a synthesized activating molecule (both described in detail herein). As will be clear given the description below, an advantageous feature of the cascade assay is that, with the exception of the gRNA in the RNP1 (i.e., the gRNA specific to the target nucleic acid of interest), the cascade assay components can stay the same no matter what target nucleic acid(s) of interest are being detected. In this sense, the cascade assay is modular.

Like the nucleic acid-guided nuclease, the gRNA may be provided in the cascade assay reaction mix in a preassembled RNP, as an RNA molecule, or may also be provided as a DNA sequence to be transcribed, in, e.g., a vector backbone. If provided as a gRNA molecule, the gRNA sequence may include multiple endoribonuclease recognition sites (e.g., Csy4) for multiplex processing. Alternatively, if provided as a DNA sequence to be transcribed, an endoribonuclease recognition site is encoded between neighboring gRNA sequences and more than one gRNA can be transcribed in a single expression cassette. Direct repeats can also serve as endoribonuclease recognition sites for multiplex processing. Guide RNAs are generally about 20 nucleotides to about 300 nucleotides in length and may contain a spacer sequence containing a plurality of bases and complementary to a protospacer sequence in the target sequence. The gRNA spacer sequence may be 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 98%, 99%, or more complementary to its intended target nucleic acid of interest.

The gRNA of RNP1 is capable of complexing with the nucleic acid-guided nuclease to perform cis-cleavage of a target nucleic acid of interest (e.g., a DNA or RNA), which triggers non-sequence specific trans-cleavage of other molecules in the reaction mix. Guide RNAs include any polynucleotide sequence having sufficient complementarity with a target nucleic acid of interest (or target sequences generated by unblocking blocked nucleic acid molecules or target sequences generated by synthesizing activating molecules as described below). Target sequences may include a protospacer-adjacent motif (PAM), and, following gRNA binding, the nucleic acid-guided nuclease induces a double-stranded break either inside or outside the protospacer region of the target sequence.

In some embodiments, the gRNA (e.g., of RNP1) is an exo-resistant circular molecule that can include several DNA bases between the 5′ end and the 3′ end of a natural guide RNA and is capable of binding a target sequence. The length of the circularized guide for RNP1 can be such that the circular form of guide can be complexed with a nucleic acid-guided nuclease to form a modified RNP1 which can still retain its cis-cleavage (specific) and trans-cleavage (non-specific) nuclease activity.

In any of the foregoing embodiments, the gRNA may be a modified or non-naturally occurring nucleic acid molecule. In some embodiments, the gRNAs of the disclosure may further contain a locked nucleic acid (LNA), a bridged nucleic acid (BNA), and/or a peptide nucleic acid (PNA). By way of further example, a modified nucleic acid molecule may contain a modified or non-naturally occurring nucleoside, nucleotide, and/or internucleoside linkage, such as a 2′-O-methyl (2′-O-Me) modified nucleoside, a 2′-fluoro (2′-F) modified nucleoside, and a phosphorothioate (PS) bond, or any other nucleic acid molecule modifications described herein.

Ribonucleoprotein (RNP) Complex

As described above, although the assay “reaction mix” may comprise separate nucleic acid-guided nucleases and gRNAs (or coding sequences therefor), the cascade assays preferably comprise preassembled ribonucleoprotein complexes (RNPs) in the reaction mix, allowing for faster detection kinetics. The present cascade assay employs at least two types of RNP complexes, RNP1 and RNP2, each type containing a nucleic acid-guided nuclease and a gRNA. RNP1 and RNP2 may comprise the same nucleic acid-guided nuclease or may comprise different nucleic acid-guided nucleases; however, the gRNAs in RNP1 and RNP2 are different and are configured to detect different nucleic acids. In some embodiments, the reaction mixture contains about 1 fM to about 10 μM of a given RNP1, or about 1 pM to about 1 μM of a given RNP1, or about 10 pM to about 500 pM of a given RNP1. In some embodiments the reaction mixture contains about 6×10⁴to about 6×10¹²complexes per microliter (μl) of a given RNP1, or about 6×10⁶to about 6×10¹⁰complexes per microliter (μl) of a given RNP1. In some embodiments, the reaction mixture contains about 1 fM to about 1 mM of a given RNP2, or about 1 pM to about 500 μM of a given RNP2, or about 10 pM to about 100 μM of a given RNP2. In some embodiments the reaction mixture contains about 6×10⁴to about 6×10¹⁴complexes per microliter (μl) of a given RNP2 or about 6×10⁶to about 6×10¹²complexes per microliter (μl) of a given RNP2. (See Example II below describing preassembling RNPs and Examples V-IX below describing various cascade assay conditions, including performing the cascade assay at room temperature.)

In any of the embodiments of the disclosure, the reaction mixture includes 1 to about 1,000 different RNP1s (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 27, 28, 19, 20, 21, 22, 23, 24, 25, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, or 1,0000 RNP1s), where different RNP1s comprise a different gRNA (or crRNA thereof) polynucleotide sequence. For example, a reaction mixture designed for syndromic testing by definition comprises more than one unique RNP1-gRNA (or RNP1-crRNA) ribonucleoprotein complex for the purpose of detecting more than one target nucleic acid of interest. More than one RNP1 may also be present for the purpose of targeting more than one target nucleic acid of interest from a single organism or condition.

In any of the foregoing embodiments, the gRNA of RNP1 may be homologous or heterologous, relative to the gRNA of other RNP1 present in the reaction mixture. A homologous mixture of RNP1 gRNAs has a number of gRNAs with the same nucleotide sequence, whereas a heterologous mixture of RNP1 gRNAs has multiple gRNAs with different nucleotide sequences (e.g., gRNAs targeting different loci, genes, variants, and/or microbial species). Therefore, the disclosed methods of identifying one or more target nucleic acids of interest may include a reaction mixture containing more than two heterologous gRNAs, more than three heterologous gRNAs, more than four heterologous gRNAs, more than five heterologous gRNAs, more than six heterologous gRNAs, more than seven heterologous gRNAs, more than eight heterologous gRNAs, more than nine heterologous gRNAs, more than ten heterologous gRNAs, more than eleven heterologous gRNAs, more than twelve heterologous gRNAs, more than thirteen heterologous gRNAs, more than fourteen heterologous gRNAs, more than fifteen heterologous gRNAs, more than sixteen heterologous gRNAs, more than seventeen heterologous gRNAs, more than eighteen heterologous gRNAs, more than nineteen heterologous gRNAs, more than twenty heterologous gRNAs, more than twenty-one heterologous gRNAs, more than twenty-three heterologous gRNAs, more than twenty-four heterologous gRNAs, or more than twenty-five heterologous gRNAs. Such a heterologous mixture of RNP1 gRNAs in a single reaction enables the capability of syndromic testing.

As a first non-limiting example of a heterologous mixture of RNP1 gRNAs, the reaction mixture may contain: a number of RNP1s having a gRNA targeting parainfluenza virus 1; a number of RNP1s having a gRNA targeting human metapneumovirus; a number of RNP1s having a gRNA targeting human rhinovirus; a number of RNP1s having a gRNA targeting human enterovirus; and a number of RNP1s having a gRNA targeting coronavirus HKU1. As a second non-limiting example of a heterologous mixture of RNP1 gRNAs, the reaction mixture may contain: a number of RNP1s containing a gRNA targeting two or more SARS-Co-V-2 variants, e.g., B.1.1.7, B.1.351, P.1, B.1.617.2, BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 and subvariants thereof.

Reporter Moieties

The cascade assay detects a target nucleic acid of interest via detection of a signal generated in the reaction mix by a reporter moiety. In some embodiments the detection of the target nucleic acid of interest occurs in about 10 minutes or less (e.g., 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 minute or less; e.g., FIGS. 6-9, and in some embodiments the detection of the target nucleic acid molecule is in about 5 minutes or less (e.g., 5, 4, 3, 2, or 1 minute or less; e.g., FIGS. 10-14). In some embodiments, the detection of the target nucleic acid molecule is in about 1 minute (e.g., FIGS. 10-13).

Depending on the type of reporter moiety used, trans- and/or cis-cleavage by the nucleic acid-guided nuclease in RNP2 releases a signal. In some embodiments, trans-cleavage of stand-alone (e.g., not bound to any blocked nucleic acid molecules) reporter moieties may generate signal changes at rates that are proportional to the cleavage rate, as new RNP2s are activated over time (shown in FIG. 1B and at top of FIG. 4). Trans-cleavage by either an activated RNP1 or an activated RNP2 may release a signal. In alternative embodiments, the reporter moiety may be bound to the blocked nucleic acid molecule, where trans-cleavage of the blocked nucleic acid molecule and conversion to an unblocked nucleic acid molecule may generate signal changes at rates that are proportional to the cleavage rate, as new RNP2s are activated over time, thus allowing for real time reporting of results (shown at FIG. 4, center). In yet another embodiment, the reporter moiety may be bound to a blocked nucleic acid molecule such that cis-cleavage following the binding of the RNP2 to an unblocked nucleic acid molecule releases a PAM distal sequence, which in turn generates a signal at rates that are proportional to the cleavage rate (shown at FIG. 4, bottom). In this case, activation of RNP2 by cis-(target specific) cleavage of the unblocked nucleic acid molecule directly produces a signal, rather than producing a signal via indiscriminate trans-cleavage activity. Alternatively. or in addition, the reporter moiety may be bound to the gRNA.

The reporter moiety may be a synthetic molecule linked or conjugated to a reporter and quencher such as, for example, a TaqMan probe with a dye label (e.g., FAM or FITC) on the 5′ end and a quencher on the 3′ end. The reporter and quencher may be about 20-30 bases apart or less for effective quenching via fluorescence resonance energy transfer (FRET). Alternatively, signal generation may occur through different mechanisms. Other detectable moieties, labels, or reporters can also be used to detect a target nucleic acid of interest as described herein. Reporter moieties can be labeled in a variety of ways, including direct or indirect attachment of a detectable moiety such as a fluorescent moiety, hapten, or colorimetric moiety. Examples of detectable moieties include various radioactive moieties, enzymes, prosthetic groups, fluorescent markers, luminescent markers, bioluminescent markers, metal particles, and protein-protein binding pairs, e.g., protein-antibody binding pairs. Examples of fluorescent moieties include, but are not limited to, yellow fluorescent protein (YFP), green fluorescence protein (GFP), cyan fluorescence protein (CFP), umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, cyanines, dansyl chloride, phycocyanin, and phycoerythrin. Examples of bioluminescent markers include, but are not limited to, luciferase (e.g., bacterial, firefly, click beetle and the like), luciferin, and aequorin. Examples of enzyme systems having visually detectable signals include, but are not limited to, galactosidases, glucuronidases, phosphatases, peroxidases, and cholinesterases. Identifiable markers also include radioactive elements such as ¹²⁵1, ³⁵S, ¹⁴C, or ³H.

The methods used to detect the generated signal will depend on the reporter moiety or moieties used. For example, a radioactive label can be detected using a scintillation counter, photographic film as in autoradiography, or storage phosphor imaging. Fluorescent labels can be detected by exciting the fluorochrome with the appropriate wavelength of light and detecting the resulting fluorescence. The fluorescence can be detected visually, by means of photographic film, by the use of electronic detectors such as charge coupled devices (CCDs) or photomultipliers and the like. Enzymatic labels can be detected by providing the appropriate substrates for the enzyme and detecting the resulting reaction product. Simple colorimetric labels can be detected by observing the color associated with the label. When pairs of fluorophores are used in an assay, fluorophores are chosen that have distinct emission patterns (wavelengths) so that they can be easily distinguished. In some embodiments, the signal can be detected by lateral flow assays (LFAs). Lateral flow tests are simple devices intended to detect the presence or absence of a target nucleic acid of interest in a sample. LFAs can use nucleic acid molecules conjugated nanoparticles (often gold, e.g., RNA-AuNPs or DNA-AuNPs) as a detection probe, which hybridizes to a complementary target sequence. (See FIGS. 5A and 5B and the description thereof below.) The classic example of an LFA is the home pregnancy test.

Single-stranded nucleic acid reporter moieties such as ssDNA reporter moieties or RNA molecules can be introduced to show a signal change proportional to the cleavage rate, which increases with every new activated RNP2 complex over time. In some embodiments and as described in detail below, single-stranded nucleic acid reporter moieties can also be embedded into the blocked nucleic acid molecules for real time reporting of results.

For example, the method of detecting a target nucleic acid molecule in a sample using a cascade assay as described herein can involve contacting the reaction mix with a labeled detection ssDNA containing a fluorescent resonance energy transfer (FRET) pair, a quencher/phosphor pair, or both. A FRET pair consists of a donor chromophore and an acceptor chromophore, where the acceptor chromophore may be a quencher molecule. FRET pairs (donor/acceptor) suitable for use include, but are not limited to, EDANS/fluorescein, IAEDANS/fluorescein, fluorescein/tetramethylrhodamine, fluorescein/Cy 5, IEDANS/DABCYL, fluorescein/QSY-7, fluorescein/LC Red 640, fluorescein/Cy 5.5, Texas Red/DABCYL, BODIPY/DABCYL, Lucifer yellow/DABCYL, coumarin/DABCYL, and fluorescein/LC Red 705. In addition, a fluorophore/quantum dot donor/acceptor pair can be used. EDANS is (5-((2-Aminoethyl)amino)naphthalene-1-sulfonic acid); IAEDANS is 5-({2-[(iodoacetyl)amino]ethyl}amino)naphthalene-1-sulfonic acid); DABCYL is 4-(4-dimethylaminophenyl)diazenylbenzoic acid. Useful quenchers include, but are not limited to, DABCYL, QSY 7 and QSY 33.

In any of the foregoing embodiments, the reporter moiety may comprise one or more modified nucleic acid molecules, containing a modified nucleoside or nucleotide. In some embodiments the modified nucleoside or nucleotide is chosen from 2′-O-methyl (2′-O-Me) modified nucleoside, a 2′-fluoro (2′-F) modified nucleoside, and a phosphorothioate (PS) bond, or any other nucleic acid molecule modifications described below.

Nucleic Acid Modifications

For any of the nucleic acid molecules described herein (e.g., blocked nucleic acid molecules, blocked primer molecules, gRNAs, template molecules, synthesized activating molecules, and reporter moieties), the nucleic acid molecules may be used in a wholly or partially modified form. Typically, modifications to the blocked nucleic acids, gRNAs, template molecules, reporter moieties, and blocked primer molecules described herein are introduced to optimize the molecule's biophysical properties (e.g., increasing endonuclease resistance and/or increasing thermal stability). Modifications typically are achieved by the incorporation of, for example, one or more alternative nucleosides, alternative sugar moieties, and/or alternative internucleoside linkages.

For example, one or more of the cascade assay components may include one or more of the following nucleoside modifications: 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (—C═C—CH₃) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine, and/or 3-deazaguanine and 3-deazaadenine. The nucleic acid molecules described herein (e.g., blocked nucleic acid molecules, blocked primer molecules, gRNAs, reporter molecules, synthesized activating molecules, and template molecules) may also include nucleobases in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine, and/or 2-pyridone. Further modification of the nucleic acid molecules described herein may include nucleobases disclosed in U.S. Pat. No. 3,687,808; Kroschwitz, ed. The Concise Encyclopedia of Polymer Science and Engineering, New York, John Wiley & Sons, 1990, pp. 858-859; Englisch, et al., Angewandte Chemie, 30:613 (1991); and Sanghvi, Chapter 16, Antisense Research and Applications, CRC Press, Gait, ed., 1993, pp. 289-302.

In addition to or as an alternative to nucleoside modifications, the cascade assay components may comprise 2′ sugar modifications, including 2′-O-methyl (2′-O-Me), 2′-methoxyethoxy (2′-O—CH₂CH₂OCH₃, also known as 2′-O-(2-methoxyethyl) or 2′-MOE), 2′-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂group, also known as 2′-DMAOE, and/or 2′-dimethylaminoethoxyethoxy (also known in the art as 2′-O-dimethylamino-ethoxy-ethyl or 2′-DMAEOE), i.e., 2′-O—CH₂OCH₂N(CH₃)₂. Other possible 2′-modifications that can modify the nucleic acid molecules described herein (i.e., blocked nucleic acids, gRNAs, synthesized activating molecules, reporter molecules, and blocked primer molecules) may include all possible orientations of OH; F; O-, S-, or N-alkyl (mono- or di-); O-, S-, or N-alkenyl (mono- or di-); O-, S- or N-alkynyl (mono- or di-); or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C1 to C10 alkyl or C2 to C10 alkenyl and alkynyl. Other potential sugar substituent groups include, e.g., aminopropoxy (—OCH₂CH₂CH₂NH₂), allyl (—CH₂—CH═CH₂), —O-allyl (—O—CH₂—CH═CH₂) and fluoro (F). 2′-sugar substituent groups may be in the arabino (up) position or ribo (down) position. In some embodiments, the 2′-arabino modification is 2′-F. Similar modifications may also be made at other positions on the interfering RNA molecule, particularly the 3′ position of the sugar on the 3′ terminal nucleoside or in 2′-5′ linked oligonucleotides and the 5′ position of 5′ terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.

Finally, modifications to the cascade assay components may comprise internucleoside modifications such as phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3′-alkylene phosphonates, 5′-alkylene phosphonates, phosphinates, phosphoramidates including 3′-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates, and boranophosphates having normal 3′-5′ linkages, 2′-5′ linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3′ to 3′, 5′ to 5′ or 2′ to 2′ linkage.

The Cascade Assay Employing Blocked Nucleic Acids

FIG. 1B depicts the cascade assay generally. A specific embodiment of the cascade assay utilizing blocked nucleic acids is depicted in FIG. 2A. In this embodiment, a blocked nucleic acid is used to prevent the activation of RNP2 in the absence of a target nucleic acid of interest. The method in FIG. 2A begins with providing the cascade assay components RNP1 (201), RNP2 (202) and blocked nucleic acid molecules (203). RNP1 (201) comprises a gRNA specific for a target nucleic acid of interest and a nucleic acid-guided nuclease (e.g., Cas 12a or Cas 14 for a DNA target nucleic acid of interest or a Cas 13a for an RNA target nucleic acid of interest) and RNP2 (202) comprises a gRNA specific for an unblocked nucleic acid molecule and a nucleic acid-guided nuclease (again, Cas 12a or Cas 14 for a DNA unblocked nucleic acid molecule or a Cas 13a for an RNA unblocked nucleic acid molecule). As described above, the nucleic acid-guided nucleases in RNP1 (201) and RNP2 (202) can be the same or different depending on the type of target nucleic acid of interest and unblocked nucleic acid molecule. What is key, however, is that the nucleic acid-guided nucleases in RNP1 and RNP2 may be activated to have trans-cleavage activity following initiation of cis-cleavage activity.

In a first step, a sample comprising a target nucleic acid of interest (204) is added to the cascade assay reaction mix. The target nucleic acid of interest (204) combines with and activates RNP1 (205) but does not interact with or activate RNP2 (202). Once activated, RNP1 cuts the target nucleic acid of interest (204) via sequence-specific cis-cleavage, which then activates non-specific trans-cleavage of other nucleic acids present in the reaction mix, including the blocked nucleic acid molecules (203). At least one of the blocked nucleic acid molecules (203) becomes an unblocked nucleic acid molecule (206) when the blocking moiety (207) is removed. As described below, “blocking moiety” may refer to nucleoside modifications, topographical configurations such as secondary structures, and/or structural modifications.

Once at least one of the blocked nucleic acid molecules (203) is unblocked, the unblocked nucleic acid molecule (206) can then interact with and activate an RNP2 (208) complex. Because the nucleic acid-guided nucleases in the RNP1x (205) and RNP2x (208) have both cis- and trans-cleavage activity, more blocked nucleic acid molecules (203) become unblocked nucleic acid molecules (206) triggering activation of more RNP2 (208) complexes and more trans-cleavage activity in a cascade. FIG. 2A at bottom depicts the concurrent activation of reporter moieties. Intact reporter moieties (209) comprise a quencher (210) and a fluorophore (211) linked by a nucleic acid sequence. As described above in relation to FIG. 1B, the reporter moieties are also subject to trans-cleavage by activated RNP1 (205) and RNP2 (208). The intact reporter moieties (209) become activated reporter moieties (212) when the quencher (210) is separated from the fluorophore (211), emitting a fluorescent signal (213). Signal strength increases rapidly as more blocked nucleic acid molecules (203) become unblocked nucleic acid molecules (206) triggering cis-cleavage activation of more RNP2s (208) and thus more trans-cleavage activity of the reporter moieties (209). Again, here the reporter moieties are shown as separate molecules from the blocked nucleic acid molecules, but other configurations may be employed and are discussed in relation to FIG. 4. One particularly advantageous feature of the cascade assay is that, with the exception of the gRNA in the RNP1 (gRNA1), the cascade assay components are modular in the sense that the components stay the same no matter what target nucleic acid(s) of interest are being detected.

FIG. 2B is a diagram showing an exemplary blocked nucleic acid molecule (220) and an exemplary technique for unblocking the blocked nucleic acid molecules described herein. A blocked single-stranded or double-stranded, circular or linear, DNA or RNA molecule (220) comprising a target strand (222) may contain a partial hybridization with a complementary non-target strand nucleic acid molecule (224) containing unhybridized and cleavable secondary loop structures (226) (e.g., hairpin loops, tetraloops, pseudoknots, junctions, kissing hairpins, internal loops, bulges, and multibranch loops). Trans-cleavage of the loops by, e.g., activated RNP1s or RNP2s, generates short strand nucleotide sequences (228) which, because of the short length and low melting temperature T_m, can dehybridize at room temperature (e.g., 15°-25° C.), thereby unblocking the blocked nucleic acid molecule (220) to create an unblocked nucleic acid molecule (230), enabling the internalization of the unblocked nucleic acid molecule (230) (target strand) into an RNP2, leading to RNP2 activation.

A blocked nucleic acid molecule may be single-stranded or double-stranded, circular or linear, and may further contain a partially hybridized nucleic acid sequence containing cleavable secondary loop structures, as exemplified by “L” in FIGS. 2C-2E. Such blocked nucleic acids typically have a low binding affinity, or high dissociation constant (K_d) in relation to binding to RNP2 and may be referred to herein as a high K_dnucleic acid molecule. In the context of the present disclosure, the binding of blocked or unblocked nucleic acid molecules or blocked or unblocked primer molecules to RNP2, low K_dvalues range from about 100 fM to about 1 aM or lower (e.g., 100 zM) and high K_dvalues are in the range of 100 nM to about 100 μM (10 mM) and thus are about 10⁵-, 10⁶-, 10⁷-, 10⁸-, 10⁹- to 10¹⁰-fold or higher as compared to low K_dvalues.

The blocked nucleic acid molecules (high K_dmolecules) described herein can be converted into unblocked nucleic acid molecules (low K_dmolecules—also in relation to binding to RNP2) via cleavage of nuclease-cleavable regions (e.g., via active RNP1s and RNP2s). The unblocked nucleic acid molecule has a higher binding affinity for the gRNA in the RNP2 than does the blocked nucleic acid molecule, although there may be some “leakiness” where some blocked nucleic acid molecules are able to interact with the gRNA in the RNP2. However, an unblocked nucleic acid molecule has a substantially higher likelihood than a blocked nucleic acid molecule to hybridize with the gRNA of RNP2.

Once the unblocked nucleic acid molecule is bound to RNP2, the RNP2 activation triggers trans-cleavage activity, which in turn leads to more RNP2 activation by further cleaving blocked nucleic acid molecules, resulting in a positive feedback loop.

In embodiments where blocked nucleic acid molecules are linear and/or form a secondary structure, the blocked nucleic acid molecules may be single-stranded (ss) or double-stranded (ds) and contain a first nucleotide sequence and a second nucleotide sequence. The first nucleotide sequence has sufficient complementarity to hybridize to a gRNA of RNP2, and the second nucleotide sequence does not. The first and second nucleotide sequences of a blocked nucleic acid molecule may be on the same nucleic acid molecule (e.g., for single-strand embodiments) or on separate nucleic acid molecules (e.g., for double strand embodiments). Trans-cleavage (e.g., via RNP1 or RNP2) of the second nucleotide sequence converts the blocked nucleic acid molecule to a single-strand unblocked nucleic acid molecule. The unblocked nucleic acid molecule contains only the first nucleotide sequence, which has sufficient complementarity to hybridize to the gRNA of RNP2, thereby activating the trans-endonuclease activity of RNP2.

In some embodiments, the second nucleotide sequence at least partially hybridizes to the first nucleotide sequence, resulting in a secondary structure containing at least one loop (e.g., hairpin loops, tetraloops, pseudoknots, junctions, kissing hairpins, internal loops, bulges, and multibranch loops). Such loops block the nucleic acid molecule from binding or incorporating into an RNP complex in a manner to initiate trans cleavage (see, e.g., the exemplary structures in FIGS. 2C-2E).

In some embodiments, the blocked nucleic acid molecule may contain a protospacer adjacent motif (PAM) sequence, or partial PAM sequence, positioned between the first and second nucleotide sequences, where the first sequence is 5′ to the PAM sequence, or partial PAM sequence, (see FIG. 2G). Inclusion of a PAM sequence may increase the reaction kinetics internalizing the unblocked nucleic acid molecule into RNP2 and thus decrease the time to detection. In other embodiments, the blocked nucleic acid molecule does not contain a PAM sequence.

In some embodiments, the blocked nucleic acid molecules (i.e., high K_dnucleic acid molecules—in relation to binding to RNP2) of the disclosure may include a structure represented by Formula I (e.g., FIG. 2C), Formula II (e.g., FIG. 2D), Formula III (e.g., FIG. 2E), or Formula IV (e.g., FIG. 2F) wherein Formulas I-IV are in the 5′-to-3 direction:

A-(B-L)_J-C-M-T-D (Formula I);

- wherein A is 0-15 nucleotides in length;
- B is 4-12 nucleotides in length;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10;
- C is 4-15 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)_J-C and T-D are separate nucleic acid strands;
- T is 17-135 nucleotides in length (e.g., 17-100, 17-50, or 17-25) and comprises a sequence complementary to B and C; and
- D is 0-10 nucleotides in length and comprises a sequence complementary to A;

D-T-T′-C-(L-B)_J-A (Formula II);

- wherein D is 0-10 nucleotides in length;
- T-T′ is 17-135 nucleotides in length (e.g., 17-100, 17-50, or 17-25);
- T′ is 1-10 nucleotides in length and does not hybridize with T;
- C is 4-15 nucleotides in length and comprises a sequence complementary to T;
- L is 3-25 nucleotides in length and does not hybridize with T;
- B is 4-12 nucleotides in length and comprises a sequence complementary to T;
- J is an integer between 1 and 10;
- A is 0-15 nucleotides in length and comprises a sequence complementary to D;

T-D-M-A-(B-L)_J-C (Formula III);

- wherein T is 17-135 nucleotides in length (e.g., 17-100, 17-50, or 17-25);
- D is 0-10 nucleotides in length;
- M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L)_J-C are separate nucleic acid strands;
- A is 0-15 nucleotides in length and comprises a sequence complementary to D;
- B is 4-12 nucleotides in length and comprises a sequence complementary to T;
- L is 3-25 nucleotides in length;
- J is an integer between 1 and 10; and
- C is 4-15 nucleotides in length;

T-D-M-A-L_p-C (Formula IV);

- wherein T is 17-31 nucleotides in length (e.g., 17-100, 17-50, or 17-25);
- D is 0-15 nucleotides in length;
- M is 1-25 nucleotides in length;
- A is 0-15 nucleotides in length and comprises a sequence complementary to D; and
- L is 3-25 nucleotides in length;
- p is 0 or 1;
- C is 4-15 nucleotides in length and comprises a sequence complementary to T.
  In alternative embodiments of any of these molecules, T (or T-T′) can have a maximum length of 1000 nucleotides, e.g., at most 200, at most 135, at most 75, at most 50, or at most 25.

Nucleotide mismatches can be introduced in any of the above structures containing double strand segments (for example, where M is absent in Formula I or Formula III) to reduce the melting temperature (Tm) of the segment such that once the loop (L) is cleaved, the double strand segment is unstable and dehybridizes rapidly. The percentage of nucleotide mismatches of a given segment may vary between 0% and 50%; however, the maximum number of nucleotide mismatches is limited to a number where the secondary loop structure still forms. “Segments” in the above statement refers to A, B, and C. In other words, the number of hybridized bases can be less than or equal to the length of each double strand segment and vary based on number of mismatches introduced.

In any blocked nucleic acid molecule having the structure of Formula I, III, or IV, T will have sequence complementarity to a nucleotide sequence (e.g., a spacer sequence) within a gRNA of RNP2. The nucleotide sequence of T is to be designed such that hybridization of T to the gRNA of RNP2 activates the trans-nuclease activity of RNP2. In any blocked nucleic acid molecule having structure of Formula II, T-T′ will have sequence complementarity to a sequence (e.g., a spacer sequence) within the gRNA of RNP2. The nucleotide sequence of T-T′ is to be designed such that hybridization of T-T′ to the gRNA of RNP2 activates the trans-nuclease activity of RNP2. For T or T-T′, full complementarity to the gRNA is not necessarily required, provided there is sufficient complementarity to cause hybridization and trans-cleavage activation of RNP2.

Exemplary nucleotide sequences of blocked nucleic acid molecules (e.g., SEQ ID NOs: 14-1421) include those in Table 1.

TABLE 1

Nucleotide sequences of blocked nucleic
acid molecules.

	SEQ ID NO:	Sequence

	SEQ ID NO: 14	GATACTTTTTATTTTTTATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATATAGTATC

	SEQ ID NO: 15	GACACTTTTTATTTTTTATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATATAGTGTC

	SEQ ID NO: 16	GATACTTTTTATTTTTGATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATATCGTATC

	SEQ ID NO: 17	GGATCTTTTTATTTTTTATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATATAGATCC

	SEQ ID NO: 18	GACACTTTTTATTTTTGATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATATCGTGTC

	SEQ ID NO: 19	GGATCTTTTTATTTTTGATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATATCGATCC

	SEQ ID NO: 20	GCGTCTTTTTATTTTTTATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATATAGACGC

	SEQ ID NO: 21	GCGTCTTTTTATTTTTGATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATATCGACGC

	SEQ ID NO: 22	GTATACTTTTTATTTTTTATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATAGTATAC

	SEQ ID NO: 23	GTGATCTTTTTATTTTTTATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATAGATCAC

	SEQ ID NO: 24	GTATACTTTTTATTTTTGATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATCGTATAC

	SEQ ID NO: 25	GTATACTTTTTATTTTTGATATA
		TGTATATATTTTTATTTTTTAT
		ATACATATATCGTATAC

	SEQ ID NO: 26	GGATACTTTTTATTTTTTATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATAGTATCC

	SEQ ID NO: 27	GTGATCTTTTTATTTTTGATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATCGATCAC

	SEQ ID NO: 28	GTGATCTTTTTATTTTTGATATA
		TGTATATATTTTTATTTTTTAT
		ATACATATATCGATCAC

	SEQ ID NO: 29	GGATACTTTTTATTTTTGATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATCGTATCC

	SEQ ID NO: 30	GGATACTTTTTATTTTTGATATA
		TGTATATATTTTTATTTTTTAT
		ATACATATATCGTATCC

	SEQ ID NO: 31	GCGATCTTTTTATTTTTTATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATAGATCGC

	SEQ ID NO: 32	GCGATCTTTTTATTTTTGATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATCGATCGC

	SEQ ID NO: 33	GCGATCTTTTTATTTTTGATATA
		TGTATATATTTTTATTTTTTAT
		ATACATATATCGATCGC

	SEQ ID NO: 34	GATATACTTTTTATTTTTTATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAGTATATC

	SEQ ID NO: 35	GATATATTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCATATATC

	SEQ ID NO: 36	GATATATTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCATATATC

	SEQ ID NO: 37	GTGATACTTTTTATTTTTTATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAGTATCAC

	SEQ ID NO: 38	GATATACTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCGTATATC

	SEQ ID NO: 39	GATATACTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCGTATATC

	SEQ ID NO: 40	GGTATACTTTTTATTTTTTATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAGTATACC

	SEQ ID NO: 41	GTGATACTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCGTATCAC

	SEQ ID NO: 42	GTGATACTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCGTATCAC

	SEQ ID NO: 43	GGTATACTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCGTATACC

	SEQ ID NO: 44	GGTATACTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCGTATACC

	SEQ ID NO: 45	GGTGTACTTTTTATTTTTTATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAGTACACC

	SEQ ID NO: 46	GGTGTACTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCGTACACC

	SEQ ID NO: 47	GGTGTACTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCGTACACC

	SEQ ID NO: 48	GTATATACTTTTTATTTTTTATA
		TATATATATTTTTATTTTTTAT
		ATATATATAGTATATAC

	SEQ ID NO: 49	GTATATACTTTTTATTTTTGATA
		TATATATATTTTTATTTTTTAT
		ATATATATCGTATATAC

	SEQ ID NO: 50	GTATATACTTTTTATTTTTGATA
		TATGTATATTTTTATTTTTTAT
		ACATATATCGTATATAC

	SEQ ID NO: 51	GTATATACTTTTTATTTTTGATC
		ATGTATATTTTTTATTTTTATA
		TACATGATCGTATATAC

	SEQ ID NO: 52	GTATATACTTTTTATTTTTGATC
		ATATATGTTTTTTATTTTTACA
		TATATGATCGTATATAC

	SEQ ID NO: 53	GGATATACTTTTTATTTTTTATA
		TATATATATTTTTATTTTTTAT
		ATATATATAGTATATCC

	SEQ ID NO: 54	GGATATACTTTTTATTTTTGATA
		TATATATATTTTTATTTTTTAT
		ATATATATCGTATATCC

	SEQ ID NO: 55	GGATATACTTTTTATTTTTGATA
		TATGTATATTTTTATTTTTTAT
		ACATATATCGTATATCC

	SEQ ID NO: 56	GGATATACTTTTTATTTTTGATC
		ATGTATATTTTTTATTTTTATA
		TACATGATCGTATATCC

	SEQ ID NO: 57	GGATATACTTTTTATTTTTGATC
		ATATATGTTTTTTATTTTTACA
		TATATGATCGTATATCC

	SEQ ID NO: 58	GGTGATACTTTTTATTTTTTATA
		TATATATATTTTTATTTTTTAT
		ATATATATAGTATCACC

	SEQ ID NO: 59	GGTGATACTTTTTATTTTTGATA
		TATATATATTTTTATTTTTTAT
		ATATATATCGTATCACC

	SEQ ID NO: 60	GGTGATACTTTTTATTTTTGATA
		TATGTATATTTTTATTTTTTAT
		ACATATATCGTATCACC

	SEQ ID NO: 61	GGTGATACTTTTTATTTTTGATC
		ATGTATATTTTTTATTTTTATA
		TACATGATCGTATCACC

	SEQ ID NO: 62	GGTGATACTTTTTATTTTTGATC
		ATATATGTTTTTTATTTTTACA
		TATATGATCGTATCACC

	SEQ ID NO: 63	GGTGATCCTTTTTATTTTTTATA
		TATATATATTTTTATTTTTTAT
		ATATATATAGGATCACC

	SEQ ID NO: 64	GGTGATCCTTTTTATTTTTGATA
		TATATATATTTTTATTTTTTAT
		ATATATATCGGATCACC

	SEQ ID NO: 65	GGTGATCCTTTTTATTTTTGATA
		TATGTATATTTTTATTTTTTAT
		ACATATATCGGATCACC

	SEQ ID NO: 66	GGTGATCCTTTTTATTTTTGATC
		ATGTATATTTTTTATTTTTATA
		TACATGATCGGATCACC

	SEQ ID NO: 67	GGTGATCCTTTTTATTTTTGATC
		ATATATGTTTTTTATTTTTACA
		TATATGATCGGATCACC

	SEQ ID NO: 68	GATATATCACTTTTTATTTTTTA
		TATATATATTTTTATTTTTTAT
		ATATATAGTGATATATC

	SEQ ID NO: 69	GTATATACATTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCATGTATATAC

	SEQ ID NO: 70	GTATATACATTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCATGTATATAC

	SEQ ID NO: 71	GTATATACATTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCATGTATATAC

	SEQ ID NO: 72	GTATATACATTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCATGTATATAC

	SEQ ID NO: 73	GGATATACACTTTTTATTTTTTA
		TATATATATTTTTATTTTTTAT
		ATATATAGTGTATATCC

	SEQ ID NO: 74	GGATATACATTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCATGTATATCC

	SEQ ID NO: 75	GGATATACATTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCATGTATATCC

	SEQ ID NO: 76	GGATATACATTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCATGTATATCC

	SEQ ID NO: 77	GGATATACATTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCATGTATATCC

	SEQ ID NO: 78	GGGTATATACTTTTTATTTTTTA
		TATATATATTTTTATTTTTTAT
		ATATATAGTATATACCC

	SEQ ID NO: 79	GGATATACACTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCGTGTATATCC

	SEQ ID NO: 80	GGATATACACTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCGTGTATATCC

	SEQ ID NO: 81	GGATATACACTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCGTGTATATCC

	SEQ ID NO: 82	GGATATACACTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCGTGTATATCC

	SEQ ID NO: 83	GGGTATATACTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCGTATATACCC

	SEQ ID NO: 84	GGGTATATACTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCGTATATACCC

	SEQ ID NO: 85	GGGTATATACTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCGTATATACCC

	SEQ ID NO: 86	GGGTATATACTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCGTATATACCC

	SEQ ID NO: 87	GGATGTACACTTTTTATTTTTTA
		TATATATATTTTTATTTTTTAT
		ATATATAGTGTACATCC

	SEQ ID NO: 88	GGATGTACACTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCGTGTACATCC

	SEQ ID NO: 89	GGATGTACACTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCGTGTACATCC

	SEQ ID NO: 90	GGATGTACACTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCGTGTACATCC

	SEQ ID NO: 91	GGATGTACACTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCGTGTACATCC

	SEQ ID NO: 92	GTATATACTTTTTATTTTTTATA
		TATATATATATTTTTTATTTTT
		ATATATATATATATAGTATATAC

	SEQ ID NO: 93	GTATATACTTTTTATTTTTGATA
		TATATATATATTTTTTATTTTT
		ATATATATATATATCGTATATAC

	SEQ ID NO: 94	GGATATACTTTTTATTTTTTATA
		TATATATATATTTTTTATTTTT
		ATATATATATATATAGTATATCC

	SEQ ID NO: 95	GGATATACTTTTTATTTTTGATA
		TATATATATATTTTTTATTTTT
		ATATATATATATATCGTATATCC

	SEQ ID NO: 96	GGTGATACTTTTTATTTTTTATA
		TATATATATATTTTTTATTTTT
		ATATATATATATATAGTATCACC

	SEQ ID NO: 97	GGTGATACTTTTTATTTTTGATA
		TATATATATATTTTTTATTTTT
		ATATATATATATATCGTATCACC

	SEQ ID NO: 98	GGTGATCCTTTTTATTTTTTATA
		TATATATATATTTTTTATTTTT
		ATATATATATATATAGGATCACC

	SEQ ID NO: 99	GGTGATCCTTTTTATTTTTGATA
		TATATATATATTTTTTATTTTT
		ATATATATATATATCGGATCACC

	SEQ ID NO: 100	GATATATCACTTTTTATTTTTTA
		TATATATATATATTTTTTATTT
		TTATATATATATATATAGTGATA
		TATC

	SEQ ID NO: 101	GTATATACATTTTTTATTTTTGA
		TATATATATATATTTTTTATTT
		TTATATATATATATATCATGTAT
		ATAC

	SEQ ID NO: 102	GGATATACACTTTTTATTTTTTA
		TATATATATATATTTTTTATTT
		TTATATATATATATATAGTGTAT
		ATCC

	SEQ ID NO: 103	GGATATACATTTTTTATTTTTGA
		TATATATATATATTTTTTATTT
		TTATATATATATATATCATGTAT
		ATCC

	SEQ ID NO: 104	GGGTATATACTTTTTATTTTTTA
		TATATATATATATTTTTTATTT
		TTATATATATATATATAGTATAT
		ACCC

	SEQ ID NO: 105	GGATATACACTTTTTATTTTTGA
		TATATATATATATTTTTTATTT
		TTATATATATATATATCGTGTAT
		ATCC

	SEQ ID NO: 106	GGGTATATACTTTTTATTTTTGA
		TATATATATATATTTTTTATTT
		TTATATATATATATATCGTATAT
		ACCC

	SEQ ID NO: 107	GTATATACTTTTTATTTTTTATA
		TATATATATATTTTTATTTTTT
		ATATATATATATAGTATATAC

	SEQ ID NO: 108	GTATATACTTTTTATTTTTGATA
		TATATATATATTTTTATTTTTT
		ATATATATATATCGTATATAC

	SEQ ID NO: 109	GTATATACTTTTTATTTTTGATA
		TATGTATATATTTTTATTTTTT
		ATATACATATATCGTATATAC

	SEQ ID NO: 110	GGATATACTTTTTATTTTTTATA
		TATATATATATTTTTATTTTTT
		ATATATATATATAGTATATCC

	SEQ ID NO: 111	GGATATACTTTTTATTTTTGATA
		TATATATATATTTTTATTTTTT
		ATATATATATATCGTATATCC

	SEQ ID NO: 112	GGATATACTTTTTATTTTTGATA
		TATGTATATATTTTTATTTTTT
		ATATACATATATCGTATATCC

	SEQ ID NO: 113	GGTGATACTTTTTATTTTTTATA
		TATATATATATTTTTATTTTTT
		ATATATATATATAGTATCACC

	SEQ ID NO: 114	GGTGATACTTTTTATTTTTGATA
		TATATATATATTTTTATTTTTT
		ATATATATATATCGTATCACC

	SEQ ID NO: 115	GGTGATACTTTTTATTTTTGATA
		TATGTATATATTTTTATTTTTT
		ATATACATATATCGTATCACC

	SEQ ID NO: 116	GGTGATCCTTTTTATTTTTTATA
		TATATATATATTTTTATTTTTT
		ATATATATATATAGGATCACC

	SEQ ID NO: 117	GGTGATCCTTTTTATTTTTGATA
		TATATATATATTTTTATTTTTT
		ATATATATATATCGGATCACC

	SEQ ID NO: 118	GGTGATCCTTTTTATTTTTGATA
		TATGTATATATTTTTATTTTTT
		ATATACATATATCGGATCACC

	SEQ ID NO: 119	GATATATCACTTTTTATTTTTTA
		TATATATATATATTTTTATTTT
		TTATATATATATATAGTGATATA
		TC

	SEQ ID NO: 120	GTATATACATTTTTTATTTTTGA
		TATATATATATATTTTTATTTT
		TTATATATATATATCATGTATAT
		AC

	SEQ ID NO: 121	GTATATACATTTTTTATTTTTGA
		TATATGTATATATTTTTATTTT
		TTATATACATATATCATGTATAT
		AC

	SEQ ID NO: 122	GGATATACACTTTTTATTTTTTA
		TATATATATATATTTTTATTTT
		TTATATATATATATAGTGTATAT
		CC

	SEQ ID NO: 123	GGATATACATTTTTTATTTTTGA
		TATATATATATATTTTTATTTT
		TTATATATATATATCATGTATAT
		CC

	SEQ ID NO: 124	GGATATACATTTTTTATTTTTGA
		TATATGTATATATTTTTATTTT
		TTATATACATATATCATGTATAT
		CC

	SEQ ID NO: 125	GGGTATATACTTTTTATTTTTTA
		TATATATATATATTTTTATTTT
		TTATATATATATATAGTATATAC
		CC

	SEQ ID NO: 126	GGATATACACTTTTTATTTTTGA
		TATATATATATATTTTTATTTT
		TTATATATATATATCGTGTATAT
		CC

	SEQ ID NO: 127	GGATATACACTTTTTATTTTTGA
		TATATGTATATATTTTTATTTT
		TTATATACATATATCGTGTATAT
		CC

	SEQ ID NO: 128	GGGTATATACTTTTTATTTTTGA
		TATATATATATATTTTTATTTT
		TTATATATATATATCGTATATAC
		CC

	SEQ ID NO: 129	GGGTATATACTTTTTATTTTTGA
		TATATGTATATATTTTTATTTT
		TTATATACATATATCGTATATAC
		CC

	SEQ ID NO: 130	GATATATCACTTTTTATTTTTTA
		TATATATATATTTTTTATTTTT
		ATATATATATATAGTGATATATC

	SEQ ID NO: 131	GTATATACATTTTTTATTTTTGA
		TATATATATATTTTTTATTTTT
		ATATATATATATCATGTATATAC

	SEQ ID NO: 132	GTATATACATTTTTTATTTTTGA
		TATATGTATATTTTTTATTTTT
		ATATACATATATCATGTATATAC

	SEQ ID NO: 133	GGATATACACTTTTTATTTTTTA
		TATATATATATTTTTTATTTTT
		ATATATATATATAGTGTATATCC

	SEQ ID NO: 134	GGATATACATTTTTTATTTTTGA
		TATATATATATTTTTTATTTTT
		ATATATATATATCATGTATATCC

	SEQ ID NO: 135	GGATATACATTTTTTATTTTTGA
		TATATGTATATTTTTTATTTTT
		ATATACATATATCATGTATATCC

	SEQ ID NO: 136	GGGTATATACTTTTTATTTTTTA
		TATATATATATTTTTTATTTTT
		ATATATATATATAGTATATACCC

	SEQ ID NO: 137	GGATATACACTTTTTATTTTTGA
		TATATATATATTTTTTATTTTT
		ATATATATATATCGTGTATATCC

	SEQ ID NO: 138	GGATATACACTTTTTATTTTTGA
		TATATGTATATTTTTTATTTTT
		ATATACATATATCGTGTATATCC

	SEQ ID NO: 139	GGGTATATACTTTTTATTTTTGA
		TATATATATATTTTTTATTTTT
		ATATATATATATCGTATATACCC

	SEQ ID NO: 140	GGGTATATACTTTTTATTTTTGA
		TATATGTATATTTTTTATTTTT
		ATATACATATATCGTATATACCC

	SEQ ID NO: 141	GATATATCACTTTTTATTTTTTA
		TATATATATATTTTTATTTTTT
		ATATATATATAGTGATATATC

	SEQ ID NO: 142	GTATATACATTTTTTATTTTTGA
		TATATATATATTTTTATTTTTT
		ATATATATATCATGTATATAC

	SEQ ID NO: 143	GTATATACATTTTTTATTTTTGA
		TATATGTATATTTTTATTTTTT
		ATACATATATCATGTATATAC

	SEQ ID NO: 144	GTATATACATTTTTTATTTTTGA
		TCATGTATATTTTTTATTTTTA
		TATACATGATCATGTATATAC

	SEQ ID NO: 145	GTATATACATTTTTTATTTTTGA
		TCATATATGTTTTTTATTTTTA
		CATATATGATCATGTATATAC

	SEQ ID NO: 146	GGATATACACTTTTTATTTTTTA
		TATATATATATTTTTATTTTTT
		ATATATATATAGTGTATATCC

	SEQ ID NO: 147	GGATATACATTTTTTATTTTTGA
		TATATATATATTTTTATTTTTT
		ATATATATATCATGTATATCC

	SEQ ID NO: 148	GGATATACATTTTTTATTTTTGA
		TATATGTATATTTTTATTTTTT
		ATACATATATCATGTATATCC

	SEQ ID NO: 149	GGATATACATTTTTTATTTTTGA
		TCATGTATATTTTTTATTTTTA
		TATACATGATCATGTATATCC

	SEQ ID NO: 150	GGATATACATTTTTTATTTTTGA
		TCATATATGTTTTTTATTTTTA
		CATATATGATCATGTATATCC

	SEQ ID NO: 151	GGGTATATACTTTTTATTTTTTA
		TATATATATATTTTTATTTTTT
		ATATATATATAGTATATACCC

	SEQ ID NO: 152	GGATATACACTTTTTATTTTTGA
		TATATATATATTTTTATTTTTT
		ATATATATATCGTGTATATCC

	SEQ ID NO: 153	GGATATACACTTTTTATTTTTGA
		TATATGTATATTTTTATTTTTT
		ATACATATATCGTGTATATCC

	SEQ ID NO: 154	GGATATACACTTTTTATTTTTGA
		TCATGTATATTTTTTATTTTTA
		TATACATGATCGTGTATATCC

	SEQ ID NO: 155	GGATATACACTTTTTATTTTTGA
		TCATATATGTTTTTTATTTTTA
		CATATATGATCGTGTATATCC

	SEQ ID NO: 156	GGGTATATACTTTTTATTTTTGA
		TATATATATATTTTTATTTTTT
		ATATATATATCGTATATACCC

	SEQ ID NO: 157	GGGTATATACTTTTTATTTTTGA
		TATATGTATATTTTTATTTTTT
		ATACATATATCGTATATACCC

	SEQ ID NO: 158	GGGTATATACTTTTTATTTTTGA
		TCATGTATATTTTTTATTTTTA
		TATACATGATCGTATATACCC

	SEQ ID NO: 159	GGGTATATACTTTTTATTTTTGA
		TCATATATGTTTTTTATTTTTA
		CATATATGATCGTATATACCC

	SEQ ID NO: 160	GTACATATATTTTTTTATTTTTG
		ATATATATATTTTTATTTTTTA
		TATATATCAATATATGTAC

	SEQ ID NO: 161	GTACATATATTTTTTTATTTTTG
		ATATATGTATTTTTATTTTTTA
		CATATATCAATATATGTAC

	SEQ ID NO: 162	GTACATATATTTTTTTATTTTTG
		ATCATGTATTTTTTATTTTTAT
		ACATGATCAATATATGTAC

	SEQ ID NO: 163	GTACATATATTTTTTTATTTTTG
		ATCATATATTTTTTATTTTTAT
		ATATGATCAATATATGTAC

	SEQ ID NO: 164	GATGTATATACTTTTTATTTTTT
		ATATATATATTTTTATTTTTTA
		TATATATAGTATATACATC

	SEQ ID NO: 165	GGTACATATATTTTTTATTTTTG
		ATATATATATTTTTATTTTTTA
		TATATATCATATATGTACC

	SEQ ID NO: 166	GGTACATATATTTTTTATTTTTG
		ATATATGTATTTTTATTTTTTA
		CATATATCATATATGTACC

	SEQ ID NO: 167	GGTACATATATTTTTTATTTTTG
		ATCATGTATTTTTTATTTTTAT
		ACATGATCATATATGTACC

	SEQ ID NO: 168	GGTACATATATTTTTTATTTTTG
		ATCATATATTTTTTATTTTTAT
		ATATGATCATATATGTACC

	SEQ ID NO: 169	CGATCATATATTTTTTTATTTTT
		GATATATATATTTTTATTTTTT
		ATATATATCAATATATGATCG

	SEQ ID NO: 170	CGATCATATATTTTTTTATTTTT
		GATATATGTATTTTTATTTTTT
		ACATATATCAATATATGATCG

	SEQ ID NO: 171	CGATCATATATTTTTTTATTTTT
		GATCATGTATTTTTTATTTTTA
		TACATGATCAATATATGATCG

	SEQ ID NO: 172	CGATCATATATTTTTTTATTTTT
		GATCATATATTTTTTATTTTTA
		TATATGATCAATATATGATCG

	SEQ ID NO: 173	GATACTTTTTATTTTTTATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATATAGTATC

	SEQ ID NO: 174	GACACTTTTTATTTTTTATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATATAGTGTC

	SEQ ID NO: 175	GATACTTTTTATTTTTGATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATATCGTATC

	SEQ ID NO: 176	GATACTTTTTATTTTTGATAAAT
		GTATATATTTTTTATTTTTATA
		TATACATATATCGTATC

	SEQ ID NO: 177	GATACTTTTTATTTTTGATGATG
		TATATATATTTTTATTTTTTAT
		ATATACATGATCGTATC

	SEQ ID NO: 178	GATACTTTTTATTTTTGATGATA
		TATGTACTTTTTTATTTTTAGT
		ACATATATGATCGTATC

	SEQ ID NO: 179	GGATCTTTTTATTTTTTATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATATAGATCC

	SEQ ID NO: 180	GACACTTTTTATTTTTGATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATATCGTGTC

	SEQ ID NO: 181	GACACTTTTTATTTTTGATAAAT
		GTATATATTTTTTATTTTTATA
		TATACATATATCGTGTC

	SEQ ID NO: 182	GACACTTTTTATTTTTGATGATG
		TATATATATTTTTATTTTTTAT
		ATATACATGATCGTGTC

	SEQ ID NO: 183	GACACTTTTTATTTTTGATGATA
		TATGTACTTTTTTATTTTTAGT
		ACATATATGATCGTGTC

	SEQ ID NO: 184	GGATCTTTTTATTTTTGATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATATCGATCC

	SEQ ID NO: 185	GGATCTTTTTATTTTTGATAAAT
		GTATATATTTTTTATTTTTATA
		TATACATATATCGATCC

	SEQ ID NO: 186	GGATCTTTTTATTTTTGATGATG
		TATATATATTTTTATTTTTTAT
		ATATACATGATCGATCC

	SEQ ID NO: 187	GGATCTTTTTATTTTTGATGATA
		TATGTACTTTTTTATTTTTAGT
		ACATATATGATCGATCC

	SEQ ID NO: 188	GCGTCTTTTTATTTTTTATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATATAGACGC

	SEQ ID NO: 189	GCGTCTTTTTATTTTTGATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATATCGACGC

	SEQ ID NO: 190	GCGTCTTTTTATTTTTGATAAAT
		GTATATATTTTTTATTTTTATA
		TATACATATATCGACGC

	SEQ ID NO: 191	GCGTCTTTTTATTTTTGATGATG
		TATATATATTTTTATTTTTTAT
		ATATACATGATCGACGC

	SEQ ID NO: 192	GCGTCTTTTTATTTTTGATGATA
		TATGTACTTTTTTATTTTTAGT
		ACATATATGATCGACGC

	SEQ ID NO: 193	GTATACTTTTTATTTTTGATAAA
		TATATATATTTTTATTTTTTAT
		ATATATATATCGTATAC

	SEQ ID NO: 194	GTATACTTTTTATTTTTGATAAA
		TGTATATATTTTTATTTTTTAT
		ATACATATATCGTATAC

	SEQ ID NO: 195	GTATACTTTTTATTTTTGATGAT
		GTATATATTTTTTATTTTTATA
		TATACATGATCGTATAC

	SEQ ID NO: 196	GTATACTTTTTATTTTTGATGAT
		ATATGTACTTTTTATTTTTGTA
		CATATATGATCGTATAC

	SEQ ID NO: 197	GTGATCTTTTTATTTTTGATAAA
		TATATATATTTTTATTTTTTAT
		ATATATATATCGATCAC

	SEQ ID NO: 198	GTGATCTTTTTATTTTTGATAAA
		TGTATATATTTTTATTTTTTAT
		ATACATATATCGATCAC

	SEQ ID NO: 199	GTGATCTTTTTATTTTTGATGAT
		GTATATATTTTTTATTTTTATA
		TATACATGATCGATCAC

	SEQ ID NO: 200	GTGATCTTTTTATTTTTGATGAT
		ATATGTACTTTTTATTTTTGTA
		CATATATGATCGATCAC

	SEQ ID NO: 201	GGATACTTTTTATTTTTGATAAA
		TATATATATTTTTATTTTTTAT
		ATATATATATCGTATCC

	SEQ ID NO: 202	GGATACTTTTTATTTTTGATAAA
		TGTATATATTTTTATTTTTTAT
		ATACATATATCGTATCC

	SEQ ID NO: 203	GGATACTTTTTATTTTTGATGAT
		GTATATATTTTTTATTTTTATA
		TATACATGATCGTATCC

	SEQ ID NO: 204	GGATACTTTTTATTTTTGATGAT
		ATATGTACTTTTTATTTTTGTA
		CATATATGATCGTATCC

	SEQ ID NO: 205	GCGATCTTTTTATTTTTGATAAA
		TATATATATTTTTATTTTTTAT
		ATATATATATCGATCGC

	SEQ ID NO: 206	GCGATCTTTTTATTTTTGATAAA
		TGTATATATTTTTATTTTTTAT
		ATACATATATCGATCGC

	SEQ ID NO: 207	GCGATCTTTTTATTTTTGATGAT
		GTATATATTTTTTATTTTTATA
		TATACATGATCGATCGC

	SEQ ID NO: 208	GCGATCTTTTTATTTTTGATGAT
		ATATGTACTTTTTATTTTTGTA
		CATATATGATCGATCGC

	SEQ ID NO: 209	GATATACTTTTTATTTTTTATAA
		ATATATATTTTTTATTTTTATA
		TATATATATAGTATATC

	SEQ ID NO: 210	GATATATTTTTTATTTTTGATAA
		ATGTATATTTTTTATTTTTATA
		TACATATATCATATATC

	SEQ ID NO: 211	GATATATTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCATATATC

	SEQ ID NO: 212	GATATATTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCATATATC

	SEQ ID NO: 213	GTGATACTTTTTATTTTTTATAA
		ATATATATTTTTTATTTTTATA
		TATATATATAGTATCAC

	SEQ ID NO: 214	GATATACTTTTTATTTTTGATAA
		ATATATATTTTTTATTTTTATA
		TATATATATCGTATATC

	SEQ ID NO: 215	GATATACTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCGTATATC

	SEQ ID NO: 216	GATATACTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCGTATATC

	SEQ ID NO: 217	GGTATACTTTTTATTTTTTATAA
		ATATATATTTTTTATTTTTATA
		TATATATATAGTATACC

	SEQ ID NO: 218	GTGATACTTTTTATTTTTGATAA
		ATATATATTTTTTATTTTTATA
		TATATATATCGTATCAC

	SEQ ID NO: 219	GTGATACTTTTTATTTTTGATAA
		ATGTATATTTTTTATTTTTATA
		TACATATATCGTATCAC

	SEQ ID NO: 220	GTGATACTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCGTATCAC

	SEQ ID NO: 221	GTGATACTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCGTATCAC

	SEQ ID NO: 222	GGTATACTTTTTATTTTTGATAA
		ATATATATTTTTTATTTTTATA
		TATATATATCGTATACC

	SEQ ID NO: 223	GGTATACTTTTTATTTTTGATAA
		ATGTATATTTTTTATTTTTATA
		TACATATATCGTATACC

	SEQ ID NO: 224	GGTATACTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCGTATACC

	SEQ ID NO: 225	GGTATACTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCGTATACC

	SEQ ID NO: 226	GGTGTACTTTTTATTTTTTATAA
		ATATATATTTTTTATTTTTATA
		TATATATATAGTACACC

	SEQ ID NO: 227	GGTGTACTTTTTATTTTTGATAA
		ATATATATTTTTTATTTTTATA
		TATATATATCGTACACC

	SEQ ID NO: 228	GGTGTACTTTTTATTTTTGATAA
		ATGTATATTTTTTATTTTTATA
		TACATATATCGTACACC

	SEQ ID NO: 229	GGTGTACTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCGTACACC

	SEQ ID NO: 230	GGTGTACTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCGTACACC

	SEQ ID NO: 231	GTATATACTTTTTATTTTTGATA
		AATATATATTTTTATTTTTTAT
		ATATATATCGTATATAC

	SEQ ID NO: 232	GTATATACTTTTTATTTTTGATA
		AATGTATATTTTTATTTTTTAT
		ACATATATCGTATATAC

	SEQ ID NO: 233	GTATATACTTTTTATTTTTGATG
		ATGTATATTTTTTATTTTTATA
		TACATGATCGTATATAC

	SEQ ID NO: 234	GTATATACTTTTTATTTTTGATG
		ATATATGTTTTTTATTTTTACA
		TATATGATCGTATATAC

	SEQ ID NO: 235	GGATATACTTTTTATTTTTGATA
		AATATATATTTTTATTTTTTAT
		ATATATATCGTATATCC

	SEQ ID NO: 236	GGATATACTTTTTATTTTTGATA
		AATGTATATTTTTATTTTTTAT
		ACATATATCGTATATCC

	SEQ ID NO: 237	GGATATACTTTTTATTTTTGATG
		ATGTATATTTTTTATTTTTATA
		TACATGATCGTATATCC

	SEQ ID NO: 238	GGATATACTTTTTATTTTTGATG
		ATATATGTTTTTTATTTTTACA
		TATATGATCGTATATCC

	SEQ ID NO: 239	GGTGATACTTTTTATTTTTGATA
		AATATATATTTTTATTTTTTAT
		ATATATATCGTATCACC

	SEQ ID NO: 240	GGTGATACTTTTTATTTTTGATA
		AATGTATATTTTTATTTTTTAT
		ACATATATCGTATCACC

	SEQ ID NO: 241	GGTGATACTTTTTATTTTTGATG
		ATGTATATTTTTTATTTTTATA
		TACATGATCGTATCACC

	SEQ ID NO: 242	GGTGATACTTTTTATTTTTGATG
		ATATATGTTTTTTATTTTTACA
		TATATGATCGTATCACC

	SEQ ID NO: 243	GGTGATCCTTTTTATTTTTGATA
		AATATATATTTTTATTTTTTAT
		ATATATATCGGATCACC

	SEQ ID NO: 244	GGTGATCCTTTTTATTTTTGATA
		AATGTATATTTTTATTTTTTAT
		ACATATATCGGATCACC

	SEQ ID NO: 245	GGTGATCCTTTTTATTTTTGATG
		ATGTATATTTTTTATTTTTATA
		TACATGATCGGATCACC

	SEQ ID NO: 246	GGTGATCCTTTTTATTTTTGATG
		ATATATGTTTTTTATTTTTACA
		TATATGATCGGATCACC

	SEQ ID NO: 247	GTATATACATTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCATGTATATAC

	SEQ ID NO: 248	GTATATACATTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCATGTATATAC

	SEQ ID NO: 249	GTATATACATTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCATGTATATAC

	SEQ ID NO: 250	GTATATACATTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCATGTATATAC

	SEQ ID NO: 251	GGATATACATTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCATGTATATCC

	SEQ ID NO: 252	GGATATACATTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCATGTATATCC

	SEQ ID NO: 253	GGATATACATTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCATGTATATCC

	SEQ ID NO: 254	GGATATACATTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCATGTATATCC

	SEQ ID NO: 255	GGATATACACTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCGTGTATATCC

	SEQ ID NO: 256	GGATATACACTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCGTGTATATCC

	SEQ ID NO: 257	GGATATACACTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCGTGTATATCC

	SEQ ID NO: 258	GGATATACACTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCGTGTATATCC

	SEQ ID NO: 259	GGGTATATACTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCGTATATACCC

	SEQ ID NO: 260	GGGTATATACTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCGTATATACCC

	SEQ ID NO: 261	GGGTATATACTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCGTATATACCC

	SEQ ID NO: 262	GGGTATATACTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCGTATATACCC

	SEQ ID NO: 263	GGATGTACACTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCGTGTACATCC

	SEQ ID NO: 264	GGATGTACACTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCGTGTACATCC

	SEQ ID NO: 265	GGATGTACACTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCGTGTACATCC

	SEQ ID NO: 266	GGATGTACACTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCGTGTACATCC

	SEQ ID NO: 267	GTATATACTTTTTATTTTTTATA
		AATATATATATTTTTTATTTTT
		ATATATATATATATAGTATATAC

	SEQ ID NO: 268	GTATATACTTTTTATTTTTGATA
		AATATATATATTTTTTATTTTT
		ATATATATATATATCGTATATAC

	SEQ ID NO: 269	GTATATACTTTTTATTTTTGATA
		AATGTATATATTTTTTATTTTT
		ATATATACATATATCGTATATAC

	SEQ ID NO: 270	GTATATACTTTTTATTTTTGATG
		ATGTATATATATTTTTATTTTT
		TATATATACATGATCGTATATAC

	SEQ ID NO: 271	GTATATACTTTTTATTTTTGATG
		ATATATGTACTTTTTTATTTTT
		AGTACATATATGATCGTATATAC

	SEQ ID NO: 272	GGATATACTTTTTATTTTTTATA
		AATATATATATTTTTTATTTTT
		ATATATATATATATAGTATATCC

	SEQ ID NO: 273	GGATATACTTTTTATTTTTGATA
		AATATATATATTTTTTATTTTT
		ATATATATATATATCGTATATCC

	SEQ ID NO: 274	GGATATACTTTTTATTTTTGATA
		AATGTATATATTTTTTATTTTT
		ATATATACATATATCGTATATCC

	SEQ ID NO: 275	GGATATACTTTTTATTTTTGATG
		ATGTATATATATTTTTATTTTT
		TATATATACATGATCGTATATCC

	SEQ ID NO: 276	GGATATACTTTTTATTTTTGATG
		ATATATGTACTTTTTTATTTTT
		AGTACATATATGATCGTATATCC

	SEQ ID NO: 277	GGTGATACTTTTTATTTTTTATA
		AATATATATATTTTTTATTTTT
		ATATATATATATATAGTATCACC

	SEQ ID NO: 278	GGTGATACTTTTTATTTTTGATA
		AATATATATATTTTTTATTTTT
		ATATATATATATATCGTATCACC

	SEQ ID NO: 279	GGTGATACTTTTTATTTTTGATA
		AATGTATATATTTTTTATTTTT
		ATATATACATATATCGTATCACC

	SEQ ID NO: 280	GGTGATACTTTTTATTTTTGATG
		ATGTATATATATTTTTATTTTT
		TATATATACATGATCGTATCACC

	SEQ ID NO: 281	GGTGATACTTTTTATTTTTGATG
		ATATATGTACTTTTTTATTTTT
		AGTACATATATGATCGTATCACC

	SEQ ID NO: 282	GGTGATCCTTTTTATTTTTTATA
		AATATATATATTTTTTATTTTT
		ATATATATATATATAGGATCACC

	SEQ ID NO: 283	GGTGATCCTTTTTATTTTTGATA
		AATATATATATTTTTTATTTTT
		ATATATATATATATCGGATCACC

	SEQ ID NO: 284	GGTGATCCTTTTTATTTTTGATA
		AATGTATATATTTTTTATTTTT
		ATATATACATATATCGGATCACC

	SEQ ID NO: 285	GGTGATCCTTTTTATTTTTGATG
		ATGTATATATATTTTTATTTTT
		TATATATACATGATCGGATCACC

	SEQ ID NO: 286	GGTGATCCTTTTTATTTTTGATG
		ATATATGTACTTTTTTATTTTT
		AGTACATATATGATCGGATCACC

	SEQ ID NO: 287	GATATATCACTTTTTATTTTTTA
		TAAATATATATATTTTTTATTT
		TTATATATATATATATAGTGATA
		TATC

	SEQ ID NO: 288	GTATATACATTTTTTATTTTTGA
		TAAATATATATATTTTTTATTT
		TTATATATATATATATCATGTAT
		ATAC

	SEQ ID NO: 289	GTATATACATTTTTTATTTTTGA
		TAAATGTATATATTTTTTATTT
		TTATATATACATATATCATGTAT
		ATAC

	SEQ ID NO: 290	GTATATACATTTTTTATTTTTGA
		TGATGTATATATATTTTTATTT
		TTTATATATACATGATCATGTAT
		ATAC

	SEQ ID NO: 291	GTATATACATTTTTTATTTTTGA
		TGATATATGTACTTTTTTATTT
		TTAGTACATATATGATCATGTAT
		ATAC

	SEQ ID NO: 292	GGATATACACTTTTTATTTTTTA
		TAAATATATATATTTTTTATTT
		TTATATATATATATATAGTGTAT
		ATCC

	SEQ ID NO: 293	GGATATACATTTTTTATTTTTGA
		TAAATATATATATTTTTTATTT
		TTATATATATATATATCATGTAT
		ATCC

	SEQ ID NO: 294	GGATATACATTTTTTATTTTTGA
		TAAATGTATATATTTTTTATTT
		TTATATATACATATATCATGTAT
		ATCC

	SEQ ID NO: 295	GGATATACATTTTTTATTTTTGA
		TGATGTATATATATTTTTATTT
		TTTATATATACATGATCATGTAT
		ATCC

	SEQ ID NO: 296	GGATATACATTTTTTATTTTTGA
		TGATATATGTACTTTTTTATTT
		TTAGTACATATATGATCATGTAT
		ATCC

	SEQ ID NO: 297	GGGTATATACTTTTTATTTTTTA
		TAAATATATATATTTTTTATTT
		TTATATATATATATATAGTATAT
		ACCC

	SEQ ID NO: 298	GGATATACACTTTTTATTTTTGA
		TAAATATATATATTTTTTATT
		TTTATATATATATATATCGTGTA
		TATCC

	SEQ ID NO: 299	GGATATACACTTTTTATTTTTGA
		TAAATGTATATATTTTTTATT
		TTTATATATACATATATCGTGTA
		TATCC

	SEQ ID NO: 300	GGATATACACTTTTTATTTTTGA
		TGATGTATATATATTTTTATT
		TTTTATATATACATGATCGTGTA
		TATCC

	SEQ ID NO: 301	GGATATACACTTTTTATTTTTGA
		TGATATATGTACTTTTTTATTT
		TTAGTACATATATGATCGTGTAT
		ATCC

	SEQ ID NO: 302	GGGTATATACTTTTTATTTTTGA
		TAAATATATATATTTTTTATTT
		TTATATATATATATATCGTATAT
		ACCC

	SEQ ID NO: 303	GGGTATATACTTTTTATTTTTGA
		TAAATGTATATATTTTTTATTT
		TTATATATACATATATCGTATAT
		ACCC

	SEQ ID NO: 304	GGGTATATACTTTTTATTTTTGA
		TGATGTATATATATTTTTATTT
		TTTATATATACATGATCGTATAT
		ACCC

	SEQ ID NO: 305	GGGTATATACTTTTTATTTTTGA
		TGATATATGTACTTTTTTATTT
		TTAGTACATATATGATCGTATAT
		ACCC

	SEQ ID NO: 306	GTATATACTTTTTATTTTTGATA
		AATATATATATTTTTATTTTTT
		ATATATATATATCGTATATAC

	SEQ ID NO: 307	GTATATACTTTTTATTTTTGATA
		AATGTATATATTTTTATTTTTT
		ATATACATATATCGTATATAC

	SEQ ID NO: 308	GTATATACTTTTTATTTTTGATG
		ATGTATATATTTTTTATTTTTA
		TATATACATGATCGTATATAC

	SEQ ID NO: 309	GTATATACTTTTTATTTTTGATG
		ATATATGTACTTTTTATTTTTG
		TACATATATGATCGTATATAC

	SEQ ID NO: 310	GGATATACTTTTTATTTTTGATA
		AATATATATATTTTTATTTTTT
		ATATATATATATCGTATATCC

	SEQ ID NO: 311	GGATATACTTTTTATTTTTGATA
		AATGTATATATTTTTATTTTTT
		ATATACATATATCGTATATCC

	SEQ ID NO: 312	GGATATACTTTTTATTTTTGATG
		ATGTATATATTTTTTATTTTTA
		TATATACATGATCGTATATCC

	SEQ ID NO: 313	GGATATACTTTTTATTTTTGATG
		ATATATGTACTTTTTATTTTTG
		TACATATATGATCGTATATCC

	SEQ ID NO: 314	GGTGATACTTTTTATTTTTGATA
		AATATATATATTTTTATTTTTT
		ATATATATATATCGTATCACC

	SEQ ID NO: 315	GGTGATACTTTTTATTTTTGATA
		AATGTATATATTTTTATTTTTT
		ATATACATATATCGTATCACC

	SEQ ID NO: 316	GGTGATACTTTTTATTTTTGATG
		ATGTATATATTTTTTATTTTTA
		TATATACATGATCGTATCACC

	SEQ ID NO: 317	GGTGATACTTTTTATTTTTGATG
		ATATATGTACTTTTTATTTTTG
		TACATATATGATCGTATCACC

	SEQ ID NO: 318	GGTGATCCTTTTTATTTTTGATA
		AATATATATATTTTTATTTTTT
		ATATATATATATCGGATCACC

	SEQ ID NO: 319	GGTGATCCTTTTTATTTTTGATA
		AATGTATATATTTTTATTTTTT
		ATATACATATATCGGATCACC

	SEQ ID NO: 320	GGTGATCCTTTTTATTTTTGATG
		ATGTATATATTTTTTATTTTTA
		TATATACATGATCGGATCACC

	SEQ ID NO: 321	GGTGATCCTTTTTATTTTTGATG
		ATATATGTACTTTTTATTTTTG
		TACATATATGATCGGATCACC

	SEQ ID NO: 322	GTATATACATTTTTTATTTTTGA
		TAAATATATATATTTTTATTTT
		TTATATATATATATCATGTATAT
		AC

	SEQ ID NO: 323	GTATATACATTTTTTATTTTTGA
		TGATGTATATATTTTTTATTTT
		TATATATACATGATCATGTATAT
		AC

	SEQ ID NO: 324	GTATATACATTTTTTATTTTTGA
		TGATATATGTACTTTTTATTTT
		TGTACATATATGATCATGTATAT
		AC

	SEQ ID NO: 325	GGATATACATTTTTTATTTTTGA
		TAAATATATATATTTTTATTTT
		TTATATATATATATCATGTATAT
		CC

	SEQ ID NO: 326	GGATATACATTTTTTATTTTTGA
		TAAATGTATATATTTTTATTTT
		TTATATACATATATCATGTATAT
		CC

	SEQ ID NO: 327	GGATATACATTTTTTATTTTTGA
		TGATGTATATATTTTTTATTTT
		TATATATACATGATCATGTATAT
		CC

	SEQ ID NO: 328	GGATATACATTTTTTATTTTTGA
		TGATATATGTACTTTTTATTTT
		TGTACATATATGATCATGTATAT
		CC

	SEQ ID NO: 329	GGATATACACTTTTTATTTTTGA
		TAAATATATATATTTTTATTT
		TTTATATATATATATCGTGTATA
		TCC

	SEQ ID NO: 330	GGATATACACTTTTTATTTTTGA
		TAAATGTATATATTTTTATTT
		TTTATATACATATATCGTGTATA
		TCC

	SEQ ID NO: 331	GGATATACACTTTTTATTTTTGA
		TGATGTATATATTTTTTATTTT
		TATATATACATGATCGTGTATAT
		CC

	SEQ ID NO: 332	GGATATACACTTTTTATTTTTGA
		TGATATATGTACTTTTTATTTT
		TGTACATATATGATCGTGTATAT
		CC

	SEQ ID NO: 333	GGGTATATACTTTTTATTTTTGA
		TAAATATATATATTTTTATTTT
		TTATATATATATATCGTATATAC
		CC

	SEQ ID NO: 334	GGGTATATACTTTTTATTTTTGA
		TAAATGTATATATTTTTATTTT
		TTATATACATATATCGTATATAC
		CC

	SEQ ID NO: 335	GGGTATATACTTTTTATTTTTGA
		TGATGTATATATTTTTTATTTT
		TATATATACATGATCGTATATAC
		CC

	SEQ ID NO: 336	GGGTATATACTTTTTATTTTTGA
		TGATATATGTACTTTTTATTTT
		TGTACATATATGATCGTATATAC
		CC

	SEQ ID NO: 337	GATATATCACTTTTTATTTTTTA
		TAAATATATATTTTTTATTTTT
		ATATATATATATAGTGATATATC

	SEQ ID NO: 338	GTATATACATTTTTTATTTTTGA
		TAAATATATATTTTTTATTTTT
		ATATATATATATCATGTATATAC

	SEQ ID NO: 339	GTATATACATTTTTTATTTTTGA
		TGATGTATATATTTTTATTTTT
		TATATACATGATCATGTATATAC

	SEQ ID NO: 340	GTATATACATTTTTTATTTTTGA
		TGATATATGTATTTTTATTTTT
		TACATATATGATCATGTATATAC

	SEQ ID NO: 341	GGATATACACTTTTTATTTTTTA
		TAAATATATATTTTTTATTTTT
		ATATATATATATAGTGTATATCC

	SEQ ID NO: 342	GGATATACATTTTTTATTTTTGA
		TAAATATATATTTTTTATTTTT
		ATATATATATATCATGTATATCC

	SEQ ID NO: 343	GGATATACATTTTTTATTTTTGA
		TAAATGTATATTTTTTATTTTT
		ATATACATATATCATGTATATCC

	SEQ ID NO: 344	GGATATACATTTTTTATTTTTGA
		TGATGTATATATTTTTATTTTT
		TATATACATGATCATGTATATCC

	SEQ ID NO: 345	GGATATACATTTTTTATTTTTGA
		TGATATATGTATTTTTATTTTT
		TACATATATGATCATGTATATCC

	SEQ ID NO: 346	GGGTATATACTTTTTATTTTTTA
		TAAATATATATTTTTTATTTTT
		ATATATATATATAGTATATACCC

	SEQ ID NO: 347	GGATATACACTTTTTATTTTTGA
		TAAATATATATTTTTTATTTTT
		ATATATATATATCGTGTATATCC

	SEQ ID NO: 348	GGATATACACTTTTTATTTTTGA
		TAAATGTATATTTTTTATTTTT
		ATATACATATATCGTGTATATCC

	SEQ ID NO: 349	GGATATACACTTTTTATTTTTGA
		TGATGTATATATTTTTATTTTT
		TATATACATGATCGTGTATATCC

	SEQ ID NO: 350	GGATATACACTTTTTATTTTTGA
		TGATATATGTATTTTTATTTTT
		TACATATATGATCGTGTATATCC

	SEQ ID NO: 351	GGGTATATACTTTTTATTTTTGA
		TAAATATATATTTTTTATTTTT
		ATATATATATATCGTATATACCC

	SEQ ID NO: 352	GGGTATATACTTTTTATTTTTGA
		TAAATGTATATTTTTTATTTTT
		ATATACATATATCGTATATACCC

	SEQ ID NO: 353	GGGTATATACTTTTTATTTTTGA
		TGATGTATATATTTTTATTTTT
		TATATACATGATCGTATATACCC

	SEQ ID NO: 354	GGGTATATACTTTTTATTTTTGA
		TGATATATGTATTTTTATTTTT
		TACATATATGATCGTATATACCC

	SEQ ID NO: 355	GTATATACATTTTTTATTTTTGA
		TAAATATATATTTTTATTTTTT
		ATATATATATCATGTATATAC

	SEQ ID NO: 356	GTATATACATTTTTTATTTTTGA
		TGATGTATATTTTTTATTTTTA
		TATACATGATCATGTATATAC

	SEQ ID NO: 357	GTATATACATTTTTTATTTTTGA
		TGATATATGTTTTTTATTTTTA
		CATATATGATCATGTATATAC

	SEQ ID NO: 358	GGATATACATTTTTTATTTTTGA
		TAAATATATATTTTTATTTTTT
		ATATATATATCATGTATATCC

	SEQ ID NO: 359	GGATATACATTTTTTATTTTTGA
		TAAATGTATATTTTTATTTTTT
		ATACATATATCATGTATATCC

	SEQ ID NO: 360	GGATATACATTTTTTATTTTTGA
		TGATGTATATTTTTTATTTTTA
		TATACATGATCATGTATATCC

	SEQ ID NO: 361	GGATATACATTTTTTATTTTTGA
		TGATATATGTTTTTTATTTTTA
		CATATATGATCATGTATATCC

	SEQ ID NO: 362	GGATATACACTTTTTATTTTTGA
		TAAATATATATTTTTATTTTTT
		ATATATATATCGTGTATATCC

	SEQ ID NO: 363	GGATATACACTTTTTATTTTTGA
		TAAATGTATATTTTTATTTTTT
		ATACATATATCGTGTATATCC

	SEQ ID NO: 364	GGATATACACTTTTTATTTTTGA
		TGATGTATATTTTTTATTTTTA
		TATACATGATCGTGTATATCC

	SEQ ID NO: 365	GGATATACACTTTTTATTTTTGA
		TGATATATGTTTTTTATTTTTA
		CATATATGATCGTGTATATCC

	SEQ ID NO: 366	GGGTATATACTTTTTATTTTTGA
		TAAATATATATTTTTATTTTTT
		ATATATATATCGTATATACCC

	SEQ ID NO: 367	GGGTATATACTTTTTATTTTTGA
		TAAATGTATATTTTTATTTTTT
		ATACATATATCGTATATACCC

	SEQ ID NO: 368	GGGTATATACTTTTTATTTTTGA
		TGATGTATATTTTTTATTTTTA
		TATACATGATCGTATATACCC

	SEQ ID NO: 369	GGGTATATACTTTTTATTTTTGA
		TGATATATGTTTTTTATTTTTA
		CATATATGATCGTATATACCC

	SEQ ID NO: 370	GTACATATATTTTTTTATTTTTG
		ATAAATATATTTTTATTTTTTA
		TATATATCAATATATGTAC

	SEQ ID NO: 371	GTACATATATTTTTTTATTTTTG
		ATAAATGTATTTTTATTTTTTA
		CATATATCAATATATGTAC

	SEQ ID NO: 372	GTACATATATTTTTTTATTTTTG
		ATGATGTATTTTTTATTTTTAT
		ACATGATCAATATATGTAC

	SEQ ID NO: 373	GTACATATATTTTTTTATTTTTG
		ATGATATATTTTTTATTTTTAT
		ATATGATCAATATATGTAC

	SEQ ID NO: 374	GGTACATATATTTTTTATTTTTG
		ATAAATATATTTTTATTTTTTA
		TATATATCATATATGTACC

	SEQ ID NO: 375	GGTACATATATTTTTTATTTTTG
		ATAAATGTATTTTTATTTTTTA
		CATATATCATATATGTACC

	SEQ ID NO: 376	GGTACATATATTTTTTATTTTTG
		ATGATGTATTTTTTATTTTTAT
		ACATGATCATATATGTACC

	SEQ ID NO: 377	GGTACATATATTTTTTATTTTTG
		ATGATATATTTTTTATTTTTAT
		ATATGATCATATATGTACC

	SEQ ID NO: 378	CGATCATATATTTTTTTATTTTT
		GATAAATATATTTTTATTTTTT
		ATATATATCAATATATGATCG

	SEQ ID NO: 379	CGATCATATATTTTTTTATTTTT
		GATAAATGTATTTTTATTTTTT
		ACATATATCAATATATGATCG

	SEQ ID NO: 380	CGATCATATATTTTTTTATTTTT
		GATGATGTATTTTTTATTTTTA
		TACATGATCAATATATGATCG

	SEQ ID NO: 381	CGATCATATATTTTTTTATTTTT
		GATGATATATTTTTTATTTTTA
		TATATGATCAATATATGATCG

	SEQ ID NO: 382	GTATATACTTTTTATTTTTGATG
		ATGTAAATATATTTTTATTTTT
		TATATATACATGATCGTATATAC

	SEQ ID NO: 383	GTATATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTTATTTTT
		AGTACATATATGATCGTATATAC

	SEQ ID NO: 384	GGATATACTTTTTATTTTTGATG
		ATGTAAATATATTTTTATTTTT
		TATATATACATGATCGTATATCC

	SEQ ID NO: 385	GGATATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTTATTTTT
		AGTACATATATGATCGTATATCC

	SEQ ID NO: 386	GGTGATACTTTTTATTTTTGATG
		ATGTAAATATATTTTTATTTTT
		TATATATACATGATCGTATCACC

	SEQ ID NO: 387	GGTGATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTTATTTTT
		AGTACATATATGATCGTATCACC

	SEQ ID NO: 388	GGTGATCCTTTTTATTTTTGATG
		ATGTAAATATATTTTTATTTTT
		TATATATACATGATCGGATCACC

	SEQ ID NO: 389	GGTGATCCTTTTTATTTTTGATG
		ATATAAGTACTTTTTTATTTTT
		AGTACATATATGATCGGATCACC

	SEQ ID NO: 390	GTATATACATTTTTTATTTTTGA
		TGATGTAAATATATTTTTATTT
		TTTATATATACATGATCATGTAT
		ATAC

	SEQ ID NO: 391	GTATATACATTTTTTATTTTTGA
		TGATATAAGTACTTTTTTATTT
		TTAGTACATATATGATCATGTAT
		ATAC

	SEQ ID NO: 392	GGATATACATTTTTTATTTTTGA
		TAAATGTAAATATTTTTTATT
		TTTATATATACATATATCATGTA
		TATCC

	SEQ ID NO: 393	GGATATACATTTTTTATTTTTGA
		TGATGTAAATATATTTTTATT
		TTTTATATATACATGATCATGTA
		TATCC

	SEQ ID NO: 394	GGATATACATTTTTTATTTTTGA
		TGATATAAGTACTTTTTTATT
		TTTAGTACATATATGATCATGTA
		TATCC

	SEQ ID NO: 395	GGATATACACTTTTTATTTTTGA
		TGATGTAAATATATTTTTATT
		TTTTATATATACATGATCGTGTA
		TATCC

	SEQ ID NO: 396	GGATATACACTTTTTATTTTTGA
		TGATATAAGTACTTTTTTATT
		TTTAGTACATATATGATCGTGTA
		TATCC

	SEQ ID NO: 397	GGGTATATACTTTTTATTTTTGA
		TGATGTAAATATATTTTTATT
		TTTTATATATACATGATCGTATA
		TACCC

	SEQ ID NO: 398	GGGTATATACTTTTTATTTTTGA
		TGATATAAGTACTTTTTTATT
		TTTAGTACATATATGATCGTATA
		TACCC

	SEQ ID NO: 399	GTATATACTTTTTATTTTTGATG
		ATGTAAATATTTTTTATTTTTA
		TATATACATGATCGTATATAC

	SEQ ID NO: 400	GTATATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTATTTTTG
		TACATATATGATCGTATATAC

	SEQ ID NO: 401	GGATATACTTTTTATTTTTGATG
		ATGTAAATATTTTTTATTTTTA
		TATATACATGATCGTATATCC

	SEQ ID NO: 402	GGATATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTATTTTT
		GTACATATATGATCGTATATCC

	SEQ ID NO: 403	GGTGATACTTTTTATTTTTGATG
		ATGTAAATATTTTTTATTTTTA
		TATATACATGATCGTATCACC

	SEQ ID NO: 404	GGTGATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTATTTTT
		GTACATATATGATCGTATCACC

	SEQ ID NO: 405	GGTGATCCTTTTTATTTTTGATG
		ATGTAAATATTTTTTATTTTTA
		TATATACATGATCGGATCACC

	SEQ ID NO: 406	GGTGATCCTTTTTATTTTTGATG
		ATATAAGTACTTTTTATTTTTG
		TACATATATGATCGGATCACC

	SEQ ID NO: 407	GTATATACATTTTTTATTTTTGA
		TGATGTAAATATTTTTTATTTT
		TATATATACATGATCATGTATAT
		AC

	SEQ ID NO: 408	GTATATACATTTTTTATTTTTGA
		TGATATAAGTACTTTTTATTTT
		TGTACATATATGATCATGTATAT
		AC

	SEQ ID NO: 409	GGATATACATTTTTTATTTTTGA
		TGATGTAAATATTTTTTATTTT
		TATATATACATGATCATGTATAT
		CC

	SEQ ID NO: 410	GGATATACATTTTTTATTTTTGA
		TGATATAAGTACTTTTTATTT
		TTGTACATATATGATCATGTATA
		TCC

	SEQ ID NO: 411	GGATATACACTTTTTATTTTTGA
		TGATGTAAATATTTTTTATTT
		TTATATATACATGATCGTGTATA
		TCC

	SEQ ID NO: 412	GGATATACACTTTTTATTTTTGA
		TGATATAAGTACTTTTTATTT
		TTGTACATATATGATCGTGTATA
		TCC

	SEQ ID NO: 413	GGGTATATACTTTTTATTTTTGA
		TGATGTAAATATTTTTTATTTT
		TATATATACATGATCGTATATAC
		CC

	SEQ ID NO: 414	GGGTATATACTTTTTATTTTTGA
		TGATATAAGTACTTTTTATTT
		TTGTACATATATGATCGTATATA
		CCC

	SEQ ID NO: 415	GTATATACATTTTTTATTTTTGA
		TGATATAAGTATTTTTATTTTT
		TACATATATGATCATGTATATAC

	SEQ ID NO: 416	GGATATACATTTTTTATTTTTGA
		TAAATGAATATTTTTTATTTTT
		ATATACATATATCATGTATATCC

	SEQ ID NO: 417	GGATATACATTTTTTATTTTTGA
		TGATATAAGTATTTTTATTTTT
		TACATATATGATCATGTATATCC

	SEQ ID NO: 418	GGATATACACTTTTTATTTTTGA
		TAAATGAATATTTTTTATTTT
		TATATACATATATCGTGTATATC
		C

	SEQ ID NO: 419	GGATATACACTTTTTATTTTTGA
		TGATATAAGTATTTTTATTTT
		TTACATATATGATCGTGTATATC
		C

	SEQ ID NO: 420	GGGTATATACTTTTTATTTTTGA
		TAAATGAATATTTTTTATTTTT
		ATATACATATATCGTATATACCC

	SEQ ID NO: 421	GGGTATATACTTTTTATTTTTGA
		TGATATAAGTATTTTTATTTTT
		TACATATATGATCGTATATACCC

	SEQ ID NO: 422	GTATATACATTTTTTATTTTTGA
		TGATGAATATTTTTTATTTTTA
		TATACATGATCATGTATATAC

	SEQ ID NO: 423	GGATATACATTTTTTATTTTTGA
		TAAATGAATATTTTTATTTTTT
		ATACATATATCATGTATATCC

	SEQ ID NO: 424	GGATATACATTTTTTATTTTTGA
		TGATGAATATTTTTTATTTTTA
		TATACATGATCATGTATATCC

	SEQ ID NO: 425	GGATATACATTTTTTATTTTTGA
		TGATAAATGTTTTTTATTTTTA
		CATATATGATCATGTATATCC

	SEQ ID NO: 426	GGATATACACTTTTTATTTTTGA
		TGATGAATATTTTTTATTTTT
		ATATACATGATCGTGTATATCC

	SEQ ID NO: 427	GGGTATATACTTTTTATTTTTGA
		TGATGAATATTTTTTATTTTTA
		TATACATGATCGTATATACCC

	SEQ ID NO: 428	GATACTTTTTATTTTTGATGATG
		TAAATATATTTTTATTTTTTAT
		ATATACATGATCGTATC

	SEQ ID NO: 429	GATACTTTTTATTTTTGATGATA
		TAAGTACTTTTTTATTTTTAGT
		ACATATATGATCGTATC

	SEQ ID NO: 430	GACACTTTTTATTTTTGATGATG
		TAAATATATTTTTATTTTTTAT
		ATATACATGATCGTGTC

	SEQ ID NO: 431	GACACTTTTTATTTTTGATGATA
		TAAGTACTTTTTTATTTTTAGT
		ACATATATGATCGTGTC

	SEQ ID NO: 432	GGATCTTTTTATTTTTGATGATG
		TAAATATATTTTTATTTTTTAT
		ATATACATGATCGATCC

	SEQ ID NO: 433	GGATCTTTTTATTTTTGATGATA
		TAAGTACTTTTTTATTTTTAGT
		ACATATATGATCGATCC

	SEQ ID NO: 434	GCGTCTTTTTATTTTTGATGATG
		TAAATATATTTTTATTTTTTAT
		ATATACATGATCGACGC

	SEQ ID NO: 435	GCGTCTTTTTATTTTTGATGATA
		TAAGTACTTTTTTATTTTTAGT
		ACATATATGATCGACGC

	SEQ ID NO: 436	GTATACTTTTTATTTTTGATGAT
		GTAAATATTTTTTATTTTTATA
		TATACATGATCGTATAC

	SEQ ID NO: 437	GTATACTTTTTATTTTTGATGAT
		ATAAGTACTTTTTATTTTTGTA
		CATATATGATCGTATAC

	SEQ ID NO: 438	GTGATCTTTTTATTTTTGATGAT
		GTAAATATTTTTTATTTTTATA
		TATACATGATCGATCAC

	SEQ ID NO: 439	GTGATCTTTTTATTTTTGATGAT
		ATAAGTACTTTTTATTTTTGTA
		CATATATGATCGATCAC

	SEQ ID NO: 440	GGATACTTTTTATTTTTGATGAT
		GTAAATATTTTTTATTTTTATA
		TATACATGATCGTATCC

	SEQ ID NO: 441	GGATACTTTTTATTTTTGATGAT
		ATAAGTACTTTTTATTTTTGT
		ACATATATGATCGTATCC

	SEQ ID NO: 442	GCGATCTTTTTATTTTTGATGAT
		GTAAATATTTTTTATTTTTATA
		TATACATGATCGATCGC

	SEQ ID NO: 443	GCGATCTTTTTATTTTTGATGAT
		ATAAGTACTTTTTATTTTTGTA
		CATATATGATCGATCGC

	SEQ ID NO: 444	GATATATTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCATATATC

	SEQ ID NO: 445	GATATACTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCGTATATC

	SEQ ID NO: 446	GTGATACTTTTTATTTTTGATAA
		ATGAATATTTTTTATTTTTATA
		TACATATATCGTATCAC

	SEQ ID NO: 447	GTGATACTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCGTATCAC

	SEQ ID NO: 448	GGTATACTTTTTATTTTTGATAA
		ATGAATATTTTTTATTTTTATA
		TACATATATCGTATACC

	SEQ ID NO: 449	GGTATACTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCGTATACC

	SEQ ID NO: 450	GGTGTACTTTTTATTTTTGATAA
		ATGAATATTTTTTATTTTTATA
		TACATATATCGTACACC

	SEQ ID NO:451	GGTGTACTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCGTACACC

	SEQ ID NO: 452	GTATATACTTTTTATTTTTGATG
		ATGAATATTTTTTATTTTTATA
		TACATGATCGTATATAC

	SEQ ID NO: 453	GTATATACTTTTTATTTTTGATG
		ATAAATGTTTTTTATTTTTACA
		TATATGATCGTATATAC

	SEQ ID NO: 454	GGATATACTTTTTATTTTTGATG
		ATGAATATTTTTTATTTTTATA
		TACATGATCGTATATCC

	SEQ ID NO: 455	GGTGATACTTTTTATTTTTGATG
		ATGAATATTTTTTATTTTTATA
		TACATGATCGTATCACC

	SEQ ID NO: 456	GGTGATACTTTTTATTTTTGATG
		ATAAATGTTTTTTATTTTTAC
		ATATATGATCGTATCACC

	SEQ ID NO: 457	GGTGATCCTTTTTATTTTTGATG
		ATGAATATTTTTTATTTTTATA
		TACATGATCGGATCACC

	SEQ ID NO: 458	GATACTTTTTATTTTTGATATAA
		ATATATAATTTTTATTTTTATA
		TATATATATATCGTATC

	SEQ ID NO: 459	GATACTTTTTATTTTTGATAAAT
		GAATATATTTTTTATTTTTATA
		TATACATATATCGTATC

	SEQ ID NO: 460	GACACTTTTTATTTTTGATATAA
		ATATATAATTTTTATTTTTAT
		ATATATATATATCGTGTC

	SEQ ID NO: 461	GACACTTTTTATTTTTGATAAAT
		GAATATATTTTTTATTTTTAT
		ATATACATATATCGTGTC

	SEQ ID NO: 462	GACACTTTTTATTTTTGATATAA
		GTAAATATTTTTTATTTTTAT
		ATATACATATATCGTGTC

	SEQ ID NO: 463	GGATCTTTTTATTTTTGATATAA
		ATATATAATTTTTATTTTTATA
		TATATATATATCGATCC

	SEQ ID NO: 464	GGATCTTTTTATTTTTGATAAAT
		GAATATATTTTTTATTTTTATA
		TATACATATATCGATCC

	SEQ ID NO: 465	GGATCTTTTTATTTTTGATATAA
		GTAAATATTTTTTATTTTTATA
		TATACATATATCGATCC

	SEQ ID NO: 466	GCGTCTTTTTATTTTTGATATAA
		ATATATAATTTTTATTTTTATA
		TATATATATATCGACGC

	SEQ ID NO: 467	GCGTCTTTTTATTTTTGATAAAT
		GAATATATTTTTTATTTTTATA
		TATACATATATCGACGC

	SEQ ID NO: 468	GCGTCTTTTTATTTTTGATATAA
		GTAAATATTTTTTATTTTTATA
		TATACATATATCGACGC

	SEQ ID NO: 469	GTATATACATTTTTTATTTTTGA
		TATAAATATATAATTTTTATTT
		TTATATATATATATATCATGTAT
		ATAC

	SEQ ID NO: 470	GTATATACATTTTTTATTTTTGA
		TAAATGAATATATTTTTTATTT
		TTATATATACATATATCATGTAT
		ATAC

	SEQ ID NO: 471	GTATATACATTTTTTATTTTTGA
		TATAAGTAAATATTTTTTATTT
		TTATATATACATATATCATGTAT
		ATAC

	SEQ ID NO: 472	GGATATACATTTTTTATTTTTGA
		TATAAATATATAATTTTTATT
		TTTATATATATATATATCATGTA
		TATCC

	SEQ ID NO: 473	GGATATACACTTTTTATTTTTGA
		TATAAATATATAATTTTTATT
		TTTATATATATATATATCGTGTA
		TATCC

	SEQ ID NO: 474	GGATATACACTTTTTATTTTTGA
		TAAATGAATATATTTTTTATT
		TTTATATATACATATATCGTGTA
		TATCC

	SEQ ID NO: 475	GGATATACACTTTTTATTTTTGA
		TATAAGTAAATATTTTTTATT
		TTTATATATACATATATCGTGTA
		TATCC

	SEQ ID NO: 476	GGGTATATACTTTTTATTTTTGA
		TATAAATATATAATTTTTATT
		TTTATATATATATATATCGTATA
		TACCC

	SEQ ID NO: 477	GGGTATATACTTTTTATTTTTGA
		TAAATGAATATATTTTTTATT
		TTTATATATACATATATCGTATA
		TACCC

	SEQ ID NO: 478	GGGTATATACTTTTTATTTTTGA
		TATAAGTAAATATTTTTTATT
		TTTATATATACATATATCGTATA
		TACCC

	SEQ ID NO: 479	GTATACTTTTTATTTTTTATAAA
		TATATATTTTTTTATTTTTTAT
		ATATATATATAGTATAC

	SEQ ID NO: 480	GTGATCTTTTTATTTTTTATAAA
		TATATATTTTTTTATTTTTTAT
		ATATATATATAGATCAC

	SEQ ID NO: 481	GTATACTTTTTATTTTTGATATA
		AATATATTTTTTTATTTTTTAT
		ATATATATATCGTATAC

	SEQ ID NO: 482	GTATACTTTTTATTTTTGATATA
		TAAATATTTTTTTATTTTTTAT
		ATATATATATCGTATAC

	SEQ ID NO: 483	GTATACTTTTTATTTTTGATAAA
		TGAATATATTTTTATTTTTTAT
		ATACATATATCGTATAC

	SEQ ID NO: 484	GGATACTTTTTATTTTTTATAAA
		TATATATTTTTTTATTTTTTAT
		ATATATATATAGTATCC

	SEQ ID NO: 485	GTGATCTTTTTATTTTTGATATA
		AATATATTTTTTTATTTTTTAT
		ATATATATATCGATCAC

	SEQ ID NO: 486	GTGATCTTTTTATTTTTGATATA
		TAAATATTTTTTTATTTTTTAT
		ATATATATATCGATCAC

	SEQ ID NO: 487	GTGATCTTTTTATTTTTGATAAA
		TGAATATATTTTTATTTTTTAT
		ATACATATATCGATCAC

	SEQ ID NO: 488	GGATACTTTTTATTTTTGATATA
		AATATATTTTTTTATTTTTTAT
		ATATATATATCGTATCC

	SEQ ID NO: 489	GGATACTTTTTATTTTTGATATA
		TAAATATTTTTTTATTTTTTAT
		ATATATATATCGTATCC

	SEQ ID NO: 490	GGATACTTTTTATTTTTGATAAA
		TGAATATATTTTTATTTTTTAT
		ATACATATATCGTATCC

	SEQ ID NO: 491	GCGATCTTTTTATTTTTTATAAA
		TATATATTTTTTTATTTTTTAT
		ATATATATATAGATCGC

	SEQ ID NO: 492	GCGATCTTTTTATTTTTGATATA
		AATATATTTTTTTATTTTTTAT
		ATATATATATCGATCGC

	SEQ ID NO: 493	GCGATCTTTTTATTTTTGATATA
		TAAATATTTTTTTATTTTTTAT
		ATATATATATCGATCGC

	SEQ ID NO: 494	GCGATCTTTTTATTTTTGATAAA
		TGAATATATTTTTATTTTTTAT
		ATACATATATCGATCGC

	SEQ ID NO: 495	GATATATCACTTTTTATTTTTTA
		TAAATATATATTTTTTTATTTT
		TTATATATATATATAGTGATATA
		TC

	SEQ ID NO: 496	GTATATACATTTTTTATTTTTGA
		TATAAATATATTTTTTTATTTT
		TTATATATATATATCATGTATAT
		AC

	SEQ ID NO: 497	GTATATACATTTTTTATTTTTGA
		TATATAAATATTTTTTTATTTT
		TTATATATATATATCATGTATAT
		AC

	SEQ ID NO: 498	GGATATACACTTTTTATTTTTTA
		TAAATATATATTTTTTTATTTT
		TTATATATATATATAGTGTATAT
		CC

	SEQ ID NO: 499	GGATATACATTTTTTATTTTTGA
		TATAAATATATTTTTTTATTTT
		TTATATATATATATCATGTATAT
		CC

	SEQ ID NO: 500	GGATATACATTTTTTATTTTTGA
		TATATAAATATTTTTTTATTTT
		TTATATATATATATCATGTATAT
		CC

	SEQ ID NO: 501	GGATATACATTTTTTATTTTTGA
		TAAATGAATATATTTTTATTT
		TTTATATACATATATCATGTATA
		TCC

	SEQ ID NO: 502	GGGTATATACTTTTTATTTTTTA
		TAAATATATATTTTTTTATTTT
		TTATATATATATATAGTATATAC
		CC

	SEQ ID NO: 503	GGATATACACTTTTTATTTTTGA
		TATAAATATATTTTTTTATTTT
		TTATATATATATATCGTGTATAT
		CC

	SEQ ID NO: 504	GGATATACACTTTTTATTTTTGA
		TATATAAATATTTTTTTATTTT
		TTATATATATATATCGTGTATAT
		CC

	SEQ ID NO: 505	GGATATACACTTTTTATTTTTGA
		TAAATGAATATATTTTTATTT
		TTTATATACATATATCGTGTATA
		TCC

	SEQ ID NO: 506	GGGTATATACTTTTTATTTTTGA
		TATAAATATATTTTTTTATTTT
		TTATATATATATATCGTATATAC
		CC

	SEQ ID NO: 507	GGGTATATACTTTTTATTTTTGA
		TATATAAATATTTTTTTATTTT
		TTATATATATATATCGTATATAC
		CC

	SEQ ID NO: 508	GGGTATATACTTTTTATTTTTGA
		TAAATGAATATATTTTTATTT
		TTTATATACATATATCGTATATA
		CCC

	SEQ ID NO: 509	GATATACTTTTTATTTTTGATAA
		ATATATAATTTTTATTTTTATA
		TATATATATCGTATATC

	SEQ ID NO: 510	GTGATACTTTTTATTTTTGATAA
		ATATATAATTTTTATTTTTATA
		TATATATATCGTATCAC

	SEQ ID NO: 511	GGTATACTTTTTATTTTTGATAA
		ATATATAATTTTTATTTTTATA
		TATATATATCGTATACC

	SEQ ID NO: 512	GGTGTACTTTTTATTTTTGATAA
		ATATATAATTTTTATTTTTATA
		TATATATATCGTACACC

	SEQ ID NO: 513	GTATATACATTTTTTATTTTTGA
		TAAATATATAATTTTTATTTTT
		ATATATATATATCATGTATATAC

	SEQ ID NO: 514	GGATATACATTTTTTATTTTTGA
		TAAATATATAATTTTTATTTTT
		ATATATATATATCATGTATATCC

	SEQ ID NO: 515	GGATATACACTTTTTATTTTTGA
		TAAATATATAATTTTTATTTT
		TATATATATATATCGTGTATATC
		C

	SEQ ID NO: 516	GGGTATATACTTTTTATTTTTGA
		TAAATATATAATTTTTATTTTT
		ATATATATATATCGTATATACCC

	SEQ ID NO: 517	GTATATACTTTTTATTTTTGATA
		AATATATTTTTTTATTTTTTAT
		ATATATATCGTATATAC

	SEQ ID NO: 518	GTATATACTTTTTATTTTTGATA
		AATGTATTTTTTTATTTTTTAT
		ACATATATCGTATATAC

	SEQ ID NO: 519	GGATATACTTTTTATTTTTGATA
		AATATATTTTTTTATTTTTTAT
		ATATATATCGTATATCC

	SEQ ID NO: 520	GGATATACTTTTTATTTTTGATA
		AATGTATTTTTTTATTTTTTAT
		ACATATATCGTATATCC

	SEQ ID NO: 521	GGATATACTTTTTATTTTTGATG
		ATAAATGTTTTTTATTTTTAC
		ATATATGATCGTATATCC

	SEQ ID NO: 522	GGTGATACTTTTTATTTTTGATA
		AATATATTTTTTTATTTTTTAT
		ATATATATCGTATCACC

	SEQ ID NO: 523	GGTGATACTTTTTATTTTTGATA
		AATGTATTTTTTTATTTTTTAT
		ACATATATCGTATCACC

	SEQ ID NO: 524	GGTGATCCTTTTTATTTTTGATA
		AATATATTTTTTTATTTTTTAT
		ATATATATCGGATCACC

	SEQ ID NO: 525	GGTGATCCTTTTTATTTTTGATA
		AATGTATTTTTTTATTTTTTAT
		ACATATATCGGATCACC

	SEQ ID NO: 526	GGTGATCCTTTTTATTTTTGATG
		ATAAATGTTTTTTATTTTTACA
		TATATGATCGGATCACC

	SEQ ID NO: 527	GTATATACATTTTTTATTTTTGA
		TAAATATATTTTTTTATTTTTT
		ATATATATATCATGTATATAC

	SEQ ID NO: 528	GTATATACATTTTTTATTTTTGA
		TAAATGTATTTTTTTATTTTTT
		ATACATATATCATGTATATAC

	SEQ ID NO: 529	GTATATACATTTTTTATTTTTGA
		TGATAAATGTTTTTTATTTTTA
		CATATATGATCATGTATATAC

	SEQ ID NO: 530	GGATATACATTTTTTATTTTTGA
		TAAATATATTTTTTTATTTTTT
		ATATATATATCATGTATATCC

	SEQ ID NO: 531	GGATATACACTTTTTATTTTTGA
		TAAATATATTTTTTTATTTTTT
		ATATATATATCGTGTATATCC

	SEQ ID NO: 532	GGATATACACTTTTTATTTTTGA
		TAAATGTATTTTTTTATTTTTT
		ATACATATATCGTGTATATCC

	SEQ ID NO: 533	GGATATACACTTTTTATTTTTGA
		TGATAAATGTTTTTTATTTTT
		ACATATATGATCGTGTATATCC

	SEQ ID NO: 534	GGGTATATACTTTTTATTTTTGA
		TAAATATATTTTTTTATTTTTT
		ATATATATATCGTATATACCC

	SEQ ID NO: 535	GGGTATATACTTTTTATTTTTGA
		TAAATGTATTTTTTTATTTTTT
		ATACATATATCGTATATACCC

	SEQ ID NO: 536	GGGTATATACTTTTTATTTTTGA
		TGATAAATGTTTTTTATTTTTA
		CATATATGATCGTATATACCC

	SEQ ID NO: 537	GTATATACATTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCATGTATATAC

	SEQ ID NO: 538	GTATATACATTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCATGTATATAC

	SEQ ID NO: 539	GGATATACATTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCATGTATATCC

	SEQ ID NO: 540	GGATATACATTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCATGTATATCC

	SEQ ID NO: 541	GGATATACATTTTTTATTTTTGA
		TGATGAATTTTTTATTTTTATA
		CATGATCATGTATATCC

	SEQ ID NO: 542	GGATATACACTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCGTGTATATCC

	SEQ ID NO: 543	GGATATACACTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCGTGTATATCC

	SEQ ID NO: 544	GGGTATATACTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCGTATATACCC

	SEQ ID NO: 545	GGGTATATACTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCGTATATACCC

	SEQ ID NO: 546	GGATGTACACTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCGTGTACATCC

	SEQ ID NO: 547	GGATGTACACTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCGTGTACATCC

	SEQ ID NO: 548	GTACATATATTTTTTTATTTTTG
		ATAAATATTTTTTTATTTTTTA
		TATATATCAATATATGTAC

	SEQ ID NO: 549	GTACATATATTTTTTTATTTTTG
		ATAAATGTTTTTTTATTTTTTA
		CATATATCAATATATGTAC

	SEQ ID NO: 550	GGTACATATATTTTTTATTTTTG
		ATAAATATTTTTTTATTTTTTA
		TATATATCATATATGTACC

	SEQ ID NO: 551	GGTACATATATTTTTTATTTTTG
		ATAAATGTTTTTTTATTTTTTA
		CATATATCATATATGTACC

	SEQ ID NO: 552	CGATCATATATTTTTTTATTTTT
		GATAAATATTTTTTTATTTTTT
		ATATATATCAATATATGATCG

	SEQ ID NO: 553	CGATCATATATTTTTTTATTTTT
		GATAAATGTTTTTTTATTTTTT
		ACATATATCAATATATGATCG

	SEQ ID NO: 554	CGATCATATATTTTTTTATTTTT
		GATGATGAATTTTTTATTTTTA
		TACATGATCAATATATGATCG

	SEQ ID NO: 555	CGATCATATATTTTTTTATTTTT
		GATGATAAATTTTTTATTTTTA
		TATATGATCAATATATGATCG

	SEQ ID NO: 556	GTATATACTTTTTATTTTTGATA
		TAAATATATAATTTTTATTTTT
		ATATATATATATATCGTATATAC

	SEQ ID NO: 557	GTATATACTTTTTATTTTTGATA
		AATGAATATATTTTTTATTTTT
		ATATATACATATATCGTATATAC

	SEQ ID NO: 558	GGATATACTTTTTATTTTTGATA
		TAAATATATAATTTTTATTTTT
		ATATATATATATATCGTATATCC

	SEQ ID NO: 559	GGATATACTTTTTATTTTTGATA
		AATGAATATATTTTTTATTTTT
		ATATATACATATATCGTATATCC

	SEQ ID NO: 560	GGTGATACTTTTTATTTTTGATA
		TAAATATATAATTTTTATTTTT
		ATATATATATATATCGTATCACC

	SEQ ID NO: 561	GGTGATACTTTTTATTTTTGATA
		AATGAATATATTTTTTATTTTT
		ATATATACATATATCGTATCACC

	SEQ ID NO: 562	GGTGATCCTTTTTATTTTTGATA
		TAAATATATAATTTTTATTTTT
		ATATATATATATATCGGATCACC

	SEQ ID NO: 563	GGTGATCCTTTTTATTTTTGATA
		AATGAATATATTTTTTATTTTT
		ATATATACATATATCGGATCACC

	SEQ ID NO: 564	GTATATACTTTTTATTTTTGATA
		TAAGTAAATATTTTTTATTTTT
		ATATATACATATATCGTATATAC

	SEQ ID NO: 565	GGATATACTTTTTATTTTTGATA
		TAAGTAAATATTTTTTATTTTT
		ATATATACATATATCGTATATCC

	SEQ ID NO: 566	GGTGATACTTTTTATTTTTGATA
		TAAGTAAATATTTTTTATTTTT
		ATATATACATATATCGTATCACC

	SEQ ID NO: 567	GGTGATCCTTTTTATTTTTGATA
		TAAGTAAATATTTTTTATTTTT
		ATATATACATATATCGGATCACC

	SEQ ID NO: 568	GTATATACTTTTTATTTTTTATA
		AATATATATTTTTTTATTTTTT
		ATATATATATATAGTATATAC

	SEQ ID NO: 569	GTATATACTTTTTATTTTTGATA
		TAAATATATTTTTTTATTTTTT
		ATATATATATATCGTATATAC

	SEQ ID NO: 570	GTATATACTTTTTATTTTTGATA
		AATGAATATATTTTTATTTTTT
		ATATACATATATCGTATATAC

	SEQ ID NO: 571	GGATATACTTTTTATTTTTTATA
		AATATATATTTTTTTATTTTTT
		ATATATATATATAGTATATCC

	SEQ ID NO: 572	GGATATACTTTTTATTTTTGATA
		TAAATATATTTTTTTATTTTTT
		ATATATATATATCGTATATCC

	SEQ ID NO: 573	GGATATACTTTTTATTTTTGATA
		AATGAATATATTTTTATTTTTT
		ATATACATATATCGTATATCC

	SEQ ID NO: 574	GGTGATACTTTTTATTTTTTATA
		AATATATATTTTTTTATTTTTT
		ATATATATATATAGTATCACC

	SEQ ID NO: 575	GGTGATACTTTTTATTTTTGATA
		TAAATATATTTTTTTATTTTTT
		ATATATATATATCGTATCACC

	SEQ ID NO: 576	GGTGATACTTTTTATTTTTGATA
		AATGAATATATTTTTATTTTTT
		ATATACATATATCGTATCACC

	SEQ ID NO: 577	GGTGATCCTTTTTATTTTTTATA
		AATATATATTTTTTTATTTTTT
		ATATATATATATAGGATCACC

	SEQ ID NO: 578	GGTGATCCTTTTTATTTTTGATA
		TAAATATATTTTTTTATTTTTT
		ATATATATATATCGGATCACC

	SEQ ID NO: 579	GGTGATCCTTTTTATTTTTGATA
		AATGAATATATTTTTATTTTTT
		ATATACATATATCGGATCACC

	SEQ ID NO: 580	GTATATACTTTTTATTTTTGATA
		TATAAATATTTTTTTATTTTTT
		ATATATATATATCGTATATAC

	SEQ ID NO: 581	GGATATACTTTTTATTTTTGATA
		TATAAATATTTTTTTATTTTTT
		ATATATATATATCGTATATCC

	SEQ ID NO: 582	GGTGATACTTTTTATTTTTGATA
		TATAAATATTTTTTTATTTTTT
		ATATATATATATCGTATCACC

	SEQ ID NO: 583	GGTGATCCTTTTTATTTTTGATA
		TATAAATATTTTTTTATTTTTT
		ATATATATATATCGGATCACC

	SEQ ID NO: 584	GATACAAAAAAAAAAATATATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATATAGTATC

	SEQ ID NO: 585	GACACAAAAAAAAAAAGATATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATATCGTGTC

	SEQ ID NO: 586	GATATACAAAAAAAAAAATATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATAGTATATC

	SEQ ID NO: 587	GATATATAAAAAAAAAAAGATAT
		ATGTATATAAAAAAAAAAA
		ATATACATATATCATATATC

	SEQ ID NO: 588	GATATACAAAAAAAAAAAGATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATCGTATATC

	SEQ ID NO: 589	GGTATACAAAAAAAAAAATATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATAGTATACC

	SEQ ID NO: 590	GATATATCACAAAAAAAAAAATA
		TATATATAAAAAAAAAAAA
		TATATATATAGTGATATATC

	SEQ ID NO: 591	GTATATACATAAAAAAAAAAAGA
		TATATGTAAAAAAAAAAAA
		TACATATATCATGTATATAC

	SEQ ID NO: 592	GGATATACATAAAAAAAAAAAGA
		TATATGTAAAAAAAAAAA
		ATACATATATCATGTATATCC

	SEQ ID NO: 593	GGATATACATAAAAAAAAAAAGA
		TCATGTATAAAAAAAAAAA
		ATACATGATCATGTATATCC

	SEQ ID NO: 594	GGGTATATACAAAAAAAAAAATA
		TATATATAAAAAAAAAAAA
		TATATATATAGTATATACCC

	SEQ ID NO: 595	GTATATACAAAAAAAAAAATATA
		TATATATATATAAAAAAAA
		AAAATATATATATATATAGTATA
		TAC

	SEQ ID NO: 596	GTATATACAAAAAAAAAAAGATA
		TATATATATATAAAAAAAA
		AAAATATATATATATATCGTATA
		TAC

	SEQ ID NO: 597	GGATATACAAAAAAAAAAATATA
		TATATATATATAAAAAAAA
		AAAATATATATATATATAGTATA
		TCC

	SEQ ID NO: 598	GGATATACAAAAAAAAAAAGATA
		TATATATATATAAAAAAAA
		AAAATATATATATATATCGTATA
		TCC

	SEQ ID NO: 599	GTATATACAAAAAAAAAAATATA
		TATATATATAAAAAAAAAA
		AATATATATATATATAGTATATA
		C

	SEQ ID NO: 600	GTATATACAAAAAAAAAAAGATA
		TATATATATAAAAAAAAAA
		AATATATATATATATCGTATATA
		C

	SEQ ID NO: 601	GGATATACAAAAAAAAAAATATA
		TATATATATAAAAAAAAAA
		AATATATATATATATAGTATATC
		C

	SEQ ID NO: 602	GGATATACAAAAAAAAAAAGATA
		TATATATATAAAAAAAAAA
		AATATATATATATATCGTATATC
		C

	SEQ ID NO: 603	GATATATCACAAAAAAAAAAATA
		TATATATATAAAAAAAAAA
		AATATATATATATAGTGATATAT
		C

	SEQ ID NO: 604	GGATATACATAAAAAAAAAAAGA
		TATATATATAAAAAAAAAA
		AATATATATATATCATGTATATC
		C

	SEQ ID NO: 605	GTACATATATTAAAAAAAAAAAG
		ATATATATAAAAAAAAAAA
		ATATATATATCAATATATGTAC

	SEQ ID NO: 606	GATGTATATACAAAAAAAAAAAT
		ATATATATAAAAAAAAAAA
		ATATATATATAGTATATACATC

	SEQ ID NO: 607	CGATCATATATTAAAAAAAAAAA
		GATATATATAAAAAAAAAA
		AATATATATATCAATATATGATC
		G

	SEQ ID NO: 608	CGATCATATATTAAAAAAAAAAA
		GATATATGTAAAAAAAAAA
		AATACATATATCAATATATGATC
		G

	SEQ ID NO: 609	GATACAAAAAAAAAAATATAAAT
		ATATATATAAAAAAAAAAA
		ATATATATATATATAGTATC

	SEQ ID NO: 610	GGATCAAAAAAAAAAATATAAAT
		ATATATATAAAAAAAAAAA
		ATATATATATATATAGATCC

	SEQ ID NO: 611	GACACAAAAAAAAAAAGATAAAT
		ATATATATAAAAAAAAAA
		AATATATATATATATCGTGTC

	SEQ ID NO: 612	GACACAAAAAAAAAAAGATGATG
		TATATATAAAAAAAAAAA
		ATATATATACATGATCGTGTC

	SEQ ID NO: 613	GCGTCAAAAAAAAAAAGATAAAT
		ATATATATAAAAAAAAAAA
		ATATATATATATATCGACGC

	SEQ ID NO: 614	GATATACAAAAAAAAAAATATAA
		ATATATATAAAAAAAAAAA
		ATATATATATATAGTATATC

	SEQ ID NO: 615	GTATATACATAAAAAAAAAAAGA
		TAAATGTAAAAAAAAAAA
		ATACATATATCATGTATATAC

	SEQ ID NO: 616	GTATATACATAAAAAAAAAAAGA
		TGATATATAAAAAAAAAAA
		ATATATGATCATGTATATAC

	SEQ ID NO: 617	GGATATACATAAAAAAAAAAAGA
		TAAATATAAAAAAAAAAA
		ATATATATATCATGTATATCC

	SEQ ID NO: 618	GGATATACATAAAAAAAAAAAGA
		TGATATATAAAAAAAAAA
		AATATATGATCATGTATATCC

	SEQ ID NO: 619	GTATATACAAAAAAAAAAATATA
		AATATATATATAAAAAAAA
		AAAATATATATATATATAGTATA
		TAC

	SEQ ID NO: 620	GTATATACAAAAAAAAAAAGATA
		AATATATATATAAAAAAAA
		AAAATATATATATATATCGTATA
		TAC

	SEQ ID NO: 621	GGATATACAAAAAAAAAAATATA
		AATATATATATAAAAAAAA
		AAAATATATATATATATAGTATA
		TCC

	SEQ ID NO: 622	GGATATACAAAAAAAAAAAGATA
		AATATATATATAAAAAAAA
		AAAATATATATATATATCGTATA
		TCC

	SEQ ID NO: 623	GTATATACAAAAAAAAAAAGATA
		AATGTATATAAAAAAAAAA
		AATATATACATATATCGTATATA
		C

	SEQ ID NO: 624	GGATATACAAAAAAAAAAAGATA
		AATGTATATAAAAAAAAA
		AAATATATACATATATCGTATAT
		CC

	SEQ ID NO: 625	GGTGATACAAAAAAAAAAAGATG
		ATGTATATATAAAAAAAAA
		AAATATATACATGATCGTATCAC
		C

	SEQ ID NO: 626	GATATATCACAAAAAAAAAAATA
		TAAATATATATAAAAAAAA
		AAAATATATATATATAGTGATAT
		ATC

	SEQ ID NO: 627	GTATATACATAAAAAAAAAAAGA
		TAAATATATAAAAAAAAAA
		AATATATATATATCATGTATATA
		C

	SEQ ID NO: 628	GTATATACATAAAAAAAAAAAGA
		TGATATATGTAAAAAAAAA
		AAACATATATGATCATGTATATA
		C

	SEQ ID NO: 629	GGATATACATAAAAAAAAAAAGA
		TAAATATATAAAAAAAAA
		AAATATATATATATCATGTATAT
		CC

	SEQ ID NO: 630	GTACATATATTAAAAAAAAAAAG
		ATAAATATAAAAAAAAAAA
		ATATATATATCAATATATGTAC

	SEQ ID NO: 631	GTACATATATTAAAAAAAAAAAG
		ATAAATGTAAAAAAAAAAA
		ATACATATATCAATATATGTAC

	SEQ ID NO: 632	GTACATATATTAAAAAAAAAAAG
		ATGATATATAAAAAAAAAA
		AATATATGATCAATATATGTAC

	SEQ ID NO: 633	GGATATACATAAAAAAAAAAAGA
		TGATGAATAAAAAAAAAA
		AATACATGATCATGTATATCC

	SEQ ID NO: 634	GTATATACATAAAAAAAAAAAGA
		TAAATGTTAAAAAAAAAAA
		TACATATATCATGTATATAC

	SEQ ID NO: 635	GATACAAAAAAAAAAAGATATAA
		ATATATAAAAAAAAAAAA
		AATATATATATATATCGTATC

	SEQ ID NO: 636	GATACAAAAAAAAAAAGATGATA
		TAAGTACTAAAAAAAAAA
		AAGTACATATATGATCGTATC

	SEQ ID NO: 637	GACACAAAAAAAAAAAGATAAAT
		GAATATATAAAAAAAAAA
		AATATATACATATATCGTGTC

	SEQ ID NO: 638	GGATATACAAAAAAAAAAAGATA
		TAAGTAAATATAAAAAAA
		AAAAATATATACATATATCGTAT
		ATCC

	SEQ ID NO: 639	GGATATACAAAAAAAAAAAGATG
		ATATAAGTACTAAAAAAAA
		AAAAGTACATATATGATCGTATA
		TCC

	SEQ ID NO: 640	GTATATACAAAAAAAAAAAGATA
		TAAGTAAATATAAAAAAAA
		AAAATATATACATATATCGTATA
		TAC

	SEQ ID NO: 641	GTATATACAAAAAAAAAAAGATG
		ATATAAGTACTAAAAAAAA
		AAAAGTACATATATGATCGTATA
		TAC

	SEQ ID NO: 642	GGATATACAAAAAAAAAAAGATA
		AATGAATATAAAAAAAAA
		AAATATATACATATATCGTATAT
		CC

	SEQ ID NO: 643	GTATATACAAAAAAAAAAAGATA
		AATGAATATAAAAAAAAA
		AAATATATACATATATCGTATAT
		AC

	SEQ ID NO: 644	GTATATACAAAAAAAAAAAGATG
		ATATAAGTACAAAAAAAAA
		AAGTACATATATGATCGTATATA
		C

	SEQ ID NO: 645	GTATATACAAAAAAAAAAATATA
		AATATATATTAAAAAAAAA
		AATATATATATATATAGTATATA
		C

	SEQ ID NO: 646	GTATATACATAAAAAAAAAAAGA
		TGATGTAAATATAAAAAAA
		AAAAATATATACATGATCATGTA
		TATAC

	SEQ ID NO: 647	GATATACAAAAAAAAAAAGATAA
		ATATATAAAAAAAAAAAA
		AATATATATATATCGTATATC

	SEQ ID NO: 648	GTGATACAAAAAAAAAAAGATAA
		ATATATAAAAAAAAAAAA
		AATATATATATATCGTATCAC

	SEQ ID NO: 649	GGTATACAAAAAAAAAAAGATAA
		ATATATAAAAAAAAAAAA
		AATATATATATATCGTATACC

	SEQ ID NO: 650	GGATATACATAAAAAAAAAAAGA
		TAAATGAATAAAAAAAAA
		AAATATACATATATCATGTATAT
		CC

	SEQ ID NO: 651	GTATATACATAAAAAAAAAAAGA
		TAAATGTATTAAAAAAAAA
		AATATACATATATCATGTATATA
		C

	SEQ ID NO: 652	GTATATACATAAAAAAAAAAAGA
		TGATAAATGTAAAAAAAAA
		AAACATATATGATCATGTATATA
		C

	SEQ ID NO: 653	GATACTTTTTATTTTTTATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*A
		GTAT*C

	SEQ ID NO: 654	GACACTTTTTATTTTTTATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*A
		GTGT*C

	SEQ ID NO: 655	GATACTTTTTATTTTTGATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*C
		GTAT*C

	SEQ ID NO: 656	GGATCTTTTTATTTTTTATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*A
		GATC*C

	SEQ ID NO: 657	GACACTTTTTATTTTTGATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*C
		GTGT*C

	SEQ ID NO: 658	GGATCTTTTTATTTTTGATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*C
		GATC*C

	SEQ ID NO: 659	GCGTCTTTTTATTTTTTATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*A
		GACG*C

	SEQ ID NO: 660	GCGTCTTTTTATTTTTGATATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*C
		GACG*C

	SEQ ID NO: 661	GTATACTTTTTATTTTTTATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATA*G
		TATA*C

	SEQ ID NO: 662	GTGATCTTTTTATTTTTTATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATA*G
		ATCA*C

	SEQ ID NO: 663	GTATACTTTTTATTTTTGATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATC*G
		TATA*C

	SEQ ID NO: 664	GTATACTTTTTATTTTTGATATA
		TGTATATATTTTTATTTTTTAT
		ATACATATATC*G
		TATA*C

	SEQ ID NO: 665	GGATACTTTTTATTTTTTATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATA*G
		TATC*C

	SEQ ID NO: 666	GTGATCTTTTTATTTTTGATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATC*G
		ATCA*C

	SEQ ID NO: 667	GTGATCTTTTTATTTTTGATATA
		TGTATATATTTTTATTTTTTAT
		ATACATATATC*G
		ATCA*C

	SEQ ID NO: 668	GGATACTTTTTATTTTTGATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATC*G
		TATC*C

	SEQ ID NO: 669	GGATACTTTTTATTTTTGATATA
		TGTATATATTTTTATTTTTTAT
		ATACATATATC*G
		TATC*C

	SEQ ID NO: 670	GCGATCTTTTTATTTTTTATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATA*G
		ATCG*C

	SEQ ID NO: 671	GCGATCTTTTTATTTTTGATATA
		TATATATATTTTTATTTTTTAT
		ATATATATATC*G
		ATCG*C

	SEQ ID NO: 672	GCGATCTTTTTATTTTTGATATA
		TGTATATATTTTTATTTTTTAT
		ATACATATATC*G
		ATCG*C

	SEQ ID NO: 673	GATATACTTTTTATTTTTTATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAG*T
		ATAT*C

	SEQ ID NO: 674	GATATATTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCA*T
		ATAT*C

	SEQ ID NO: 675	GATATATTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCA*T
		ATAT*C

	SEQ ID NO: 676	GTGATACTTTTTATTTTTTATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAG*T
		ATCA*C

	SEQ ID NO: 677	GATATACTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCG*T
		ATAT*C

	SEQ ID NO: 678	GATATACTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCG*T
		ATAT*C

	SEQ ID NO: 679	GGTATACTTTTTATTTTTTATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAG*T
		ATAC*C

	SEQ ID NO: 680	GTGATACTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCG*T
		ATCA*C

	SEQ ID NO: 681	GTGATACTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCG*T
		ATCA*C

	SEQ ID NO: 682	GGTATACTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCG*T
		ATAC*C

	SEQ ID NO: 683	GGTATACTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCG*T
		ATAC*C

	SEQ ID NO: 684	GGTGTACTTTTTATTTTTTATAT
		ATATATATTTTTTATTTTTATA
		TATATATATAG*T
		ACAC*C

	SEQ ID NO: 685	GGTGTACTTTTTATTTTTGATAT
		ATATATATTTTTTATTTTTATA
		TATATATATCG*T
		ACAC*C

	SEQ ID NO: 686	GGTGTACTTTTTATTTTTGATAT
		ATGTATATTTTTTATTTTTATA
		TACATATATCG*T
		ACAC*C

	SEQ ID NO: 687	GTATATACTTTTTATTTTTTATA
		TATATATATTTTTATTTTTTAT
		ATATATATAGT*A
		TATA*C

	SEQ ID NO: 688	GTATATACTTTTTATTTTTGATA
		TATATATATTTTTATTTTTTAT
		ATATATATCGT*A
		TATA*C

	SEQ ID NO: 689	GTATATACTTTTTATTTTTGATA
		TATGTATATTTTTATTTTTTAT
		ACATATATCGT*A
		TATA*C

	SEQ ID NO: 690	GTATATACTTTTTATTTTTGATC
		ATGTATATTTTTTATTTTTATA
		TACATGATCGT*A
		TATA*C

	SEQ ID NO: 691	GTATATACTTTTTATTTTTGATC
		ATATATGTTTTTTATTTTTACA
		TATATGATCGT*A
		TATA*C

	SEQ ID NO: 692	GGATATACTTTTTATTTTTTATA
		TATATATATTTTTATTTTTTAT
		ATATATATAGT*A
		TATC*C

	SEQ ID NO: 693	GGATATACTTTTTATTTTTGATA
		TATATATATTTTTATTTTTTAT
		ATATATATCGT*A
		TATC*C

	SEQ ID NO: 694	GGATATACTTTTTATTTTTGATA
		TATGTATATTTTTATTTTTTAT
		ACATATATCGT*A
		TATC*C

	SEQ ID NO: 695	GGATATACTTTTTATTTTTGATC
		ATGTATATTTTTTATTTTTATA
		TACATGATCGT*A
		TATC*C

	SEQ ID NO: 696	GGATATACTTTTTATTTTTGATC
		ATATATGTTTTTTATTTTTACA
		TATATGATCGT*A
		TATC*C

	SEQ ID NO: 697	GGTGATACTTTTTATTTTTTATA
		TATATATATTTTTATTTTTTAT
		ATATATATAGT*A
		TCAC*C

	SEQ ID NO: 698	GGTGATACTTTTTATTTTTGATA
		TATATATATTTTTATTTTTTAT
		ATATATATCGT*A
		TCAC*C

	SEQ ID NO: 699	GGTGATACTTTTTATTTTTGATA
		TATGTATATTTTTATTTTTTAT
		ACATATATCGT*A
		TCAC*C

	SEQ ID NO: 700	GGTGATACTTTTTATTTTTGATC
		ATGTATATTTTTTATTTTTATA
		TACATGATCGT*A
		TCAC*C

	SEQ ID NO: 701	GGTGATACTTTTTATTTTTGATC
		ATATATGTTTTTTATTTTTACA
		TATATGATCGT*A
		TCAC*C

	SEQ ID NO: 702	GGTGATCCTTTTTATTTTTTATA
		TATATATATTTTTATTTTTTAT
		ATATATATAGG*A
		TCAC*C

	SEQ ID NO: 703	GGTGATCCTTTTTATTTTTGATA
		TATATATATTTTTATTTTTTAT
		ATATATATCGG*A
		TCAC*C

	SEQ ID NO: 704	GGTGATCCTTTTTATTTTTGATA
		TATGTATATTTTTATTTTTTAT
		ACATATATCGG*A
		TCAC*C

	SEQ ID NO: 705	GGTGATCCTTTTTATTTTTGATC
		ATGTATATTTTTTATTTTTATA
		TACATGATCGG*A
		TCAC*C

	SEQ ID NO: 706	GGTGATCCTTTTTATTTTTGATC
		ATATATGTTTTTTATTTTTACA
		TATATGATCGG*A
		TCAC*C

	SEQ ID NO: 707	GATATATCACTTTTTATTTTTTA
		TATATATATTTTTATTTTTTAT
		ATATATAGTGA*T
		ATAT*C

	SEQ ID NO: 708	GTATATACATTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCATGT*A
		TATA*C

	SEQ ID NO: 709	GTATATACATTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCATGT*A
		TATA*C

	SEQ ID NO: 710	GTATATACATTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCATGT*A
		TATA*C

	SEQ ID NO: 711	GTATATACATTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCATGT*A
		TATA*C

	SEQ ID NO: 712	GGATATACACTTTTTATTTTTTA
		TATATATATTTTTATTTTTTAT
		ATATATAGTGT*A
		TATC*C

	SEQ ID NO: 713	GGATATACATTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCATGT*A
		TATC*C

	SEQ ID NO: 714	GGATATACATTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCATGT*A
		TATC*C

	SEQ ID NO: 715	GGATATACATTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCATGT*A
		TATC*C

	SEQ ID NO: 716	GGATATACATTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCATGT*A
		TATC*C

	SEQ ID NO: 717	GGGTATATACTTTTTATTTTTTA
		TATATATATTTTTATTTTTTAT
		ATATATAGTAT*A
		TACC*C

	SEQ ID NO: 718	GGATATACACTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCGTGT*A
		TATC*C

	SEQ ID NO: 719	GGATATACACTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCGTGT*A
		TATC*C

	SEQ ID NO: 720	GGATATACACTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCGTGT*A
		TATC*C

	SEQ ID NO: 721	GGATATACACTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCGTGT*A
		TATC*C

	SEQ ID NO: 722	GGGTATATACTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCGTAT*A
		TACC*C

	SEQ ID NO: 723	GGGTATATACTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCGTAT*A
		TACC*C

	SEQ ID NO: 724	GGGTATATACTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCGTAT*A
		TACC*C

	SEQ ID NO: 725	GGGTATATACTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCGTAT*A
		TACC*C

	SEQ ID NO: 726	GGATGTACACTTTTTATTTTTTA
		TATATATATTTTTATTTTTTAT
		ATATATAGTGT*A
		CATC*C

	SEQ ID NO: 727	GGATGTACACTTTTTATTTTTGA
		TATATATATTTTTATTTTTTAT
		ATATATCGTGT*A
		CATC*C

	SEQ ID NO: 728	GGATGTACACTTTTTATTTTTGA
		TATATGTATTTTTATTTTTTAC
		ATATATCGTGT*A
		CATC*C

	SEQ ID NO: 729	GGATGTACACTTTTTATTTTTGA
		TCATGTATTTTTTATTTTTATA
		CATGATCGTGT*A
		CATC*C

	SEQ ID NO: 730	GGATGTACACTTTTTATTTTTGA
		TCATATATTTTTTATTTTTATA
		TATGATCGTGT*A
		CATC*C

	SEQ ID NO: 731	GTATATACTTTTTATTTTTTATA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		TAGTATATAC

	SEQ ID NO: 732	GTATATACTTTTTATTTTTGATA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		TCGTATATAC

	SEQ ID NO: 733	GGATATACTTTTTATTTTTTATA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		TAGTATATCC

	SEQ ID NO: 734	GGATATACTTTTTATTTTTGATA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		TCGTATATCC

	SEQ ID NO: 735	GGTGATACTTTTTATTTTTTATA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		TAGTATCACC

	SEQ ID NO: 736	GGTGATACTTTTTATTTTTGATA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		TCGTATCACC

	SEQ ID NO: 737	GGTGATCCTTTTTATTTTTTATA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		TAGGATCACC

	SEQ ID NO: 738	GGTGATCCTTTTTATTTTTGATA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		TCGGATCACC

	SEQ ID NO: 739	GATATATCACTTTTTATTTTTTA
		TATATATATATATTTTTTATTT
		TTATATATATATAT*
		ATAGTGA*TATATC

	SEQ ID NO: 740	GTATATACATTTTTTATTTTTGA
		TATATATATATATTTTTTATTT
		TTATATATATATAT*
		ATCATGT*ATATAC

	SEQ ID NO: 741	GGATATACACTTTTTATTTTTTA
		TATATATATATATTTTTTATTT
		TTATATATATATAT*
		ATAGTGT*ATATCC

	SEQ ID NO: 742	GGATATACATTTTTTATTTTTGA
		TATATATATATATTTTTTATTT
		TTATATATATATAT*
		ATCATGT*ATATCC

	SEQ ID NO: 743	GGGTATATACTTTTTATTTTTTA
		TATATATATATATTTTTTATTT
		TTATATATATATAT*
		ATAGTAT*ATACCC

	SEQ ID NO: 744	GGATATACACTTTTTATTTTTGA
		TATATATATATATTTTTTATTT
		TTATATATATATAT*
		ATCGTGT*ATATCC

	SEQ ID NO: 745	GGGTATATACTTTTTATTTTTGA
		TATATATATATATTTTTTATTT
		TTATATATATATAT*
		ATCGTAT*ATACCC

	SEQ ID NO: 746	GTATATACTTTTTATTTTTTATA
		TATATATATATTTTTATTTTTT
		ATATATATATATA
		GTATATAC

	SEQ ID NO: 747	GTATATACTTTTTATTTTTGATA
		TATATATATATTTTTATTTTTT
		ATATATATATATC
		GTATATAC

	SEQ ID NO: 748	GTATATACTTTTTATTTTTGATA
		TATGTATATATTTTTATTTTTT
		ATATACATATATC
		GTATATAC

	SEQ ID NO: 749	GGATATACTTTTTATTTTTTATA
		TATATATATATTTTTATTTTTT
		ATATATATATATA
		GTATATCC

	SEQ ID NO: 750	GGATATACTTTTTATTTTTGATA
		TATATATATATTTTTATTTTTT
		ATATATATATATC
		GTATATCC

	SEQ ID NO: 751	GGATATACTTTTTATTTTTGATA
		TATGTATATATTTTTATTTTTT
		ATATACATATATC
		GTATATCC

	SEQ ID NO: 752	GGTGATACTTTTTATTTTTTATA
		TATATATATATTTTTATTTTTT
		ATATATATATATA
		GTATCACC

	SEQ ID NO: 753	GGTGATACTTTTTATTTTTGATA
		TATATATATATTTTTATTTTTT
		ATATATATATATC
		GTATCACC

	SEQ ID NO: 754	GGTGATACTTTTTATTTTTGATA
		TATGTATATATTTTTATTTTTT
		ATATACATATATC
		GTATCACC

	SEQ ID NO: 755	GGTGATCCTTTTTATTTTTTATA
		TATATATATATTTTTATTTTTT
		ATATATATATATA
		GGATCACC

	SEQ ID NO: 756	GGTGATCCTTTTTATTTTTGATA
		TATATATATATTTTTATTTTTT
		ATATATATATATC
		GGATCACC

	SEQ ID NO: 757	GGTGATCCTTTTTATTTTTGATA
		TATGTATATATTTTTATTTTTT
		ATATACATATATC
		GGATCACC

	SEQ ID NO: 758	GATATATCACTTTTTATTTTTTA
		TATATATATATATTTTTATTTT
		TTATATATATATA*T
		AGTGAT*ATATC

	SEQ ID NO: 759	GTATATACATTTTTTATTTTTGA
		TATATATATATATTTTTATTTT
		TTATATATATATA*T
		CATGTA*TATAC

	SEQ ID NO: 760	GTATATACATTTTTTATTTTTGA
		TATATGTATATATTTTTATTTT
		TTATATACATATA*T
		CATGTA*TATAC

	SEQ ID NO: 761	GGATATACACTTTTTATTTTTTA
		TATATATATATATTTTTATTTT
		TTATATATATATA*T
		AGTGTA*TATCC

	SEQ ID NO: 762	GGATATACATTTTTTATTTTTGA
		TATATATATATATTTTTATTTT
		TTATATATATATA*T
		CATGTA*TATCC

	SEQ ID NO: 763	GGATATACATTTTTTATTTTTGA
		TATATGTATATATTTTTATTTT
		TTATATACATATA*T
		CATGTA*TATCC

	SEQ ID NO: 764	GGGTATATACTTTTTATTTTTTA
		TATATATATATATTTTTATTTT
		TTATATATATATA*T
		AGTATA*TACCC

	SEQ ID NO: 765	GGATATACACTTTTTATTTTTGA
		TATATATATATATTTTTATTTT
		TTATATATATATA*T
		CGTGTA*TATCC

	SEQ ID NO: 766	GGATATACACTTTTTATTTTTGA
		TATATGTATATATTTTTATTTT
		TTATATACATATA*T
		CGTGTA*TATCC

	SEQ ID NO: 767	GGGTATATACTTTTTATTTTTGA
		TATATATATATATTTTTATTTT
		TTATATATATATA*T
		CGTATA*TACCC

	SEQ ID NO: 768	GGGTATATACTTTTTATTTTTGA
		TATATGTATATATTTTTATTTT
		TTATATACATATA*T
		CGTATA*TACCC

	SEQ ID NO: 769	GATATATCACTTTTTATTTTTTA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		GTGATATATC

	SEQ ID NO: 770	GTATATACATTTTTTATTTTTGA
		TATATATATATTTTTTATTTTT
		ATATATATATATC
		ATGTATATAC

	SEQ ID NO: 771	GTATATACATTTTTTATTTTTGA
		TATATGTATATTTTTTATTTTT
		ATATACATATATC
		ATGTATATAC

	SEQ ID NO: 772	GGATATACACTTTTTATTTTTTA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		GTGTATATCC

	SEQ ID NO: 773	GGATATACATTTTTTATTTTTGA
		TATATATATATTTTTTATTTTT
		ATATATATATATC
		ATGTATATCC

	SEQ ID NO: 774	GGATATACATTTTTTATTTTTGA
		TATATGTATATTTTTTATTTTT
		ATATACATATATC
		ATGTATATCC

	SEQ ID NO: 775	GGGTATATACTTTTTATTTTTTA
		TATATATATATTTTTTATTTTT
		ATATATATATATA
		GTATATACCC

	SEQ ID NO: 776	GGATATACACTTTTTATTTTTGA
		TATATATATATTTTTTATTTTT
		ATATATATATATC
		GTGTATATCC

	SEQ ID NO: 777	GGATATACACTTTTTATTTTTGA
		TATATGTATATTTTTTATTTTT
		ATATACATATATC
		GTGTATATCC

	SEQ ID NO: 778	GGGTATATACTTTTTATTTTTGA
		TATATATATATTTTTTATTTTT
		ATATATATATATC
		GTATATACCC

	SEQ ID NO: 779	GGGTATATACTTTTTATTTTTGA
		TATATGTATATTTTTTATTTTT
		ATATACATATATC
		GTATATACCC

	SEQ ID NO: 780	GATATATCACTTTTTATTTTTTA
		TATATATATATTTTTATTTTTT
		ATATATATATAGT
		GATATATC

	SEQ ID NO: 781	GTATATACATTTTTTATTTTTGA
		TATATATATATTTTTATTTTTT
		ATATATATATCAT
		GTATATAC

	SEQ ID NO: 782	GTATATACATTTTTTATTTTTGA
		TATATGTATATTTTTATTTTTT
		ATACATATATCAT
		GTATATAC

	SEQ ID NO: 783	GTATATACATTTTTTATTTTTGA
		TCATGTATATTTTTTATTTTTA
		TATACATGATCAT
		GTATATAC

	SEQ ID NO: 784	GTATATACATTTTTTATTTTTGA
		TCATATATGTTTTTTATTTTTA
		CATATATGATCAT
		GTATATAC

	SEQ ID NO: 785	GGATATACACTTTTTATTTTTTA
		TATATATATATTTTTATTTTTT
		ATATATATATAGT
		GTATATCC

	SEQ ID NO: 786	GGATATACATTTTTTATTTTTGA
		TATATATATATTTTTATTTTTT
		ATATATATATCAT
		GTATATCC

	SEQ ID NO: 787	GGATATACATTTTTTATTTTTGA
		TATATGTATATTTTTATTTTTT
		ATACATATATCAT
		GTATATCC

	SEQ ID NO: 788	GGATATACATTTTTTATTTTTGA
		TCATGTATATTTTTTATTTTTA
		TATACATGATCAT
		GTATATCC

	SEQ ID NO: 789	GGATATACATTTTTTATTTTTGA
		TCATATATGTTTTTTATTTTTA
		CATATATGATCAT
		GTATATCC

	SEQ ID NO: 790	GGGTATATACTTTTTATTTTTTA
		TATATATATATTTTTATTTTTT
		ATATATATATAGT
		ATATACCC

	SEQ ID NO: 791	GGATATACACTTTTTATTTTTGA
		TATATATATATTTTTATTTTTT
		ATATATATATCGT
		GTATATCC

	SEQ ID NO: 792	GGATATACACTTTTTATTTTTGA
		TATATGTATATTTTTATTTTTT
		ATACATATATCGT
		GTATATCC

	SEQ ID NO: 793	GGATATACACTTTTTATTTTTGA
		TCATGTATATTTTTTATTTTTA
		TATACATGATCGT
		GTATATCC

	SEQ ID NO: 794	GGATATACACTTTTTATTTTTGA
		TCATATATGTTTTTTATTTTTA
		CATATATGATCGT
		GTATATCC

	SEQ ID NO: 795	GGGTATATACTTTTTATTTTTGA
		TATATATATATTTTTATTTTTT
		ATATATATATCGT
		ATATACCC

	SEQ ID NO: 796	GGGTATATACTTTTTATTTTTGA
		TATATGTATATTTTTATTTTTT
		ATACATATATCGT
		ATATACCC

	SEQ ID NO: 797	GGGTATATACTTTTTATTTTTGA
		TCATGTATATTTTTTATTTTTA
		TATACATGATCGT
		ATATACCC

	SEQ ID NO: 798	GGGTATATACTTTTTATTTTTGA
		TCATATATGTTTTTTATTTTTA
		CATATATGATCGT
		ATATACCC

	SEQ ID NO: 799	GTACATATATTTTTTTATTTTTG
		ATATATATATTTTTATTTTTTA
		TATATATCAATA*
		TATGT*AC

	SEQ ID NO: 800	GTACATATATTTTTTTATTTTTG
		ATATATGTATTTTTATTTTTTA
		CATATATCAATA*
		TATGT*AC

	SEQ ID NO: 801	GTACATATATTTTTTTATTTTTG
		ATCATGTATTTTTTATTTTTAT
		ACATGATCAATA*
		TATGT*AC

	SEQ ID NO: 802	GTACATATATTTTTTTATTTTTG
		ATCATATATTTTTTATTTTTAT
		ATATGATCAATA*
		TATGT*AC

	SEQ ID NO: 803	GATGTATATACTTTTTATTTTTT
		ATATATATATTTTTATTTTTTA
		TATATATAGTAT*
		ATACA*TC

	SEQ ID NO: 804	GGTACATATATTTTTTATTTTTG
		ATATATATATTTTTATTTTTTA
		TATATATCATAT*
		ATGTA*CC

	SEQ ID NO: 805	GGTACATATATTTTTTATTTTTG
		ATATATGTATTTTTATTTTTTA
		CATATATCATAT*
		ATGTA*CC

	SEQ ID NO: 806	GGTACATATATTTTTTATTTTTG
		ATCATGTATTTTTTATTTTTAT
		ACATGATCATAT*
		ATGTA*CC

	SEQ ID NO: 807	GGTACATATATTTTTTATTTTTG
		ATCATATATTTTTTATTTTTAT
		ATATGATCATAT*
		ATGTA*CC

	SEQ ID NO: 808	CGATCATATATTTTTTTATTTTT
		GATATATATATTTTTATTTTTT
		ATATATATCAATA
		TATGATCG

	SEQ ID NO: 809	CGATCATATATTTTTTTATTTTT
		GATATATGTATTTTTATTTTTT
		ACATATATCAATA
		TATGATCG

	SEQ ID NO: 810	CGATCATATATTTTTTTATTTTT
		GATCATGTATTTTTTATTTTTA
		TACATGATCAATA
		TATGATCG

	SEQ ID NO: 811	CGATCATATATTTTTTTATTTTT
		GATCATATATTTTTTATTTTTA
		TATATGATCAATA
		TATGATCG

	SEQ ID NO: 812	GATACTTTTTATTTTTTATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*A
		GTAT*C

	SEQ ID NO: 813	GACACTTTTTATTTTTTATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*A
		GTGT*C

	SEQ ID NO: 814	GATACTTTTTATTTTTGATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*C
		GTAT*C

	SEQ ID NO: 815	GATACTTTTTATTTTTGATAAAT
		GTATATATTTTTTATTTTTATA
		TATACATATAT*C
		GTAT*C

	SEQ ID NO: 816	GATACTTTTTATTTTTGATGATG
		TATATATATTTTTATTTTTTAT
		ATATACATGAT*C
		GTAT*C

	SEQ ID NO: 817	GATACTTTTTATTTTTGATGATA
		TATGTACTTTTTTATTTTTAGT
		ACATATATGAT*C
		GTAT*C

	SEQ ID NO: 818	GGATCTTTTTATTTTTTATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*A
		GATC*C

	SEQ ID NO: 819	GACACTTTTTATTTTTGATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*C
		GTGT*C

	SEQ ID NO: 820	GACACTTTTTATTTTTGATAAAT
		GTATATATTTTTTATTTTTATA
		TATACATATAT*C
		GTGT*C

	SEQ ID NO: 821	GACACTTTTTATTTTTGATGATG
		TATATATATTTTTATTTTTTAT
		ATATACATGAT*C
		GTGT*C

	SEQ ID NO: 822	GACACTTTTTATTTTTGATGATA
		TATGTACTTTTTTATTTTTAGT
		ACATATATGAT*C
		GTGT*C

	SEQ ID NO: 823	GGATCTTTTTATTTTTGATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*C
		GATC*C

	SEQ ID NO: 824	GGATCTTTTTATTTTTGATAAAT
		GTATATATTTTTTATTTTTATA
		TATACATATAT*C
		GATC*C

	SEQ ID NO: 825	GGATCTTTTTATTTTTGATGATG
		TATATATATTTTTATTTTTTAT
		ATATACATGAT*C
		GATC*C

	SEQ ID NO: 826	GGATCTTTTTATTTTTGATGATA
		TATGTACTTTTTTATTTTTAGT
		ACATATATGAT*C
		GATC*C

	SEQ ID NO: 827	GCGTCTTTTTATTTTTTATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*A
		GACG*C

	SEQ ID NO: 828	GCGTCTTTTTATTTTTGATAAAT
		ATATATATTTTTTATTTTTATA
		TATATATATAT*C
		GACG*C

	SEQ ID NO: 829	GCGTCTTTTTATTTTTGATAAAT
		GTATATATTTTTTATTTTTATA
		TATACATATAT*C
		GACG*C

	SEQ ID NO: 830	GCGTCTTTTTATTTTTGATGATG
		TATATATATTTTTATTTTTTAT
		ATATACATGAT*C
		GACG*C

	SEQ ID NO: 831	GCGTCTTTTTATTTTTGATGATA
		TATGTACTTTTTTATTTTTAGT
		ACATATATGAT*C
		GACG*C

	SEQ ID NO: 832	GTATACTTTTTATTTTTGATAAA
		TATATATATTTTTATTTTTTAT
		ATATATATATC*G
		TATA*C

	SEQ ID NO: 833	GTATACTTTTTATTTTTGATAAA
		TGTATATATTTTTATTTTTTAT
		ATACATATATC*G
		TATA*C

	SEQ ID NO: 834	GTATACTTTTTATTTTTGATGAT
		GTATATATTTTTTATTTTTATA
		TATACATGATC*G
		TATA*C

	SEQ ID NO: 835	GTATACTTTTTATTTTTGATGAT
		ATATGTACTTTTTATTTTTGTA
		CATATATGATC*G
		TATA*C

	SEQ ID NO: 836	GTGATCTTTTTATTTTTGATAAA
		TATATATATTTTTATTTTTTAT
		ATATATATATC*G
		ATCA*C

	SEQ ID NO: 837	GTGATCTTTTTATTTTTGATAAA
		TGTATATATTTTTATTTTTTAT
		ATACATATATC*G
		ATCA*C

	SEQ ID NO: 838	GTGATCTTTTTATTTTTGATGAT
		GTATATATTTTTTATTTTTATA
		TATACATGATC*G
		ATCA*C

	SEQ ID NO: 839	GTGATCTTTTTATTTTTGATGAT
		ATATGTACTTTTTATTTTTGTA
		CATATATGATC*G
		ATCA*C

	SEQ ID NO: 840	GGATACTTTTTATTTTTGATAAA
		TATATATATTTTTATTTTTTAT
		ATATATATATC*G
		TATC*C

	SEQ ID NO: 841	GGATACTTTTTATTTTTGATAAA
		TGTATATATTTTTATTTTTTAT
		ATACATATATC*G
		TATC*C

	SEQ ID NO: 842	GGATACTTTTTATTTTTGATGAT
		GTATATATTTTTTATTTTTATA
		TATACATGATC*G
		TATC*C

	SEQ ID NO: 843	GGATACTTTTTATTTTTGATGAT
		ATATGTACTTTTTATTTTTGTA
		CATATATGATC*G
		TATC*C

	SEQ ID NO: 844	GCGATCTTTTTATTTTTGATAAA
		TATATATATTTTTATTTTTTAT
		ATATATATATC*G
		ATCG*C

	SEQ ID NO: 845	GCGATCTTTTTATTTTTGATAAA
		TGTATATATTTTTATTTTTTAT
		ATACATATATC*G
		ATCG*C

	SEQ ID NO: 846	GCGATCTTTTTATTTTTGATGAT
		GTATATATTTTTTATTTTTATA
		TATACATGATC*G
		ATCG*C

	SEQ ID NO: 847	GCGATCTTTTTATTTTTGATGAT
		ATATGTACTTTTTATTTTTGTA
		CATATATGATC*G
		ATCG*C

	SEQ ID NO: 848	GATATACTTTTTATTTTTTATAA
		ATATATATTTTTTATTTTTATA
		TATATATATAG*T
		ATAT*C

	SEQ ID NO: 849	GATATATTTTTTATTTTTGATAA
		ATGTATATTTTTTATTTTTATA
		TACATATATCA*T
		ATAT*C

	SEQ ID NO: 850	GATATATTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCA*T
		ATAT*C

	SEQ ID NO: 851	GATATATTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCA*T
		ATAT*C

	SEQ ID NO: 852	GTGATACTTTTTATTTTTTATAA
		ATATATATTTTTTATTTTTATA
		TATATATATAG*T
		ATCA*C

	SEQ ID NO: 853	GATATACTTTTTATTTTTGATAA
		ATATATATTTTTTATTTTTATA
		TATATATATCG*T
		ATAT*C

	SEQ ID NO: 854	GATATACTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCG*T
		ATAT*C

	SEQ ID NO: 855	GATATACTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCG*T
		ATAT*C

	SEQ ID NO: 856	GGTATACTTTTTATTTTTTATAA
		ATATATATTTTTTATTTTTATA
		TATATATATAG*T
		ATAC*C

	SEQ ID NO: 857	GTGATACTTTTTATTTTTGATAA
		ATATATATTTTTTATTTTTATA
		TATATATATCG*T
		ATCA*C

	SEQ ID NO: 858	GTGATACTTTTTATTTTTGATAA
		ATGTATATTTTTTATTTTTATA
		TACATATATCG*T
		ATCA*C

	SEQ ID NO: 859	GTGATACTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCG*T
		ATCA*C

	SEQ ID NO: 860	GTGATACTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCG*T
		ATCA*C

	SEQ ID NO: 861	GGTATACTTTTTATTTTTGATAA
		ATATATATTTTTTATTTTTATA
		TATATATATCG*T
		ATAC*C

	SEQ ID NO: 862	GGTATACTTTTTATTTTTGATAA
		ATGTATATTTTTTATTTTTATA
		TACATATATCG*T
		ATAC*C

	SEQ ID NO: 863	GGTATACTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCG*T
		ATAC*C

	SEQ ID NO: 864	GGTATACTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCG*T
		ATAC*C

	SEQ ID NO: 865	GGTGTACTTTTTATTTTTTATAA
		ATATATATTTTTTATTTTTATA
		TATATATATAG*T
		ACAC*C

	SEQ ID NO: 866	GGTGTACTTTTTATTTTTGATAA
		ATATATATTTTTTATTTTTATA
		TATATATATCG*T
		ACAC*C

	SEQ ID NO: 867	GGTGTACTTTTTATTTTTGATAA
		ATGTATATTTTTTATTTTTATA
		TACATATATCG*T
		ACAC*C

	SEQ ID NO: 868	GGTGTACTTTTTATTTTTGATGA
		TGTATATATTTTTATTTTTTAT
		ATACATGATCG*T
		ACAC*C

	SEQ ID NO: 869	GGTGTACTTTTTATTTTTGATGA
		TATATGTATTTTTATTTTTTAC
		ATATATGATCG*T
		ACAC*C

	SEQ ID NO: 870	GTATATACTTTTTATTTTTGATA
		AATATATATTTTTATTTTTTAT
		ATATATATCGT*A
		TATA*C

	SEQ ID NO: 871	GTATATACTTTTTATTTTTGATA
		AATGTATATTTTTATTTTTTAT
		ACATATATCGT*A
		TATA*C

	SEQ ID NO: 872	GTATATACTTTTTATTTTTGATG
		ATGTATATTTTTTATTTTTATA
		TACATGATCGT*A
		TATA*C

	SEQ ID NO: 873	GTATATACTTTTTATTTTTGATG
		ATATATGTTTTTTATTTTTACA
		TATATGATCGT*A
		TATA*C

	SEQ ID NO: 874	GGATATACTTTTTATTTTTGATA
		AATATATATTTTTATTTTTTAT
		ATATATATCGT*A
		TATC*C

	SEQ ID NO: 875	GGATATACTTTTTATTTTTGATA
		AATGTATATTTTTATTTTTTAT
		ACATATATCGT*A
		TATC*C

	SEQ ID NO: 876	GGATATACTTTTTATTTTTGATG
		ATGTATATTTTTTATTTTTATA
		TACATGATCGT*A
		TATC*C

	SEQ ID NO: 877	GGATATACTTTTTATTTTTGATG
		ATATATGTTTTTTATTTTTACA
		TATATGATCGT*A
		TATC*C

	SEQ ID NO: 878	GGTGATACTTTTTATTTTTGATA
		AATATATATTTTTATTTTTTAT
		ATATATATCGT*A
		TCAC*C

	SEQ ID NO: 879	GGTGATACTTTTTATTTTTGATA
		AATGTATATTTTTATTTTTTAT
		ACATATATCGT*A
		TCAC*C

	SEQ ID NO: 880	GGTGATACTTTTTATTTTTGATG
		ATGTATATTTTTTATTTTTATA
		TACATGATCGT*A
		TCAC*C

	SEQ ID NO: 881	GGTGATACTTTTTATTTTTGATG
		ATATATGTTTTTTATTTTTACA
		TATATGATCGT*A
		TCAC*C

	SEQ ID NO: 882	GGTGATCCTTTTTATTTTTGATA
		AATATATATTTTTATTTTTTAT
		ATATATATCGG*A
		TCAC*C

	SEQ ID NO: 883	GGTGATCCTTTTTATTTTTGATA
		AATGTATATTTTTATTTTTTAT
		ACATATATCGG*A
		TCAC*C

	SEQ ID NO: 884	GGTGATCCTTTTTATTTTTGATG
		ATGTATATTTTTTATTTTTATA
		TACATGATCGG*A
		TCAC*C

	SEQ ID NO: 885	GGTGATCCTTTTTATTTTTGATG
		ATATATGTTTTTTATTTTTACA
		TATATGATCGG*A
		TCAC*C

	SEQ ID NO: 886	GTATATACATTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCATGT*A
		TATA*C

	SEQ ID NO: 887	GTATATACATTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCATGT*A
		TATA*C

	SEQ ID NO: 888	GTATATACATTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCATGT*A
		TATA*C

	SEQ ID NO: 889	GTATATACATTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCATGT*A
		TATA*C

	SEQ ID NO: 890	GGATATACATTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCATGT*A
		TATC*C

	SEQ ID NO: 891	GGATATACATTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCATGT*A
		TATC*C

	SEQ ID NO: 892	GGATATACATTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCATGT*A
		TATC*C

	SEQ ID NO: 893	GGATATACATTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCATGT*A
		TATC*C

	SEQ ID NO: 894	GGATATACACTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCGTGT*A
		TATC*C

	SEQ ID NO: 895	GGATATACACTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCGTGT*A
		TATC*C

	SEQ ID NO: 896	GGATATACACTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCGTGT*A
		TATC*C

	SEQ ID NO: 897	GGATATACACTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCGTGT*A
		TATC*C

	SEQ ID NO: 898	GGGTATATACTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCGTAT*A
		TACC*C

	SEQ ID NO: 899	GGGTATATACTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCGTAT*A
		TACC*C

	SEQ ID NO: 900	GGGTATATACTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCGTAT*A
		TACC*C

	SEQ ID NO: 901	GGGTATATACTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCGTAT*A
		TACC*C

	SEQ ID NO: 902	GGATGTACACTTTTTATTTTTGA
		TAAATATATTTTTATTTTTTAT
		ATATATCGTGT*A
		CATC*C

	SEQ ID NO: 903	GGATGTACACTTTTTATTTTTGA
		TAAATGTATTTTTATTTTTTAC
		ATATATCGTGT*A
		CATC*C

	SEQ ID NO: 904	GGATGTACACTTTTTATTTTTGA
		TGATGTATTTTTTATTTTTATA
		CATGATCGTGT*A
		CATC*C

	SEQ ID NO: 905	GGATGTACACTTTTTATTTTTGA
		TGATATATTTTTTATTTTTATA
		TATGATCGTGT*A
		CATC*C

	SEQ ID NO: 906	GTATATACTTTTTATTTTTTATA
		AATATATATATTTTTTATTTTT
		ATATATATATATA
		TAGTATATAC

	SEQ ID NO: 907	GTATATACTTTTTATTTTTGATA
		AATATATATATTTTTTATTTTT
		ATATATATATATA
		TCGTATATAC

	SEQ ID NO: 908	GTATATACTTTTTATTTTTGATA
		AATGTATATATTTTTTATTTTT
		ATATATACATATA
		TCGTATATAC

	SEQ ID NO: 909	GTATATACTTTTTATTTTTGATG
		ATGTATATATATTTTTATTTTT
		TATATATACATGA
		TCGTATATAC

	SEQ ID NO: 910	GTATATACTTTTTATTTTTGATG
		ATATATGTACTTTTTTATTTTT
		AGTACATATATGA
		TCGTATATAC

	SEQ ID NO: 911	GGATATACTTTTTATTTTTTATA
		AATATATATATTTTTTATTTTT
		ATATATATATATA
		TAGTATATCC

	SEQ ID NO: 912	GGATATACTTTTTATTTTTGATA
		AATATATATATTTTTTATTTTT
		ATATATATATATA
		TCGTATATCC

	SEQ ID NO: 913	GGATATACTTTTTATTTTTGATA
		AATGTATATATTTTTTATTTTT
		ATATATACATATA
		TCGTATATCC

	SEQ ID NO: 914	GGATATACTTTTTATTTTTGATG
		ATGTATATATATTTTTATTTTT
		TATATATACATGA
		TCGTATATCC

	SEQ ID NO: 915	GGATATACTTTTTATTTTTGATG
		ATATATGTACTTTTTTATTTTT
		AGTACATATATGA
		TCGTATATCC

	SEQ ID NO: 916	GGTGATACTTTTTATTTTTTATA
		AATATATATATTTTTTATTTTT
		ATATATATATATA
		TAGTATCACC

	SEQ ID NO: 917	GGTGATACTTTTTATTTTTGATA
		AATATATATATTTTTTATTTTT
		ATATATATATATA
		TCGTATCACC

	SEQ ID NO: 918	GGTGATACTTTTTATTTTTGATA
		AATGTATATATTTTTTATTTTT
		ATATATACATATA
		TCGTATCACC

	SEQ ID NO: 919	GGTGATACTTTTTATTTTTGATG
		ATGTATATATATTTTTATTTTT
		TATATATACATGA
		TCGTATCACC

	SEQ ID NO: 920	GGTGATACTTTTTATTTTTGATG
		ATATATGTACTTTTTTATTTTT
		AGTACATATATGA
		TCGTATCACC

	SEQ ID NO: 921	GGTGATCCTTTTTATTTTTTATA
		AATATATATATTTTTTATTTTT
		ATATATATATATA
		TAGGATCACC

	SEQ ID NO: 922	GGTGATCCTTTTTATTTTTGATA
		AATATATATATTTTTTATTTTT
		ATATATATATATA
		TCGGATCACC

	SEQ ID NO: 923	GGTGATCCTTTTTATTTTTGATA
		AATGTATATATTTTTTATTTTT
		ATATATACATATA
		TCGGATCACC

	SEQ ID NO: 924	GGTGATCCTTTTTATTTTTGATG
		ATGTATATATATTTTTATTTTT
		TATATATACATGA
		TCGGATCACC

	SEQ ID NO: 925	GGTGATCCTTTTTATTTTTGATG
		ATATATGTACTTTTTTATTTTT
		AGTACATATATGA
		TCGGATCACC

	SEQ ID NO: 926	GATATATCACTTTTTATTTTTTA
		TAAATATATATATTTTTTATTT
		TTATATATATATAT*
		ATAGTGA*TATATC

	SEQ ID NO: 927	GTATATACATTTTTTATTTTTGA
		TAAATATATATATTTTTTATTT
		TTATATATATATAT*
		ATCATGT*ATATAC

	SEQ ID NO: 928	GTATATACATTTTTTATTTTTGA
		TAAATGTATATATTTTTTATTT
		TTATATATACATAT*
		ATCATGT*ATATAC

	SEQ ID NO: 929	GTATATACATTTTTTATTTTTGA
		TGATGTATATATATTTTTATTT
		TTTATATATACATG*
		ATCATGT*ATATAC

	SEQ ID NO: 930	GTATATACATTTTTTATTTTTGA
		TGATATATGTACTTTTTTATTT
		TTAGTACATATATG*
		ATCATGT*ATATAC

	SEQ ID NO: 931	GGATATACACTTTTTATTTTTTA
		TAAATATATATATTTTTTATTT
		TTATATATATATAT*
		ATAGTGT*ATATCC

	SEQ ID NO: 932	GGATATACATTTTTTATTTTTGA
		TAAATATATATATTTTTTATTT
		TTATATATATATAT*
		ATCATGT*ATATCC

	SEQ ID NO: 933	GGATATACATTTTTTATTTTTGA
		TAAATGTATATATTTTTTATTT
		TTATATATACATAT*
		ATCATGT*ATATCC

	SEQ ID NO: 934	GGATATACATTTTTTATTTTTGA
		TGATGTATATATATTTTTATTT
		TTTATATATACATG*
		ATCATGT*ATATCC

	SEQ ID NO: 935	GGATATACATTTTTTATTTTTGA
		TGATATATGTACTTTTTTATTT
		TTAGTACATATATG*
		ATCATGT*ATATCC

	SEQ ID NO: 936	GGGTATATACTTTTTATTTTTTA
		TAAATATATATATTTTTTATTT
		TTATATATATATAT*
		ATAGTAT*ATACCC

	SEQ ID NO: 937	GGATATACACTTTTTATTTTTGA
		TAAATATATATATTTTTTATT
		TTTATATATATATAT
		ATCGTGTATATCC

	SEQ ID NO: 938	GGATATACACTTTTTATTTTTGA
		TAAATGTATATATTTTTTATT
		TTTATATATACATAT
		ATCGTGTATATCC

	SEQ ID NO: 939	GGATATACACTTTTTATTTTTGA
		TGATGTATATATATTTTTATT
		TTTTATATATACATG
		ATCGTGTATATCC

	SEQ ID NO: 940	GGATATACACTTTTTATTTTTGA
		TGATATATGTACTTTTTTATTT
		TTAGTACATATATG*
		ATCGTGT*ATATCC

	SEQ ID NO: 941	GGGTATATACTTTTTATTTTTGA
		TAAATATATATATTTTTTATTT
		TTATATATATATAT*
		ATCGTAT*ATACCC

	SEQ ID NO: 942	GGGTATATACTTTTTATTTTTGA
		TAAATGTATATATTTTTTATTT
		TTATATATACATAT*
		ATCGTAT*ATACCC

	SEQ ID NO: 943	GGGTATATACTTTTTATTTTTGA
		TGATGTATATATATTTTTATTT
		TTTATATATACATG*
		ATCGTAT*ATACCC

	SEQ ID NO: 944	GGGTATATACTTTTTATTTTTGA
		TGATATATGTACTTTTTTATTT
		TTAGTACATATATG*
		ATCGTAT*ATACCC

	SEQ ID NO: 945	GTATATACTTTTTATTTTTGATA
		AATATATATATTTTTATTTTTT
		ATATATATATATC
		GTATATAC

	SEQ ID NO: 946	GTATATACTTTTTATTTTTGATA
		AATGTATATATTTTTATTTTTT
		ATATACATATATC
		GTATATAC

	SEQ ID NO: 947	GTATATACTTTTTATTTTTGATG
		ATGTATATATTTTTTATTTTTA
		TATATACATGATC
		GTATATAC

	SEQ ID NO: 948	GTATATACTTTTTATTTTTGATG
		ATATATGTACTTTTTATTTTTG
		TACATATATGATC
		GTATATAC

	SEQ ID NO: 949	GGATATACTTTTTATTTTTGATA
		AATATATATATTTTTATTTTTT
		ATATATATATATC
		GTATATCC

	SEQ ID NO: 950	GGATATACTTTTTATTTTTGATA
		AATGTATATATTTTTATTTTTT
		ATATACATATATC
		GTATATCC

	SEQ ID NO: 951	GGATATACTTTTTATTTTTGATG
		ATGTATATATTTTTTATTTTTA
		TATATACATGATC
		GTATATCC

	SEQ ID NO: 952	GGATATACTTTTTATTTTTGATG
		ATATATGTACTTTTTATTTTTG
		TACATATATGATC
		GTATATCC

	SEQ ID NO: 953	GGTGATACTTTTTATTTTTGATA
		AATATATATATTTTTATTTTTT
		ATATATATATATC
		GTATCACC

	SEQ ID NO: 954	GGTGATACTTTTTATTTTTGATA
		AATGTATATATTTTTATTTTTT
		ATATACATATATC
		GTATCACC

	SEQ ID NO: 955	GGTGATACTTTTTATTTTTGATG
		ATGTATATATTTTTTATTTTTA
		TATATACATGATC
		GTATCACC

	SEQ ID NO: 956	GGTGATACTTTTTATTTTTGATG
		ATATATGTACTTTTTATTTTTG
		TACATATATGATC
		GTATCACC

	SEQ ID NO: 957	GGTGATCCTTTTTATTTTTGATA
		AATATATATATTTTTATTTTTT
		ATATATATATATC
		GGATCACC

	SEQ ID NO: 958	GGTGATCCTTTTTATTTTTGATA
		AATGTATATATTTTTATTTTTT
		ATATACATATATC
		GGATCACC

	SEQ ID NO: 959	GGTGATCCTTTTTATTTTTGATG
		ATGTATATATTTTTTATTTTTA
		TATATACATGATC
		GGATCACC

	SEQ ID NO: 960	GGTGATCCTTTTTATTTTTGATG
		ATATATGTACTTTTTATTTTTG
		TACATATATGATC
		GGATCACC

	SEQ ID NO: 961	GTATATACATTTTTTATTTTTGA
		TAAATATATATATTTTTATTTT
		TTATATATATATA*T
		CATGTA*TATAC

	SEQ ID NO: 962	GTATATACATTTTTTATTTTTGA
		TGATGTATATATTTTTTATTTT
		TATATATACATGA*T
		CATGTA*TATAC

	SEQ ID NO: 963	GTATATACATTTTTTATTTTTGA
		TGATATATGTACTTTTTATTTT
		TGTACATATATGA*T
		CATGTA*TATAC

	SEQ ID NO: 964	GGATATACATTTTTTATTTTTGA
		TAAATATATATATTTTTATTTT
		TTATATATATATA*T
		CATGTA*TATCC

	SEQ ID NO: 965	GGATATACATTTTTTATTTTTGA
		TAAATGTATATATTTTTATTTT
		TTATATACATATA*T
		CATGTA*TATCC

	SEQ ID NO: 966	GGATATACATTTTTTATTTTTGA
		TGATGTATATATTTTTTATTTT
		TATATATACATGA*T
		CATGTA*TATCC

	SEQ ID NO: 967	GGATATACATTTTTTATTTTTGA
		TGATATATGTACTTTTTATTTT
		TGTACATATATGA*T
		CATGTA*TATCC

	SEQ ID NO: 968	GGATATACACTTTTTATTTTTGA
		TAAATATATATATTTTTATTT
		TTTATATATATATA*
		TCGTGTA*TATCC

	SEQ ID NO: 969	GGATATACACTTTTTATTTTTGA
		TAAATGTATATATTTTTATTT
		TTTATATACATATA*
		TCGTGTA*TATCC

	SEQ ID NO: 970	GGATATACACTTTTTATTTTTGA
		TGATGTATATATTTTTTATTTT
		TATATATACATGA*T
		CGTGTA*TATCC

	SEQ ID NO: 971	GGATATACACTTTTTATTTTTGA
		TGATATATGTACTTTTTATTTT
		TGTACATATATGA*T
		CGTGTA*TATCC

	SEQ ID NO: 972	GGGTATATACTTTTTATTTTTGA
		TAAATATATATATTTTTATTTT
		TTATATATATATA*T
		CGTATA*TACCC

	SEQ ID NO: 973	GGGTATATACTTTTTATTTTTGA
		TAAATGTATATATTTTTATTTT
		TTATATACATATA*T
		CGTATA*TACCC

	SEQ ID NO: 974	GGGTATATACTTTTTATTTTTGA
		TGATGTATATATTTTTTATTTT
		TATATATACATGA*T
		CGTATA*TACCC

	SEQ ID NO: 975	GGGTATATACTTTTTATTTTTGA
		TGATATATGTACTTTTTATTTT
		TGTACATATATGA*T
		CGTATA*TACCC

	SEQ ID NO: 976	GATATATCACTTTTTATTTTTTA
		TAAATATATATTTTTTATTTTT
		ATATATATATATA
		GTGATATATC

	SEQ ID NO: 977	GTATATACATTTTTTATTTTTGA
		TAAATATATATTTTTTATTTTT
		ATATATATATATC
		ATGTATATAC

	SEQ ID NO: 978	GTATATACATTTTTTATTTTTGA
		TGATGTATATATTTTTATTTTT
		TATATACATGATC
		ATGTATATAC

	SEQ ID NO: 979	GTATATACATTTTTTATTTTTGA
		TGATATATGTATTTTTATTTTT
		TACATATATGATC
		ATGTATATAC

	SEQ ID NO: 980	GGATATACACTTTTTATTTTTTA
		TAAATATATATTTTTTATTTTT
		ATATATATATATA
		GTGTATATCC

	SEQ ID NO: 981	GGATATACATTTTTTATTTTTGA
		TAAATATATATTTTTTATTTTT
		ATATATATATATC
		ATGTATATCC

	SEQ ID NO: 982	GGATATACATTTTTTATTTTTGA
		TAAATGTATATTTTTTATTTTT
		ATATACATATATC
		ATGTATATCC

	SEQ ID NO: 983	GGATATACATTTTTTATTTTTGA
		TGATGTATATATTTTTATTTTT
		TATATACATGATC
		ATGTATATCC

	SEQ ID NO: 984	GGATATACATTTTTTATTTTTGA
		TGATATATGTATTTTTATTTTT
		TACATATATGATC
		ATGTATATCC

	SEQ ID NO: 985	GGGTATATACTTTTTATTTTTTA
		TAAATATATATTTTTTATTTTT
		ATATATATATATA
		GTATATACCC

	SEQ ID NO: 986	GGATATACACTTTTTATTTTTGA
		TAAATATATATTTTTTATTTTT
		ATATATATATATC
		GTGTATATCC

	SEQ ID NO: 987	GGATATACACTTTTTATTTTTGA
		TAAATGTATATTTTTTATTTTT
		ATATACATATATC
		GTGTATATCC

	SEQ ID NO: 988	GGATATACACTTTTTATTTTTGA
		TGATGTATATATTTTTATTTTT
		TATATACATGATC
		GTGTATATCC

	SEQ ID NO: 989	GGATATACACTTTTTATTTTTGA
		TGATATATGTATTTTTATTTTT
		TACATATATGATC
		GTGTATATCC

	SEQ ID NO: 990	GGGTATATACTTTTTATTTTTGA
		TAAATATATATTTTTTATTTTT
		ATATATATATATC
		GTATATACCC

	SEQ ID NO: 991	GGGTATATACTTTTTATTTTTGA
		TAAATGTATATTTTTTATTTTT
		ATATACATATATC
		GTATATACCC

	SEQ ID NO: 992	GGGTATATACTTTTTATTTTTGA
		TGATGTATATATTTTTATTTTT
		TATATACATGATC
		GTATATACCC

	SEQ ID NO: 993	GGGTATATACTTTTTATTTTTGA
		TGATATATGTATTTTTATTTTT
		TACATATATGATC
		GTATATACCC

	SEQ ID NO: 994	GTATATACATTTTTTATTTTTGA
		TAAATATATATTTTTATTTTTT
		ATATATATATCAT
		GTATATAC

	SEQ ID NO: 995	GTATATACATTTTTTATTTTTGA
		TGATGTATATTTTTTATTTTTA
		TATACATGATCAT
		GTATATAC

	SEQ ID NO: 996	GTATATACATTTTTTATTTTTGA
		TGATATATGTTTTTTATTTTTA
		CATATATGATCAT
		GTATATAC

	SEQ ID NO: 997	GGATATACATTTTTTATTTTTGA
		TAAATATATATTTTTATTTTTT
		ATATATATATCAT
		GTATATCC

	SEQ ID NO: 998	GGATATACATTTTTTATTTTTGA
		TAAATGTATATTTTTATTTTTT
		ATACATATATCAT
		GTATATCC

	SEQ ID NO: 999	GGATATACATTTTTTATTTTTGA
		TGATGTATATTTTTTATTTTTA
		TATACATGATCAT
		GTATATCC

	SEQ ID NO: 1000	GGATATACATTTTTTATTTTTGA
		TGATATATGTTTTTTATTTTTA
		CATATATGATCAT
		GTATATCC

	SEQ ID NO: 1001	GGATATACACTTTTTATTTTTGA
		TAAATATATATTTTTATTTTTT
		ATATATATATCGT
		GTATATCC

	SEQ ID NO: 1002	GGATATACACTTTTTATTTTTGA
		TAAATGTATATTTTTATTTTTT
		ATACATATATCGT
		GTATATCC

	SEQ ID NO: 1003	GGATATACACTTTTTATTTTTGA
		TGATGTATATTTTTTATTTTTA
		TATACATGATCGT
		GTATATCC

	SEQ ID NO: 1004	GGATATACACTTTTTATTTTTGA
		TGATATATGTTTTTTATTTTTA
		CATATATGATCGT
		GTATATCC

	SEQ ID NO: 1005	GGGTATATACTTTTTATTTTTGA
		TAAATATATATTTTTATTTTTT
		ATATATATATCGT
		ATATACCC

	SEQ ID NO: 1006	GGGTATATACTTTTTATTTTTGA
		TAAATGTATATTTTTATTTTTT
		ATACATATATCGT
		ATATACCC

	SEQ ID NO: 1007	GGGTATATACTTTTTATTTTTGA
		TGATGTATATTTTTTATTTTTA
		TATACATGATCGT
		ATATACCC

	SEQ ID NO: 1008	GGGTATATACTTTTTATTTTTGA
		TGATATATGTTTTTTATTTTTA
		CATATATGATCGT
		ATATACCC

	SEQ ID NO: 1009	GTACATATATTTTTTTATTTTTG
		ATAAATATATTTTTATTTTTTA
		TATATATCAATA*
		TATGT*AC

	SEQ ID NO: 1010	GTACATATATTTTTTTATTTTTG
		ATAAATGTATTTTTATTTTTTA
		CATATATCAATA*
		TATGT*AC

	SEQ ID NO: 1011	GTACATATATTTTTTTATTTTTG
		ATGATGTATTTTTTATTTTTAT
		ACATGATCAATA*
		TATGT*AC

	SEQ ID NO: 1012	GTACATATATTTTTTTATTTTTG
		ATGATATATTTTTTATTTTTAT
		ATATGATCAATA*
		TATGT*AC

	SEQ ID NO: 1013	GGTACATATATTTTTTATTTTTG
		ATAAATATATTTTTATTTTTTA
		TATATATCATAT*
		ATGTA*CC

	SEQ ID NO: 1014	GGTACATATATTTTTTATTTTTG
		ATAAATGTATTTTTATTTTTTA
		CATATATCATAT*
		ATGTA*CC

	SEQ ID NO: 1015	GGTACATATATTTTTTATTTTTG
		ATGATGTATTTTTTATTTTTAT
		ACATGATCATAT*
		ATGTA*CC

	SEQ ID NO: 1016	GGTACATATATTTTTTATTTTTG
		ATGATATATTTTTTATTTTTAT
		ATATGATCATAT*
		ATGTA*CC

	SEQ ID NO: 1017	CGATCATATATTTTTTTATTTTT
		GATAAATATATTTTTATTTTTT
		ATATATATCAATA
		TATGATCG

	SEQ ID NO: 1018	CGATCATATATTTTTTTATTTTT
		GATAAATGTATTTTTATTTTTT
		ACATATATCAATA
		TATGATCG

	SEQ ID NO: 1019	CGATCATATATTTTTTTATTTTT
		GATGATGTATTTTTTATTTTTA
		TACATGATCAATA
		TATGATCG

	SEQ ID NO: 1020	CGATCATATATTTTTTTATTTTT
		GATGATATATTTTTTATTTTTA
		TATATGATCAATA
		TATGATCG

	SEQ ID NO: 1021	GTATATACTTTTTATTTTTGATG
		ATGTAAATATATTTTTATTTTT
		TATATATACATGA
		TCGTATATAC

	SEQ ID NO: 1022	GTATATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTTATTTTT
		AGTACATATATGA
		TCGTATATAC

	SEQ ID NO: 1023	GGATATACTTTTTATTTTTGATG
		ATGTAAATATATTTTTATTTTT
		TATATATACATGA
		TCGTATATCC

	SEQ ID NO: 1024	GGATATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTTATTTTT
		AGTACATATATGA
		TCGTATATCC

	SEQ ID NO: 1025	GGTGATACTTTTTATTTTTGATG
		ATGTAAATATATTTTTATTTTT
		TATATATACATGA
		TCGTATCACC

	SEQ ID NO: 1026	GGTGATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTTATTTTT
		AGTACATATATGA
		TCGTATCACC

	SEQ ID NO: 1027	GGTGATCCTTTTTATTTTTGATG
		ATGTAAATATATTTTTATTTTT
		TATATATACATGA
		TCGGATCACC

	SEQ ID NO: 1028	GGTGATCCTTTTTATTTTTGATG
		ATATAAGTACTTTTTTATTTTT
		AGTACATATATGA
		TCGGATCACC

	SEQ ID NO: 1029	GTATATACATTTTTTATTTTTGA
		TGATGTAAATATATTTTTATTT
		TTTATATATACATG*
		ATCATGT*ATATAC

	SEQ ID NO: 1030	GTATATACATTTTTTATTTTTGA
		TGATATAAGTACTTTTTTATTT
		TTAGTACATATATG*
		ATCATGT*ATATAC

	SEQ ID NO: 1031	GGATATACATTTTTTATTTTTGA
		TAAATGTAAATATTTTTTATT
		TTTATATATACATAT
		ATCATGTATATCC

	SEQ ID NO: 1032	GGATATACATTTTTTATTTTTGA
		TGATGTAAATATATTTTTATT
		TTTTATATATACATG
		ATCATGTATATCC

	SEQ ID NO: 1033	GGATATACATTTTTTATTTTTGA
		TGATATAAGTACTTTTTTATT
		TTTAGTACATATATG
		ATCATGTATATCC

	SEQ ID NO: 1034	GGATATACACTTTTTATTTTTGA
		TGATGTAAATATATTTTTATT
		TTTTATATATACATG
		ATCGTGTATATCC

	SEQ ID NO: 1035	GGATATACACTTTTTATTTTTGA
		TGATATAAGTACTTTTTTATT
		TTTAGTACATATATG
		ATCGTGTATATCC

	SEQ ID NO: 1036	GGGTATATACTTTTTATTTTTGA
		TGATGTAAATATATTTTTATT
		TTTTATATATACATG
		ATCGTATATACCC

	SEQ ID NO: 1037	GGGTATATACTTTTTATTTTTGA
		TGATATAAGTACTTTTTTATT
		TTTAGTACATATATG
		ATCGTATATACCC

	SEQ ID NO: 1038	GTATATACTTTTTATTTTTGATG
		ATGTAAATATTTTTTATTTTTA
		TATATACATGATC
		GTATATAC

	SEQ ID NO: 1039	GTATATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTATTTTTG
		TACATATATGATC
		GTATATAC

	SEQ ID NO: 1040	GGATATACTTTTTATTTTTGATG
		ATGTAAATATTTTTTATTTTTA
		TATATACATGATC
		GTATATCC

	SEQ ID NO: 1041	GGATATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTATTTTT
		GTACATATATGAT
		CGTATATCC

	SEQ ID NO: 1042	GGTGATACTTTTTATTTTTGATG
		ATGTAAATATTTTTTATTTTTA
		TATATACATGATC
		GTATCACC

	SEQ ID NO: 1043	GGTGATACTTTTTATTTTTGATG
		ATATAAGTACTTTTTATTTTT
		GTACATATATGAT
		CGTATCACC

	SEQ ID NO: 1044	GGTGATCCTTTTTATTTTTGATG
		ATGTAAATATTTTTTATTTTTA
		TATATACATGATC
		GGATCACC

	SEQ ID NO: 1045	GGTGATCCTTTTTATTTTTGATG
		ATATAAGTACTTTTTATTTTTG
		TACATATATGATC
		GGATCACC

	SEQ ID NO: 1046	GTATATACATTTTTTATTTTTGA
		TGATGTAAATATTTTTTATTTT
		TATATATACATGA*T
		CATGTA*TATAC

	SEQ ID NO: 1047	GTATATACATTTTTTATTTTTGA
		TGATATAAGTACTTTTTATTTT
		TGTACATATATGA*T
		CATGTA*TATAC

	SEQ ID NO: 1048	GGATATACATTTTTTATTTTTGA
		TGATGTAAATATTTTTTATTTT
		TATATATACATGA*T
		CATGTA*TATCC

	SEQ ID NO: 1049	GGATATACATTTTTTATTTTTGA
		TGATATAAGTACTTTTTATTT
		TTGTACATATATGA*
		TCATGTA*TATCC

	SEQ ID NO: 1050	GGATATACACTTTTTATTTTTGA
		TGATGTAAATATTTTTTATTT
		TTATATATACATGA*
		TCGTGTA*TATCC

	SEQ ID NO: 1051	GGATATACACTTTTTATTTTTGA
		TGATATAAGTACTTTTTATTT
		TTGTACATATATGA*
		TCGTGTA*TATCC

	SEQ ID NO: 1052	GGGTATATACTTTTTATTTTTGA
		TGATGTAAATATTTTTTATTTT
		TATATATACATGA*T
		CGTATA*TACCC

	SEQ ID NO: 1053	GGGTATATACTTTTTATTTTTGA
		TGATATAAGTACTTTTTATTT
		TTGTACATATATGA*
		TCGTATA*TACCC

	SEQ ID NO: 1054	GTATATACATTTTTTATTTTTGA
		TGATATAAGTATTTTTATTTTT
		TACATATATGATC
		ATGTATATAC

	SEQ ID NO: 1055	GGATATACATTTTTTATTTTTGA
		TAAATGAATATTTTTTATTTTT
		ATATACATATATC
		ATGTATATCC

	SEQ ID NO: 1056	GGATATACATTTTTTATTTTTGA
		TGATATAAGTATTTTTATTTTT
		TACATATATGATC
		ATGTATATCC

	SEQ ID NO: 1057	GGATATACACTTTTTATTTTTGA
		TAAATGAATATTTTTTATTTT
		TATATACATATAT*C
		GTGTAT*ATCC

	SEQ ID NO: 1058	GGATATACACTTTTTATTTTTGA
		TGATATAAGTATTTTTATTTT
		TTACATATATGAT*C
		GTGTAT*ATCC

	SEQ ID NO: 1059	GGGTATATACTTTTTATTTTTGA
		TAAATGAATATTTTTTATTTTT
		ATATACATATATC
		GTATATACCC

	SEQ ID NO: 1060	GGGTATATACTTTTTATTTTTGA
		TGATATAAGTATTTTTATTTTT
		TACATATATGATC
		GTATATACCC

	SEQ ID NO: 1061	GTATATACATTTTTTATTTTTGA
		TGATGAATATTTTTTATTTTTA
		TATACATGATCAT
		GTATATAC

	SEQ ID NO: 1062	GGATATACATTTTTTATTTTTGA
		TAAATGAATATTTTTATTTTTT
		ATACATATATCAT
		GTATATCC

	SEQ ID NO: 1063	GGATATACATTTTTTATTTTTGA
		TGATGAATATTTTTTATTTTTA
		TATACATGATCAT
		GTATATCC

	SEQ ID NO: 1064	GGATATACATTTTTTATTTTTGA
		TGATAAATGTTTTTTATTTTTA
		CATATATGATCAT
		GTATATCC

	SEQ ID NO: 1065	GGATATACACTTTTTATTTTTGA
		TGATGAATATTTTTTATTTTT
		ATATACATGATCG
		TGTATATCC

	SEQ ID NO: 1066	GGGTATATACTTTTTATTTTTGA
		TGATGAATATTTTTTATTTTTA
		TATACATGATCGT
		ATATACCC

	SEQ ID NO: 1067	GATACTTTTTATTTTTGATGATG
		TAAATATATTTTTATTTTTTAT
		ATATACATGAT*C
		GTAT*C

	SEQ ID NO: 1068	GATACTTTTTATTTTTGATGATA
		TAAGTACTTTTTTATTTTTAGT
		ACATATATGAT*C
		GTAT*C

	SEQ ID NO: 1069	GACACTTTTTATTTTTGATGATG
		TAAATATATTTTTATTTTTTAT
		ATATACATGAT*C
		GTGT*C

	SEQ ID NO: 1070	GACACTTTTTATTTTTGATGATA
		TAAGTACTTTTTTATTTTTAGT
		ACATATATGAT*C
		GTGT*C

	SEQ ID NO: 1071	GGATCTTTTTATTTTTGATGATG
		TAAATATATTTTTATTTTTTAT
		ATATACATGAT*C
		GATC*C

	SEQ ID NO: 1072	GGATCTTTTTATTTTTGATGATA
		TAAGTACTTTTTTATTTTTAGT
		ACATATATGAT*C
		GATC*C

	SEQ ID NO: 1073	GCGTCTTTTTATTTTTGATGATG
		TAAATATATTTTTATTTTTTAT
		ATATACATGAT*C
		GACG*C

	SEQ ID NO: 1074	GCGTCTTTTTATTTTTGATGATA
		TAAGTACTTTTTTATTTTTAGT
		ACATATATGAT*C
		GACG*C

	SEQ ID NO: 1075	GTATACTTTTTATTTTTGATGAT
		GTAAATATTTTTTATTTTTATA
		TATACATGATC*G
		TATA*C

	SEQ ID NO: 1076	GTATACTTTTTATTTTTGATGAT
		ATAAGTACTTTTTATTTTTGTA
		CATATATGATC*G
		TATA*C

	SEQ ID NO: 1077	GTGATCTTTTTATTTTTGATGAT
		GTAAATATTTTTTATTTTTATA
		TATACATGATC*G
		ATCA*C

	SEQ ID NO: 1078	GTGATCTTTTTATTTTTGATGAT
		ATAAGTACTTTTTATTTTTGTA
		CATATATGATC*G
		ATCA*C

	SEQ ID NO: 1079	GGATACTTTTTATTTTTGATGAT
		GTAAATATTTTTTATTTTTATA
		TATACATGATC*G
		TATC*C

	SEQ ID NO: 1080	GGATACTTTTTATTTTTGATGAT
		ATAAGTACTTTTTATTTTTGT
		ACATATATGATC*
		GTATC*C

	SEQ ID NO: 1081	GCGATCTTTTTATTTTTGATGAT
		GTAAATATTTTTTATTTTTATA
		TATACATGATC*G
		ATCG*C

	SEQ ID NO: 1082	GCGATCTTTTTATTTTTGATGAT
		ATAAGTACTTTTTATTTTTGTA
		CATATATGATC*G
		ATCG*C

	SEQ ID NO: 1083	GATATATTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCA*T
		ATAT*C

	SEQ ID NO: 1084	GATATACTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCG*T
		ATAT*C

	SEQ ID NO: 1085	GTGATACTTTTTATTTTTGATAA
		ATGAATATTTTTTATTTTTATA
		TACATATATCG*T
		ATCA*C

	SEQ ID NO: 1086	GTGATACTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCG*T
		ATCA*C

	SEQ ID NO: 1087	GGTATACTTTTTATTTTTGATAA
		ATGAATATTTTTTATTTTTATA
		TACATATATCG*T
		ATAC*C

	SEQ ID NO: 1088	GGTATACTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCG*T
		ATAC*C

	SEQ ID NO: 1089	GGTGTACTTTTTATTTTTGATAA
		ATGAATATTTTTTATTTTTATA
		TACATATATCG*T
		ACAC*C

	SEQ ID NO: 1090	GGTGTACTTTTTATTTTTGATGA
		TATAAGTATTTTTATTTTTTAC
		ATATATGATCG*T
		ACAC*C

	SEQ ID NO: 1091	GTATATACTTTTTATTTTTGATG
		ATGAATATTTTTTATTTTTATA
		TACATGATCGT*A
		TATA*C

	SEQ ID NO: 1092	GTATATACTTTTTATTTTTGATG
		ATAAATGTTTTTTATTTTTACA
		TATATGATCGT*A
		TATA*C

	SEQ ID NO: 1093	GGATATACTTTTTATTTTTGATG
		ATGAATATTTTTTATTTTTATA
		TACATGATCGT*A
		TATC*C

	SEQ ID NO: 1094	GGTGATACTTTTTATTTTTGATG
		ATGAATATTTTTTATTTTTATA
		TACATGATCGT*A
		TCAC*C

	SEQ ID NO: 1095	GGTGATACTTTTTATTTTTGATG
		ATAAATGTTTTTTATTTTTAC
		ATATATGATCGT*
		ATCAC*C

	SEQ ID NO: 1096	GGTGATCCTTTTTATTTTTGATG
		ATGAATATTTTTTATTTTTATA
		TACATGATCGG*A
		TCAC*C

	SEQ ID NO: 1097	GATACTTTTTATTTTTGATATAA
		ATATATAATTTTTATTTTTATA
		TATATATATAT*C
		GTAT*C

	SEQ ID NO: 1098	GATACTTTTTATTTTTGATAAAT
		GAATATATTTTTTATTTTTATA
		TATACATATAT*C
		GTAT*C

	SEQ ID NO: 1099	GACACTTTTTATTTTTGATATAA
		ATATATAATTTTTATTTTTAT
		ATATATATATAT*
		CGTGT*C

	SEQ ID NO: 1100	GACACTTTTTATTTTTGATAAAT
		GAATATATTTTTTATTTTTAT
		ATATACATATAT*
		CGTGT*C

	SEQ ID NO: 1101	GACACTTTTTATTTTTGATATAA
		GTAAATATTTTTTATTTTTAT
		ATATACATATAT*
		CGTGT*C

	SEQ ID NO: 1102	GGATCTTTTTATTTTTGATATAA
		ATATATAATTTTTATTTTTATA
		TATATATATAT*C
		GATC*C

	SEQ ID NO: 1103	GGATCTTTTTATTTTTGATAAAT
		GAATATATTTTTTATTTTTATA
		TATACATATAT*C
		GATC*C

	SEQ ID NO: 1104	GGATCTTTTTATTTTTGATATAA
		GTAAATATTTTTTATTTTTATA
		TATACATATAT*C
		GATC*C

	SEQ ID NO: 1105	GCGTCTTTTTATTTTTGATATAA
		ATATATAATTTTTATTTTTATA
		TATATATATAT*C
		GACG*C

	SEQ ID NO: 1106	GCGTCTTTTTATTTTTGATAAAT
		GAATATATTTTTTATTTTTATA
		TATACATATAT*C
		GACG*C

	SEQ ID NO: 1107	GCGTCTTTTTATTTTTGATATAA
		GTAAATATTTTTTATTTTTATA
		TATACATATAT*C
		GACG*C

	SEQ ID NO: 1108	GTATATACATTTTTTATTTTTGA
		TATAAATATATAATTTTTATTT
		TTATATATATATAT*
		ATCATGT*ATATAC

	SEQ ID NO: 1109	GTATATACATTTTTTATTTTTGA
		TAAATGAATATATTTTTTATTT
		TTATATATACATAT*
		ATCATGT*ATATAC

	SEQ ID NO: 1110	GTATATACATTTTTTATTTTTGA
		TATAAGTAAATATTTTTTATTT
		TTATATATACATAT*
		ATCATGT*ATATAC

	SEQ ID NO: 1111	GGATATACATTTTTTATTTTTGA
		TATAAATATATAATTTTTATT
		TTTATATATATATAT
		ATCATGTATATCC

	SEQ ID NO: 1112	GGATATACACTTTTTATTTTTGA
		TATAAATATATAATTTTTATT
		TTTATATATATATAT
		ATCGTGTATATCC

	SEQ ID NO: 1113	GGATATACACTTTTTATTTTTGA
		TAAATGAATATATTTTTTATT
		TTTATATATACATAT
		ATCGTGTATATCC

	SEQ ID NO: 1114	GGATATACACTTTTTATTTTTGA
		TATAAGTAAATATTTTTTATT
		TTTATATATACATAT
		ATCGTGTATATCC

	SEQ ID NO: 1115	GGGTATATACTTTTTATTTTTGA
		TATAAATATATAATTTTTATT
		TTTATATATATATAT
		ATCGTATATACCC

	SEQ ID NO: 1116	GGGTATATACTTTTTATTTTTGA
		TAAATGAATATATTTTTTATT
		TTTATATATACATAT
		ATCGTATATACCC

	SEQ ID NO: 1117	GGGTATATACTTTTTATTTTTGA
		TATAAGTAAATATTTTTTATT
		TTTATATATACATAT
		ATCGTATATACCC

	SEQ ID NO: 1118	GTATACTTTTTATTTTTTATAAA
		TATATATTTTTTTATTTTTTAT
		ATATATATATA*G
		TATA*C

	SEQ ID NO: 1119	GTGATCTTTTTATTTTTTATAAA
		TATATATTTTTTTATTTTTTAT
		ATATATATATA*G
		ATCA*C

	SEQ ID NO: 1120	GTATACTTTTTATTTTTGATATA
		AATATATTTTTTTATTTTTTAT
		ATATATATATC*G
		TATA*C

	SEQ ID NO: 1121	GTATACTTTTTATTTTTGATATA
		TAAATATTTTTTTATTTTTTAT
		ATATATATATC*G
		TATA*C

	SEQ ID NO: 1122	GTATACTTTTTATTTTTGATAAA
		TGAATATATTTTTATTTTTTAT
		ATACATATATC*G
		TATA*C

	SEQ ID NO: 1123	GGATACTTTTTATTTTTTATAAA
		TATATATTTTTTTATTTTTTAT
		ATATATATATA*G
		TATC*C

	SEQ ID NO: 1124	GTGATCTTTTTATTTTTGATATA
		AATATATTTTTTTATTTTTTAT
		ATATATATATC*G
		ATCA*C

	SEQ ID NO: 1125	GTGATCTTTTTATTTTTGATATA
		TAAATATTTTTTTATTTTTTAT
		ATATATATATC*G
		ATCA*C

	SEQ ID NO: 1126	GTGATCTTTTTATTTTTGATAAA
		TGAATATATTTTTATTTTTTAT
		ATACATATATC*G
		ATCA*C

	SEQ ID NO: 1127	GGATACTTTTTATTTTTGATATA
		AATATATTTTTTTATTTTTTAT
		ATATATATATC*G
		TATC*C

	SEQ ID NO: 1128	GGATACTTTTTATTTTTGATATA
		TAAATATTTTTTTATTTTTTAT
		ATATATATATC*G
		TATC*C

	SEQ ID NO: 1129	GGATACTTTTTATTTTTGATAAA
		TGAATATATTTTTATTTTTTAT
		ATACATATATC*G
		TATC*C

	SEQ ID NO: 1130	GCGATCTTTTTATTTTTTATAAA
		TATATATTTTTTTATTTTTTAT
		ATATATATATA*G
		ATCG*C

	SEQ ID NO: 1131	GCGATCTTTTTATTTTTGATATA
		AATATATTTTTTTATTTTTTAT
		ATATATATATC*G
		ATCG*C

	SEQ ID NO: 1132	GCGATCTTTTTATTTTTGATATA
		TAAATATTTTTTTATTTTTTAT
		ATATATATATC*G
		ATCG*C

	SEQ ID NO: 1133	GCGATCTTTTTATTTTTGATAAA
		TGAATATATTTTTATTTTTTAT
		ATACATATATC*G
		ATCG*C

	SEQ ID NO: 1134	GATATATCACTTTTTATTTTTTA
		TAAATATATATTTTTTTATTTT
		TTATATATATATA*T
		AGTGAT*ATATC

	SEQ ID NO: 1135	GTATATACATTTTTTATTTTTGA
		TATAAATATATTTTTTTATTTT
		TTATATATATATA*T
		CATGTA*TATAC

	SEQ ID NO: 1136	GTATATACATTTTTTATTTTTGA
		TATATAAATATTTTTTTATTTT
		TTATATATATATA*T
		CATGTA*TATAC

	SEQ ID NO: 1137	GGATATACACTTTTTATTTTTTA
		TAAATATATATTTTTTTATTTT
		TTATATATATATA*T
		AGTGTA*TATCC

	SEQ ID NO: 1138	GGATATACATTTTTTATTTTTGA
		TATAAATATATTTTTTTATTTT
		TTATATATATATA*T
		CATGTA*TATCC

	SEQ ID NO: 1139	GGATATACATTTTTTATTTTTGA
		TATATAAATATTTTTTTATTTT
		TTATATATATATA*T
		CATGTA*TATCC

	SEQ ID NO: 1140	GGATATACATTTTTTATTTTTGA
		TAAATGAATATATTTTTATTT
		TTTATATACATATA*
		TCATGTA*TATCC

	SEQ ID NO: 1141	GGGTATATACTTTTTATTTTTTA
		TAAATATATATTTTTTTATTTT
		TTATATATATATA*T
		AGTATA*TACCC

	SEQ ID NO: 1142	GGATATACACTTTTTATTTTTGA
		TATAAATATATTTTTTTATTTT
		TTATATATATATA*T
		CGTGTA*TATCC

	SEQ ID NO: 1143	GGATATACACTTTTTATTTTTGA
		TATATAAATATTTTTTTATTTT
		TTATATATATATA*T
		CGTGTA*TATCC

	SEQ ID NO: 1144	GGATATACACTTTTTATTTTTGA
		TAAATGAATATATTTTTATTT
		TTTATATACATATA*
		TCGTGTA*TATCC

	SEQ ID NO: 1145	GGGTATATACTTTTTATTTTTGA
		TATAAATATATTTTTTTATTTT
		TTATATATATATA*T
		CGTATA*TACCC

	SEQ ID NO: 1146	GGGTATATACTTTTTATTTTTGA
		TATATAAATATTTTTTTATTTT
		TTATATATATATA*T
		CGTATA*TACCC

	SEQ ID NO: 1147	GGGTATATACTTTTTATTTTTGA
		TAAATGAATATATTTTTATTT
		TTTATATACATATA*
		TCGTATA*TACCC

	SEQ ID NO: 1148	GATATACTTTTTATTTTTGATAA
		ATATATAATTTTTATTTTTATA
		TATATATATCG*T
		ATAT*C

	SEQ ID NO: 1149	GTGATACTTTTTATTTTTGATAA
		ATATATAATTTTTATTTTTATA
		TATATATATCG*T
		ATCA*C

	SEQ ID NO: 1150	GGTATACTTTTTATTTTTGATAA
		ATATATAATTTTTATTTTTATA
		TATATATATCG*T
		ATAC*C

	SEQ ID NO: 1151	GGTGTACTTTTTATTTTTGATAA
		ATATATAATTTTTATTTTTATA
		TATATATATCG*T
		ACAC*C

	SEQ ID NO: 1152	GTATATACATTTTTTATTTTTGA
		TAAATATATAATTTTTATTTTT
		ATATATATATATC
		ATGTATATAC

	SEQ ID NO: 1153	GGATATACATTTTTTATTTTTGA
		TAAATATATAATTTTTATTTTT
		ATATATATATATC
		ATGTATATCC

	SEQ ID NO: 1154	GGATATACACTTTTTATTTTTGA
		TAAATATATAATTTTTATTTT
		TATATATATATAT*C
		GTGTAT*ATCC

	SEQ ID NO: 1155	GGGTATATACTTTTTATTTTTGA
		TAAATATATAATTTTTATTTTT
		ATATATATATATC
		GTATATACCC

	SEQ ID NO: 1156	GTATATACTTTTTATTTTTGATA
		AATATATTTTTTTATTTTTTAT
		ATATATATCGT*A
		TATA*C

	SEQ ID NO: 1157	GTATATACTTTTTATTTTTGATA
		AATGTATTTTTTTATTTTTTAT
		ACATATATCGT*A
		TATA*C

	SEQ ID NO: 1158	GGATATACTTTTTATTTTTGATA
		AATATATTTTTTTATTTTTTAT
		ATATATATCGT*A
		TATC*C

	SEQ ID NO: 1159	GGATATACTTTTTATTTTTGATA
		AATGTATTTTTTTATTTTTTAT
		ACATATATCGT*A
		TATC*C

	SEQ ID NO: 1160	GGATATACTTTTTATTTTTGATG
		ATAAATGTTTTTTATTTTTAC
		ATATATGATCGT*
		ATATC*C

	SEQ ID NO: 1161	GGTGATACTTTTTATTTTTGATA
		AATATATTTTTTTATTTTTTAT
		ATATATATCGT*A
		TCAC*C

	SEQ ID NO: 1162	GGTGATACTTTTTATTTTTGATA
		AATGTATTTTTTTATTTTTTAT
		ACATATATCGT*A
		TCAC*C

	SEQ ID NO: 1163	GGTGATCCTTTTTATTTTTGATA
		AATATATTTTTTTATTTTTTAT
		ATATATATCGG*A
		TCAC*C

	SEQ ID NO: 1164	GGTGATCCTTTTTATTTTTGATA
		AATGTATTTTTTTATTTTTTAT
		ACATATATCGG*A
		TCAC*C

	SEQ ID NO: 1165	GGTGATCCTTTTTATTTTTGATG
		ATAAATGTTTTTTATTTTTACA
		TATATGATCGG*A
		TCAC*C

	SEQ ID NO: 1166	GTATATACATTTTTTATTTTTGA
		TAAATATATTTTTTTATTTTTT
		ATATATATATCAT
		GTATATAC

	SEQ ID NO: 1167	GTATATACATTTTTTATTTTTGA
		TAAATGTATTTTTTTATTTTTT
		ATACATATATCAT
		GTATATAC

	SEQ ID NO: 1168	GTATATACATTTTTTATTTTTGA
		TGATAAATGTTTTTTATTTTTA
		CATATATGATCAT
		GTATATAC

	SEQ ID NO: 1169	GGATATACATTTTTTATTTTTGA
		TAAATATATTTTTTTATTTTTT
		ATATATATATCAT
		GTATATCC

	SEQ ID NO: 1170	GGATATACACTTTTTATTTTTGA
		TAAATATATTTTTTTATTTTTT
		ATATATATATCGT
		GTATATCC

	SEQ ID NO: 1171	GGATATACACTTTTTATTTTTGA
		TAAATGTATTTTTTTATTTTTT
		ATACATATATCGT
		GTATATCC

	SEQ ID NO: 1172	GGATATACACTTTTTATTTTTGA
		TGATAAATGTTTTTTATTTTT
		ACATATATGATCG
		TGTATATCC

	SEQ ID NO: 1173	GGGTATATACTTTTTATTTTTGA
		TAAATATATTTTTTTATTTTTT
		ATATATATATCGT
		ATATACCC

	SEQ ID NO: 1174	GGGTATATACTTTTTATTTTTGA
		TAAATGTATTTTTTTATTTTTT
		ATACATATATCGT
		ATATACCC

	SEQ ID NO: 1175	GGGTATATACTTTTTATTTTTGA
		TGATAAATGTTTTTTATTTTTA
		CATATATGATCGT
		ATATACCC

	SEQ ID NO: 1176	GTATATACATTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCATGT*A
		TATA*C

	SEQ ID NO: 1177	GTATATACATTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCATGT*A
		TATA*C

	SEQ ID NO: 1178	GGATATACATTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCATGT*A
		TATC*C

	SEQ ID NO: 1179	GGATATACATTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCATGT*A
		TATC*C

	SEQ ID NO: 1180	GGATATACATTTTTTATTTTTGA
		TGATGAATTTTTTATTTTTATA
		CATGATCATGT*A
		TATC*C

	SEQ ID NO: 1181	GGATATACACTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCGTGT*A
		TATC*C

	SEQ ID NO: 1182	GGATATACACTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCGTGT*A
		TATC*C

	SEQ ID NO: 1183	GGGTATATACTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCGTAT*A
		TACC*C

	SEQ ID NO: 1184	GGGTATATACTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCGTAT*A
		TACC*C

	SEQ ID NO: 1185	GGATGTACACTTTTTATTTTTGA
		TAAATATTTTTTTATTTTTTAT
		ATATATCGTGT*A
		CATC*C

	SEQ ID NO: 1186	GGATGTACACTTTTTATTTTTGA
		TAAATGTTTTTTTATTTTTTAC
		ATATATCGTGT*A
		CATC*C

	SEQ ID NO: 1187	GTACATATATTTTTTTATTTTTG
		ATAAATATTTTTTTATTTTTTA
		TATATATCAATA*
		TATGT*AC

	SEQ ID NO: 1188	GTACATATATTTTTTTATTTTTG
		ATAAATGTTTTTTTATTTTTTA
		CATATATCAATA*
		TATGT*AC

	SEQ ID NO: 1189	GGTACATATATTTTTTATTTTTG
		ATAAATATTTTTTTATTTTTTA
		TATATATCATAT*
		ATGTA*CC

	SEQ ID NO: 1190	GGTACATATATTTTTTATTTTTG
		ATAAATGTTTTTTTATTTTTTA
		CATATATCATAT*
		ATGTA*CC

	SEQ ID NO: 1191	CGATCATATATTTTTTTATTTTT
		GATAAATATTTTTTTATTTTTT
		ATATATATCAATA
		TATGATCG

	SEQ ID NO: 1192	CGATCATATATTTTTTTATTTTT
		GATAAATGTTTTTTTATTTTTT
		ACATATATCAATA
		TATGATCG

	SEQ ID NO: 1193	CGATCATATATTTTTTTATTTTT
		GATGATGAATTTTTTATTTTTA
		TACATGATCAATA
		TATGATCG

	SEQ ID NO: 1194	CGATCATATATTTTTTTATTTTT
		GATGATAAATTTTTTATTTTTA
		TATATGATCAATA
		TATGATCG

	SEQ ID NO: 1195	GTATATACTTTTTATTTTTGATA
		TAAATATATAATTTTTATTTTT
		ATATATATATATA
		TCGTATATAC

	SEQ ID NO: 1196	GTATATACTTTTTATTTTTGATA
		AATGAATATATTTTTTATTTTT
		ATATATACATATA
		TCGTATATAC

	SEQ ID NO: 1197	GGATATACTTTTTATTTTTGATA
		TAAATATATAATTTTTATTTTT
		ATATATATATATA
		TCGTATATCC

	SEQ ID NO: 1198	GGATATACTTTTTATTTTTGATA
		AATGAATATATTTTTTATTTTT
		ATATATACATATA
		TCGTATATCC

	SEQ ID NO: 1199	GGTGATACTTTTTATTTTTGATA
		TAAATATATAATTTTTATTTTT
		ATATATATATATA
		TCGTATCACC

	SEQ ID NO: 1200	GGTGATACTTTTTATTTTTGATA
		AATGAATATATTTTTTATTTTT
		ATATATACATATA
		TCGTATCACC

	SEQ ID NO: 1201	GGTGATCCTTTTTATTTTTGATA
		TAAATATATAATTTTTATTTTT
		ATATATATATATA
		TCGGATCACC

	SEQ ID NO: 1202	GGTGATCCTTTTTATTTTTGATA
		AATGAATATATTTTTTATTTTT
		ATATATACATATA
		TCGGATCACC

	SEQ ID NO: 1203	GTATATACTTTTTATTTTTGATA
		TAAGTAAATATTTTTTATTTTT
		ATATATACATATA
		TCGTATATAC

	SEQ ID NO: 1204	GGATATACTTTTTATTTTTGATA
		TAAGTAAATATTTTTTATTTTT
		ATATATACATATA
		TCGTATATCC

	SEQ ID NO: 1205	GGTGATACTTTTTATTTTTGATA
		TAAGTAAATATTTTTTATTTTT
		ATATATACATATA
		TCGTATCACC

	SEQ ID NO: 1206	GGTGATCCTTTTTATTTTTGATA
		TAAGTAAATATTTTTTATTTTT
		ATATATACATATA
		TCGGATCACC

	SEQ ID NO: 1207	GTATATACTTTTTATTTTTTATA
		AATATATATTTTTTTATTTTTT
		ATATATATATATA
		GTATATAC

	SEQ ID NO: 1208	GTATATACTTTTTATTTTTGATA
		TAAATATATTTTTTTATTTTTT
		ATATATATATATC
		GTATATAC

	SEQ ID NO: 1209	GTATATACTTTTTATTTTTGATA
		AATGAATATATTTTTATTTTTT
		ATATACATATATC
		GTATATAC

	SEQ ID NO: 1210	GGATATACTTTTTATTTTTTATA
		AATATATATTTTTTTATTTTTT
		ATATATATATATA
		GTATATCC

	SEQ ID NO: 1211	GGATATACTTTTTATTTTTGATA
		TAAATATATTTTTTTATTTTTT
		ATATATATATATC
		GTATATCC

	SEQ ID NO: 1212	GGATATACTTTTTATTTTTGATA
		AATGAATATATTTTTATTTTTT
		ATATACATATATC
		GTATATCC

	SEQ ID NO: 1213	GGTGATACTTTTTATTTTTTATA
		AATATATATTTTTTTATTTTTT
		ATATATATATATA
		GTATCACC

	SEQ ID NO: 1214	GGTGATACTTTTTATTTTTGATA
		TAAATATATTTTTTTATTTTTT
		ATATATATATATC
		GTATCACC

	SEQ ID NO: 1215	GGTGATACTTTTTATTTTTGATA
		AATGAATATATTTTTATTTTTT
		ATATACATATATC
		GTATCACC

	SEQ ID NO: 1216	GGTGATCCTTTTTATTTTTTATA
		AATATATATTTTTTTATTTTTT
		ATATATATATATA
		GGATCACC

	SEQ ID NO: 1217	GGTGATCCTTTTTATTTTTGATA
		TAAATATATTTTTTTATTTTTT
		ATATATATATATC
		GGATCACC

	SEQ ID NO: 1218	GGTGATCCTTTTTATTTTTGATA
		AATGAATATATTTTTATTTTTT
		ATATACATATATC
		GGATCACC

	SEQ ID NO: 1219	GTATATACTTTTTATTTTTGATA
		TATAAATATTTTTTTATTTTTT
		ATATATATATATC
		GTATATAC

	SEQ ID NO: 1220	GGATATACTTTTTATTTTTGATA
		TATAAATATTTTTTTATTTTTT
		ATATATATATATC
		GTATATCC

	SEQ ID NO: 1221	GGTGATACTTTTTATTTTTGATA
		TATAAATATTTTTTTATTTTTT
		ATATATATATATC
		GTATCACC

	SEQ ID NO: 1222	GGTGATCCTTTTTATTTTTGATA
		TATAAATATTTTTTTATTTTTT
		ATATATATATATC
		GGATCACC

	SEQ ID NO: 1223	GATACAAAAAAAAAAATATATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATA
		TAGTATC

	SEQ ID NO: 1224	GACACAAAAAAAAAAAGATATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATA
		TCGTGTC

	SEQ ID NO: 1225	GATATACAAAAAAAAAAATATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATA
		GTATATC

	SEQ ID NO: 1226	GATATATAAAAAAAAAAAGATAT
		ATGTATATAAAAAAAAAAA
		ATATACATATATC
		ATATATC

	SEQ ID NO: 1227	GATATACAAAAAAAAAAAGATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATC
		GTATATC

	SEQ ID NO: 1228	GGTATACAAAAAAAAAAATATAT
		ATATATATAAAAAAAAAAA
		ATATATATATATA
		GTATACC

	SEQ ID NO: 1229	GATATATCACAAAAAAAAAAATA
		TATATATAAAAAAAAAAAA
		TATATATATAGTG
		ATATATC

	SEQ ID NO: 1230	GTATATACATAAAAAAAAAAAGA
		TATATGTAAAAAAAAAAAA
		TACATATATCATG
		TATATAC

	SEQ ID NO: 1231	GGATATACATAAAAAAAAAAAGA
		TATATGTAAAAAAAAAAA
		ATACATATATCAT*G
		TATATC*C

	SEQ ID NO: 1232	GGATATACATAAAAAAAAAAAGA
		TCATGTATAAAAAAAAAAA
		ATACATGATCATG
		TATATCC

	SEQ ID NO: 1233	GGGTATATACAAAAAAAAAAATA
		TATATATAAAAAAAAAAAA
		TATATATATAGTA
		TATACCC

	SEQ ID NO: 1234	GTATATACAAAAAAAAAAATATA
		TATATATATATAAAAAAAA
		AAAATATATATATAT
		ATAGTATATAC

	SEQ ID NO: 1235	GTATATACAAAAAAAAAAAGATA
		TATATATATATAAAAAAAA
		AAAATATATATATAT
		ATCGTATATAC

	SEQ ID NO: 1236	GGATATACAAAAAAAAAAATATA
		TATATATATATAAAAAAAA
		AAAATATATATATAT
		ATAGTATATCC

	SEQ ID NO: 1237	GGATATACAAAAAAAAAAAGATA
		TATATATATATAAAAAAAA
		AAAATATATATATAT
		ATCGTATATCC

	SEQ ID NO: 1238	GTATATACAAAAAAAAAAATATA
		TATATATATAAAAAAAAAA
		AATATATATATATA*
		TAGTATA*TAC

	SEQ ID NO: 1239	GTATATACAAAAAAAAAAAGATA
		TATATATATAAAAAAAAAA
		AATATATATATATA*
		TCGTATA*TAC

	SEQ ID NO: 1240	GGATATACAAAAAAAAAAATATA
		TATATATATAAAAAAAAAA
		AATATATATATATA*
		TAGTATA*TCC

	SEQ ID NO: 1241	GGATATACAAAAAAAAAAAGATA
		TATATATATAAAAAAAAAA
		AATATATATATATA*
		TCGTATA*TCC

	SEQ ID NO: 1242	GATATATCACAAAAAAAAAAATA
		TATATATATAAAAAAAAAA
		AATATATATATATA*
		GTGATAT*ATC

	SEQ ID NO: 1243	GGATATACATAAAAAAAAAAAGA
		TATATATATAAAAAAAAAA
		AATATATATATATC*
		ATGTATA*TCC

	SEQ ID NO: 1244	GTACATATATTAAAAAAAAAAAG
		ATATATATAAAAAAAAAAA
		ATATATATATCAA*T
		ATATGT*AC

	SEQ ID NO: 1245	GATGTATATACAAAAAAAAAAAT
		ATATATATAAAAAAAAAAA
		ATATATATATAGT*A
		TATACA*TC

	SEQ ID NO: 1246	CGATCATATATTAAAAAAAAAAA
		GATATATATAAAAAAAAAA
		AATATATATATCAA*
		TATATGA*TCG

	SEQ ID NO: 1247	CGATCATATATTAAAAAAAAAAA
		GATATATGTAAAAAAAAAA
		AATACATATATCAA*
		TATATGA*TCG

	SEQ ID NO: 1248	GATACAAAAAAAAAAATATAAAT
		ATATATATAAAAAAAAAAA
		ATATATATATATA
		TAGTATC

	SEQ ID NO: 1249	GGATCAAAAAAAAAAATATAAAT
		ATATATATAAAAAAAAAAA
		ATATATATATATA
		TAGATCC

	SEQ ID NO: 1250	GACACAAAAAAAAAAAGATAAAT
		ATATATATAAAAAAAAAA
		AATATATATATAT*A
		TCGTGT*C

	SEQ ID NO: 1251	GACACAAAAAAAAAAAGATGATG
		TATATATAAAAAAAAAAA
		ATATATATACATG*A
		TCGTGT*C

	SEQ ID NO: 1252	GCGTCAAAAAAAAAAAGATAAAT
		ATATATATAAAAAAAAAAA
		ATATATATATATA
		TCGACGC

	SEQ ID NO: 1253	GATATACAAAAAAAAAAATATAA
		ATATATATAAAAAAAAAAA
		ATATATATATATA
		GTATATC

	SEQ ID NO: 1254	GTATATACATAAAAAAAAAAAGA
		TAAATGTAAAAAAAAAAA
		ATACATATATCAT*G
		TATATA*C

	SEQ ID NO: 1255	GTATATACATAAAAAAAAAAAGA
		TGATATATAAAAAAAAAAA
		ATATATGATCATG
		TATATAC

	SEQ ID NO: 1256	GGATATACATAAAAAAAAAAAGA
		TAAATATAAAAAAAAAAA
		ATATATATATCAT*G
		TATATC*C

	SEQ ID NO: 1257	GGATATACATAAAAAAAAAAAGA
		TGATATATAAAAAAAAAA
		AATATATGATCAT*G
		TATATC*C

	SEQ ID NO: 1258	GTATATACAAAAAAAAAAATATA
		AATATATATATAAAAAAAA
		AAAATATATATATAT
		ATAGTATATAC

	SEQ ID NO: 1259	GTATATACAAAAAAAAAAAGATA
		AATATATATATAAAAAAAA
		AAAATATATATATAT
		ATCGTATATAC

	SEQ ID NO: 1260	GGATATACAAAAAAAAAAATATA
		AATATATATATAAAAAAAA
		AAAATATATATATAT
		ATAGTATATCC

	SEQ ID NO: 1261	GGATATACAAAAAAAAAAAGATA
		AATATATATATAAAAAAAA
		AAAATATATATATAT
		ATCGTATATCC

	SEQ ID NO: 1262	GTATATACAAAAAAAAAAAGATA
		AATGTATATAAAAAAAAAA
		AATATATACATATA*
		TCGTATA*TAC

	SEQ ID NO: 1263	GGATATACAAAAAAAAAAAGATA
		AATGTATATAAAAAAAAA
		AAATATATACATATA
		TCGTATATCC

	SEQ ID NO: 1264	GGTGATACAAAAAAAAAAAGATG
		ATGTATATATAAAAAAAAA
		AAATATATACATGA*
		TCGTATC*ACC

	SEQ ID NO: 1265	GATATATCACAAAAAAAAAAATA
		TAAATATATATAAAAAAAA
		AAAATATATATATAT
		AGTGATATATC

	SEQ ID NO: 1266	GTATATACATAAAAAAAAAAAGA
		TAAATATATAAAAAAAAAA
		AATATATATATATC*
		ATGTATA*TAC

	SEQ ID NO: 1267	GTATATACATAAAAAAAAAAAGA
		TGATATATGTAAAAAAAAA
		AAACATATATGATC*
		ATGTATA*TAC

	SEQ ID NO: 1268	GGATATACATAAAAAAAAAAAGA
		TAAATATATAAAAAAAAA
		AAATATATATATATC
		ATGTATATCC

	SEQ ID NO: 1269	GTACATATATTAAAAAAAAAAAG
		ATAAATATAAAAAAAAAAA
		ATATATATATCAA*T
		ATATGT*AC

	SEQ ID NO: 1270	GTACATATATTAAAAAAAAAAAG
		ATAAATGTAAAAAAAAAAA
		ATACATATATCAA*T
		ATATGT*AC

	SEQ ID NO: 1271	GTACATATATTAAAAAAAAAAAG
		ATGATATATAAAAAAAAAA
		AATATATGATCAA*T
		ATATGT*AC

	SEQ ID NO: 1272	GGATATACATAAAAAAAAAAAGA
		TGATGAATAAAAAAAAAA
		AATACATGATCAT*G
		TATATC*C

	SEQ ID NO: 1273	GTATATACATAAAAAAAAAAAGA
		TAAATGTTAAAAAAAAAAA
		TACATATATCATG
		TATATAC

	SEQ ID NO: 1274	GATACAAAAAAAAAAAGATATAA
		ATATATAAAAAAAAAAAA
		AATATATATATAT*A
		TCGTAT*C

	SEQ ID NO: 1275	GATACAAAAAAAAAAAGATGATA
		TAAGTACTAAAAAAAAAA
		AAGTACATATATG*A
		TCGTAT*C

	SEQ ID NO: 1276	GACACAAAAAAAAAAAGATAAAT
		GAATATATAAAAAAAAAA
		AATATATACATAT*A
		TCGTGT*C

	SEQ ID NO: 1277	GGATATACAAAAAAAAAAAGATA
		TAAGTAAATATAAAAAAA
		AAAAATATATACATA
		TATCGTATATCC

	SEQ ID NO: 1278	GGATATACAAAAAAAAAAAGATG
		ATATAAGTACTAAAAAAAA
		AAAAGTACATATATG
		ATCGTATATCC

	SEQ ID NO: 1279	GTATATACAAAAAAAAAAAGATA
		TAAGTAAATATAAAAAAAA
		AAAATATATACATAT
		ATCGTATATAC

	SEQ ID NO: 1280	GTATATACAAAAAAAAAAAGATG
		ATATAAGTACTAAAAAAAA
		AAAAGTACATATATG
		ATCGTATATAC

	SEQ ID NO: 1281	GGATATACAAAAAAAAAAAGATA
		AATGAATATAAAAAAAAA
		AAATATATACATATA
		TCGTATATCC

	SEQ ID NO: 1282	GTATATACAAAAAAAAAAAGATA
		AATGAATATAAAAAAAAA
		AAATATATACATATA
		TCGTATATAC

	SEQ ID NO: 1283	GTATATACAAAAAAAAAAAGATG
		ATATAAGTACAAAAAAAAA
		AAGTACATATATGA*
		TCGTATA*TAC

	SEQ ID NO: 1284	GTATATACAAAAAAAAAAATATA
		AATATATATTAAAAAAAAA
		AATATATATATATA*
		TAGTATA*TAC

	SEQ ID NO: 1285	GTATATACATAAAAAAAAAAAGA
		TGATGTAAATATAAAAAAA
		AAAAATATATACATG
		ATCATGTATATAC

	SEQ ID NO: 1286	GATATACAAAAAAAAAAAGATAA
		ATATATAAAAAAAAAAAA
		AATATATATATAT*C
		GTATAT*C

	SEQ ID NO: 1287	GTGATACAAAAAAAAAAAGATAA
		ATATATAAAAAAAAAAAA
		AATATATATATAT*C
		GTATCA*C

	SEQ ID NO: 1288	GGTATACAAAAAAAAAAAGATAA
		ATATATAAAAAAAAAAAA
		AATATATATATAT*C
		GTATAC*C

	SEQ ID NO: 1289	GGATATACATAAAAAAAAAAAGA
		TAAATGAATAAAAAAAAA
		AAATATACATATATC
		ATGTATATCC

	SEQ ID NO: 1290	GTATATACATAAAAAAAAAAAGA
		TAAATGTATTAAAAAAAAA
		AATATACATATATC*
		ATGTATA*TAC

	SEQ ID NO: 1291	GTATATACATAAAAAAAAAAAGA
		TGATAAATGTAAAAAAAAA
		AAACATATATGATC*
		ATGTATA*TAC

	SEQ ID NO: 1292	TATATATTATTTTATTTTAATCG
		AGTCTTTTTGACTCGATATAC
		AATATATA

	SEQ ID NO: 1293	GATATATTATTTTATTTTAATCG
		AGTCTTTTTGACTCGATATAC
		AATATATC

	SEQ ID NO: 1294	GATATATCATTTTATTTTAATCG
		AGTCTTTTTGACTCGATATAC
		GATATATC

	SEQ ID NO: 1295	GATATGTCATTTTATTTTAATCG
		AGTCTTTTTGACTCGATATAC
		GACATATC

	SEQ ID NO: 1296	GTGATGTCATTTTATTTTAATCG
		AGTCTTTTTGACTCGATATAC
		GACATCAC

	SEQ ID NO: 1297	TATATATTATTTTATTTTATGCG
		AGTCTTTTTGACTCGCAGCCC
		AATATATA

	SEQ ID NO: 1298	GATATATTATTTTATTTTATGCG
		AGTCTTTTTGACTCGCAGCCC
		AATATATC

	SEQ ID NO: 1299	GATATATCATTTTATTTTATGCG
		AGTCTTTTTGACTCGCAGCCC
		GATATATC

	SEQ ID NO: 1300	GATATGTCATTTTATTTTATGCG
		AGTCTTTTTGACTCGCAGCCC
		GACATATC

	SEQ ID NO: 1301	GTGATGTCATTTTATTTTATGCG
		AGTCTTTTTGACTCGCAGCCC
		GACATCAC

	SEQ ID NO: 1302	TATATATTATTTTATTTTAGTAT
		ATCGGACTCGATATACAATAT
		ATA

	SEQ ID NO: 1303	GATATATTATTTTATTTTAGTAT
		ATCGGACTCGATATACAATAT
		ATC

	SEQ ID NO: 1304	GATATATCATTTTATTTTAGTAT
		ATCGGACTCGATATACGATAT
		ATC

	SEQ ID NO: 1305	GATATGTCATTTTATTTTAGTAT
		ATCGGACTCGATATACGACAT
		ATC

	SEQ ID NO: 1306	GTGATGTCATTTTATTTTAGTAT
		ATCGGACTCGATATACGACAT
		CAC

	SEQ ID NO: 1307	TATATATTATTTTATTTTAGGGC
		TGCGGACTCGCAGCCCAATAT
		ATA

	SEQ ID NO: 1308	GATATATTATTTTATTTTAGGGC
		TGCGGACTCGCAGCCCAATA
		TATC

	SEQ ID NO: 1309	GATATATCATTTTATTTTAGGGC
		TGCGGACTCGCAGCCCGATA
		TATC

	SEQ ID NO: 1310	GATATGTCATTTTATTTTAGGGC
		TGCGGACTCGCAGCCCGACA
		TATC

	SEQ ID NO: 1311	GTGATGTCATTTTATTTTAGGGC
		TGCGGACTCGCAGCCCGACA
		TCAC

	SEQ ID NO: 1312	TATATATATTATTACTATATGGA
		CTCGCATATAGATATATA

	SEQ ID NO: 1313	GATATATATTATTACTATATGGA
		CTCGCATATAGATATATC

	SEQ ID NO: 1314	GATATACATTATTACTATATGGA
		CTCGCATATAGGTATATC

	SEQ ID NO: 1315	GATATCCATTATTACTATATGGA
		CTCGCATATAGGGATATC

	SEQ ID NO: 1316	GTGATACATTATTACTATATGGA
		CTCGCATATAGGTATCAC

	SEQ ID NO: 1317	TATATATTTTATTTCGGGCTGGA
		CTCGCAGCCCGATATATA

	SEQ ID NO: 1318	GATATATATTATTACGGGCTGGA
		CTCGCAGCCCGATATATC

	SEQ ID NO: 1319	GATATACATTATTACGGGCTGGA
		CTCGCAGCCCGGTATATC

	SEQ ID NO: 1320	GATATCCATTATTACGGGCTGGA
		CTCGCAGCCCGGGATATC

	SEQ ID NO: 1321	GTGATACATTATTACGGGCTGGA
		CTCGCAGCCCGGTATCAC

	SEQ ID NO: 1322	TATATATTTTATTTCTATATGTT
		TATTTCGAGTCTTTTGACTCGC
		ATATAGATATATA

	SEQ ID NO: 1323	GATATATATTATTACTATATGAT
		TATTACGAGTCTTTTGACTCG
		CATATAGATATATC

	SEQ ID NO: 1324	GATATACATTATTACTATATGAT
		TATTACGAGTCTTTTGACTCG
		CATATAGGTATATC

	SEQ ID NO: 1325	GATATCCATTATTACTATATGAT
		TATTACGAGTCTTTTGACTCG
		CATATAGGGATATC

	SEQ ID NO: 1326	GTGATACATTATTACTATATGAT
		TATTACGAGTCTTTTGACTCG
		CATATAGGTATCAC

	SEQ ID NO: 1327	TATATATATTATTACGGGCTGAT
		TATTACGAGTCTTTTGACTCG
		CAGCCCGATATATA

	SEQ ID NO: 1328	GATATATATTATTACGGGCTGAT
		TATTACGAGTCTTTTGACTCG
		CAGCCCGATATATC

	SEQ ID NO: 1329	GATATACATTATTACGGGCTGAT
		TATTACGAGTCTTTTGACTC
		GCAGCCCGGTATATC

	SEQ ID NO: 1330	GATATCCATTATTACGGGCTGAT
		TATTACGAGTCTTTTGACTCG
		CAGCCCGGGATATC

	SEQ ID NO: 1331	GTGATACATTATTACGGGCTGAT
		TATTACGAGTCTTTTGACTC
		GCAGCCCGGTATCAC

	SEQ ID NO: 1332	TATATATTTATTTCATATCGACT
		CGCAGATATGTATATA

	SEQ ID NO: 1333	GATATCATTATTACATATCGACT
		CGCAGATATGGATATC

	SEQ ID NO: 1334	GTGATCATTATTACATATCGACT
		CGCAGATATGGATCAC

	SEQ ID NO: 1335	GTGTGCATTATTACATATCGACT
		CGCAGATATGGCACAC

	SEQ ID NO: 1336	GATATCATTATTACCGGGCGACT
		CGCAGCCCGGGATATC

	SEQ ID NO: 1337	GTGATCATTATTACCGGGCGACT
		CGCAGCCCGGGATCAC

	SEQ ID NO: 1338	GTGTGCATTATTACCGGGCGACT
		CGCAGCCCGGGCACAC

	SEQ ID NO: 1339	TATATATTTATTTCATATCTTTA
		TTTTGCGAGTCTTTTGACTCGC
		AGATATGTATATA

	SEQ ID NO: 1340	GATATCATTATTACATATCATTA
		TTATGCGAGTCTTTTGACTCG
		CAGATATGGATATC

	SEQ ID NO: 1341	GTGATCATTATTACATATCATTA
		TTATGCGAGTCTTTTGACTCG
		CAGATATGGATCAC

	SEQ ID NO: 1342	GTGTGCATTATTACATATCATTA
		TTATGCGAGTCTTTTGACTCG
		CAGATATGGCACAC

	SEQ ID NO: 1343	GATATCATTATTACCGGGCATTA
		TTATGCGAGTCTTTTGACTCG
		CAGCCCGGGATATC

	SEQ ID NO: 1344	GTGATCATTATTACCGGGCATTA
		TTATGCGAGTCTTTTGACTCG
		CAGCCCGGGATCAC

	SEQ ID NO: 1345	GTGTGCATTATTACCGGGCATTA
		TTATGCGAGTCTTTTGACTCG
		CAGCCCGGGCACAC

	SEQ ID NO: 1346	GTATGATTATTACACAGGACTCG
		CAGCCTGTGCATAC

	SEQ ID NO: 1347	GTGTGATTATTACACAGGACTCG
		CAGCCTGTGCACAC

	SEQ ID NO: 1348	GTATGATTATTACCCGGGACTCG
		CAGCCCGGGCATAC

	SEQ ID NO: 1349	GTGTGATTATTACCCGGGACTCG
		CAGCCCGGGCACAC

	SEQ ID NO: 1350	GTATGATTATTACACAGATTATT
		AGCTGCATTATTAGAGTCTTT
		TGACTCGCAGCCTGTGCATAC

	SEQ ID NO: 1351	GTGTGATTATTACACAGATTATT
		AGCTGCATTATTAGAGTCTTT
		TGACTCGCAGCCTGTGCACAC

	SEQ ID NO: 1352	TATATATTATTACCCGGATTATT
		AGCTGCATTATTAGAGTCTTT
		TGACTCGCAGCCCGGGATATA

	SEQ ID NO: 1353	GATATATTATTACCCGGATTATT
		AGCTGCATTATTAGAGTCTTT
		TGACTCGCAGCCCGGGATATC

	SEQ ID NO: 1354	GTATGATTATTACCCGGATTATT
		AGCTGCATTATTAGAGTCTTT
		TGACTCGCAGCCCGGGCATAC

	SEQ ID NO: 1355	GTGTGATTATTACCCGGATTATT
		AGCTGCATTATTAGAGTCTTT
		TGACTCGCAGCCCGGGCACAC

	SEQ ID NO: 1356	GACTCGATATACAATATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATAATTATTATTGT
		ATAT

	SEQ ID NO: 1357	GACTCGATATACAATATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATAATTATTATTGTA
		TAT

	SEQ ID NO: 1358	GACTCGATATACGATATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATAATTATTATCGTA
		TAT

	SEQ ID NO: 1359	GACTCGATATACGACATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATGATTATTATCGT
		ATAT

	SEQ ID NO: 1360	GACTCGATATACGACATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATGATTATTATCGT
		ATAT

	SEQ ID NO: 1361	GACTCGCAGCCCAATATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATAATTATTATTGG
		GCTG

	SEQ ID NO: 1362	GACTCGCAGCCCAATATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATAATTATTATTGG
		GCTG

	SEQ ID NO: 1363	GACTCGCAGCCCGATATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATAATTATTATCGG
		GCTG

	SEQ ID NO: 1364	GACTCGCAGCCCGACATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATGATTATTATCGG
		GCTG

	SEQ ID NO: 1365	GACTCGCAGCCCGACATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATGATTATTATCGG
		GCTG

	SEQ ID NO: 1366	GACTCGATATACAATATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATAATTATTATTGT
		ATATTATTAATCGAGTC

	SEQ ID NO: 1367	GACTCGATATACAATATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATAATTATTATTGTA
		TATTATTAATCGAGTC

	SEQ ID NO: 1368	GACTCGATATACGATATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATAATTATTATCGTA
		TATTATTAATCGAGTC

	SEQ ID NO: 1369	GACTCGATATACGACATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATGATTATTATCGT
		ATATTATTAATCGAGTC

	SEQ ID NO: 1370	GACTCGATATACGACATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATGATTATTATCGT
		ATATTATTAATCGAGTC

	SEQ ID NO: 1371	GACTCGCAGCCCAATATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATAATTATTATTGG
		GCATTATTATGCGAGTC

	SEQ ID NO: 1372	GACTCGCAGCCCAATATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATAATTATTATTGG
		GCATTATTATGCGAGTC

	SEQ ID NO: 1373	GACTCGCAGCCCGATATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATAATTATTATCGG
		GCATTATTATGCGAGTC

	SEQ ID NO: 1374	GACTCGCAGCCCGACATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATGATTATTATCGG
		GCATTATTATGCGAGTC

	SEQ ID NO: 1375	GACTCGCAGCCCGACATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATGATTATTATCGG
		GCATTATTATGCGAGTC

	SEQ ID NO: 1376	GACTCGCATATAGATATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATATTATTAATCTA
		TA

	SEQ ID NO: 1377	GACTCGCATATAGATATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATATTATTAATCTAT
		A

	SEQ ID NO: 1378	GACTCGCATATAGGTATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATATTATTAACCTAT
		A

	SEQ ID NO: 1379	GACTCGCATATAGGGATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATATTATTACCCTA
		TA

	SEQ ID NO: 1380	GACTCGCATATAGGTATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATATTATTAACCTA
		TA

	SEQ ID NO: 1381	GACTCGCAGCCCGATATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATATTATTAATCGG
		GC

	SEQ ID NO: 1382	GACTCGCAGCCCGATATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATATTATTAATCGG
		GC

	SEQ ID NO: 1383	GACTCGCAGCCCGGTATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATATTATTAACCGG
		GC

	SEQ ID NO: 1384	GACTCGCAGCCCGGGATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATATTATTACCCGG
		GC

	SEQ ID NO: 1385	GACTCGCAGCCCGGTATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATATTATTAACCGG
		GC

	SEQ ID NO: 1386	GACTCGCATATAGATATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATATTATTAATCTA
		TAATTATTATGCGAGT

	SEQ ID NO: 1387	GACTCGCATATAGATATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATATTATTAATCTAT
		AATTATTATGCGAGT

	SEQ ID NO: 1388	GACTCGCATATAGGTATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATATTATTAACCTAT
		AATTATTATGCGAGT

	SEQ ID NO: 1389	GACTCGCATATAGGGATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATATTATTACCCTA
		TAATTATTATGCGAGT

	SEQ ID NO: 1390	GACTCGCATATAGGTATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATATTATTAACCTA
		TAATTATTATGCGAGT

	SEQ ID NO: 1391	GACTCGCAGCCCGATATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATATTATTAATCGG
		GCATTATTATGCGAGT

	SEQ ID NO: 1392	GACTCGCAGCCCGATATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATATTATTAATCGG
		GCATTATTATGCGAGT

	SEQ ID NO: 1393	GACTCGCAGCCCGGTATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATATTATTAACCGG
		GCATTATTATGCGAGT

	SEQ ID NO: 1394	GACTCGCAGCCCGGGATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATATTATTACCCGG
		GCATTATTATGCGAGT

	SEQ ID NO: 1395	GACTCGCAGCCCGGTATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATATTATTAACCGG
		GCATTATTATGCGAGT

	SEQ ID NO: 1396	GACTCGCAGATATGTATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATAATTATTATACATA

	SEQ ID NO: 1397	GACTCGCAGATATGTATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATAATTATTATACATA

	SEQ ID NO: 1398	GACTCGCAGATATGGATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATAATTATTATCCATA

	SEQ ID NO: 1399	GACTCGCAGATATGGATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGAATTATTATCCATA

	SEQ ID NO: 1400	GACTCGCAGATATGGCACACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGTATTATTAGCCATA

	SEQ ID NO: 1401	GACTCGCAGCCCGGTATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATAATTATTATACCGG

	SEQ ID NO: 1402	GACTCGCAGCCCGGTATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATAATTATTATACCGG

	SEQ ID NO: 1403	GACTCGCAGCCCGGGATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATAATTATTATCCCGG

	SEQ ID NO: 1404	GACTCGCAGCCCGGGATCACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGAATTATTATCCCGG

	SEQ ID NO: 1405	GACTCGCAGCCCGGGCACACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGTATTATTAGCCCGG

	SEQ ID NO: 1406	GACTCGCAGCCTGTGATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATTATTAATCAC

	SEQ ID NO: 1407	GACTCGCAGCCTGTGATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATTATTAATCAC

	SEQ ID NO: 1408	GACTCGCAGCCTGTGCATACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTAATTATTATGCAC

	SEQ ID NO: 1409	GACTCGCAGCCTGTGCACACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATTATTATGCAC

	SEQ ID NO: 1410	GACTCGCAGCCCGGGATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATTATTAATCCC

	SEQ ID NO: 1411	GACTCGCAGCCCGGGATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATTATTAATCCC

	SEQ ID NO: 1412	GACTCGCAGCCCGGGCATACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTAATTATTATGCCC

	SEQ ID NO: 1413	GACTCGCAGCCCGGGCACACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATTATTATGCCC

	SEQ ID NO: 1414	GACTCGCAGCCTGTGATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATTATTAATCACAT
		TATTAAGGCTATTATTAGCG
		AG

	SEQ ID NO: 1415	GACTCGCAGCCTGTGATATCGCG
		CGCGCAATAAGCGCGCATTA
		TTAGCGATATTATTAATCACATT
		ATTAAGGCTATTATTAGCGA
		G

	SEQ ID NO: 1416	GACTCGCAGCCTGTGCATACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTAATTATTATGCACAT
		TATTAAGGCTATTATTAGCG
		AG

	SEQ ID NO: 1417	GACTCGCAGCCTGTGCACACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATTATTATGCACAT
		TATTAAGGCTATTATTAGCG
		AG

	SEQ ID NO: 1418	GACTCGCAGCCCGGGATATAGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCTATATTATTAATCCCAT
		TATTAGGGCTATTATTAGCGA
		G

	SEQ ID NO: 1419	GACTCGCAGCCCGGGATATCGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGATATTATTAATCCCAT
		TATTAGGGCTATTATTAGCG
		AG

	SEQ ID NO: 1420	GACTCGCAGCCCGGGCATACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTAATTATTATGCCCAT
		TATTAGGGCTATTATTAGCG
		AG

	SEQ ID NO: 1421	GACTCGCAGCCCGGGCACACGCG
		CGCGCAATAAGCGCGCATT
		ATTAGCGTGATTATTATGCCCAT
		TATTAGGGCTATTATTAGCG
		AG

	*indicate the bonds that are phosphorothioate (PS) modified. These sequences may include nuclease resistant modifications such as PS modifications in all bases except the Loop sequences, where Loop sequences are the unhybridized bases. The number of modifications, e.g., PS, can vary from “0” to “max = total number of bases − number of bases in loops.

In any of the foregoing embodiments, the blocked nucleic acid molecules of the disclosure may further contain a reporter moiety attached thereto such that cleavage of the blocked nucleic acid releases a signal from the reporter moiety. (See FIG. 4, mechanisms depicted at center and bottom.)

Also, in any of the foregoing embodiments, the blocked nucleic acid molecule may be a modified or non-naturally occurring nucleic acid molecule. In some embodiments, the blocked nucleic acid molecules of the disclosure may further contain a locked nucleic acid (LNA), a bridged nucleic acid (BNA), and/or a peptide nucleic acid (PNA). The blocked nucleic acid molecule may contain a modified or non-naturally occurring nucleoside, nucleotide, and/or internucleoside linkage, such as a 2′-O-methyl (2′—O-Me) modified nucleoside, a 2′-fluoro (2′-F) modified nucleoside, and a phosphorothioate (PS) bond, any other nucleic acid molecule modifications described above, and any combination thereof.

FIG. 2G at left shows an exemplary single-strand blocked nucleic acid molecule and how the configuration of this blocked nucleic acid molecule is able to block R-loop formation with an RNP complex, thereby blocking activation of the trans-cleavage activity of RNP2. The single-strand blocked nucleic acid molecule is self-hybridized and comprises: a target strand (TS) sequence complementary to the gRNA (e.g., crRNA) of RNP2; a cleavable non-target strand (NTS) sequence that is partially hybridized (e.g., it contains secondary loop structures) to the TS sequence; and a protospacer adjacent motif (PAM) sequence (e.g., 5′ NAAA 3′) that is specifically located at the 3′ end of the TS sequence. An RNP complex with 3′→+5′ diffusion (e.g., 1D diffusion) initiates R-loop formation upon PAM recognition. R-loop formation is completed upon a stabilizing ≥17 base hybridization of the TS to the gRNA of RNP2; however, because of the orientation of the PAM sequence relative to the secondary loop structure(s), the blocked nucleic acid molecule sterically prevents the TS sequence from hybridizing with the gRNA of RNP2, thereby blocking the stable R-loop formation required for the cascade reaction.

FIG. 2G at right shows the blocked nucleic acid molecule being unblocked via trans-cleavage (e.g., by RNP1) and subsequent dehybridization of the NTS's secondary loop structures, followed by binding of the TS sequence to the gRNA of RNP2, thereby completing stable R-loop formation and activating the trans-cleavage activity of the RNP2 complex.

In some embodiments, the blocked nucleic acid molecules provided herein are circular DNAs, RNAs or chimeric (DNA-RNA) molecules (FIG. 2H), and the blocked nucleic acid molecules may include different base compositions depending on the Cas enzyme used for RNP1 and RNP2. For the circular design of blocked nucleic acid molecules, the 5′ and 3′ ends are covalently linked together. This configuration makes internalization of the blocked nucleic acid molecule into RNP2—and subsequent RNP2 activation—sterically unfavorable, thereby blocking the progression of a CRISPR Cascade reaction. Thus, RNP2 activation (e.g., trans-cleavage activity) happens after cleavage of a portion of the blocked nucleic acid molecule followed by linearization and internalization of unblocked nucleic acid molecule into RNP2.

In some embodiments, the blocked nucleic acid molecules are topologically circular molecules with 5′ and 3′ portions hybridized to each other using DNA, RNA, LNA, BNA, or PNA bases which have a very high melting temperature (Tm). The high Tm causes the structure to effectively behave as a circular molecule even though the 5′ and 3′ ends are not covalently linked. The 5′ and 3′ ends can also have base non-naturally occurring modifications such as phosphorothioate bonds to provide increased stability.

In embodiments where the blocked nucleic acid molecules are circularized (e.g., circular or topologically circular), as illustrated in FIG. 2H, each blocked nucleic acid molecule includes a first region, which is a target sequence specific to the gRNA of RNP2, and a second region, which is a sequence that can be cleaved by nuclease enzymes of activated RNP1 and/or RNP2. The first region may include a nuclease-resistant nucleic acid sequence such as, for example, a phosphorothioate group or other non-naturally occurring nuclease-resistant base modifications, for protection from trans-endonuclease activity. In some embodiments, when the Cas enzyme in both RNP1 and RNP2 is Cas12a, the first region of the blocked nucleic acid molecule includes a nuclease-resistant DNA sequence, and the second region of the blocked nucleic acid molecule includes a cleavable DNA sequence. In other embodiments, when the Cas enzyme in RNP1 is Cas12a and the Cas enzyme in RNP2 is Cas13a, the first region of the blocked nucleic acid molecule includes a nuclease-resistant RNA sequence, and the second region of the blocked nucleic acid molecule includes a cleavable DNA sequence and a cleavable RNA sequence. In yet other embodiments, when the Cas enzyme in RNP1 is Cas13a and the Cas enzyme in RNP2 is Cas12a, the first region of the blocked nucleic acid molecule includes a nuclease-resistant DNA sequence, and the second region of the blocked nucleic acid molecule includes a cleavable DNA sequence and a cleavable RNA sequence. In some other embodiments, when the Cas enzyme in both RNP1 and RNP2 is Cas13a, the first region of the blocked nucleic acid molecule includes a nuclease-resistant RNA sequence, and the second region of the blocked nucleic acid molecule includes a cleavable RNA sequence.

The Cascade Assay Employing Blocked Primer Molecules

The blocked nucleic acids described above may also be blocked primer molecules. Blocked primer molecules include a sequence complementary to a primer binding domain (PBD) on a template molecule (see description below in reference to FIGS. 3A and 3B) and can have the same general structures as the blocked nucleic acid molecules described above. A PBD serves as a nucleotide sequence for primer hybridization followed by primer polymerization by a polymerase. In any of Formulas I, II, or III described above, the blocked primer nucleic acid molecule may include a sequence complementary to the PBD on the 5′ end of T. The unblocked primer nucleic acid molecule can bind to a template molecule at the PBD and copy the template molecule via polymerization by a polymerase.

Other specific embodiments of the cascade assay that utilize blocked primer molecules and are depicted in FIGS. 3A and 3B. In the embodiments using blocked nucleic acid molecules described above, activation of RNP1 and trans-cleavage of the blocked nucleic acid molecules were used to activate RNP2—that is, the unblocked nucleic acid molecules are a target sequence for the gRNA in RNP2. In contrast, in the embodiments using blocked primers, activation of RNP1 and trans-cleavage unblocks a blocked primer molecule that is then used to prime a template molecule for extension by a polymerase, thereby synthesizing activating molecules that are the target sequence for the gRNA in RNP2.

FIG. 3A is a diagram showing the sequence of steps in an exemplary cascade assay involving circular blocked primer molecules and linear template molecules. At left of FIG. 3A is a cascade assay reaction mix comprising 1) RNP1s (301) (only one RNP1 is shown); 2) RNP2s (302); 3) linear template molecules (330) (which is the non-target strand); 4) a circular blocked primer molecule (334) (i.e., a high K_dmolecule); and 5) a polymerase (338), such as a D29 polymerase. The linear template molecule (330) (non-target strand) comprises a PAM sequence (331), a primer binding domain (PBD) (332) and, optionally, a nucleoside modification (333) to protect the linear template molecule (330) from 3′→5′ exonuclease activity. Blocked primer molecule (334) comprises a cleavable region (335) and a complement to the PBD (332) on the linear template molecule (330).

Upon addition of a sample comprising a target nucleic acid of interest (304) (capable of complexing with the gRNA in RNP1 (301)), the target nucleic acid of interest (304) combines with and activates RNP1 (305) but does not interact with or activate RNP2 (302). Once activated, RNP1 cuts the target nucleic acid of interest (304) via sequence specific cis-cleavage, which activates non-specific trans-cleavage of other nucleic acids present in the reaction mix, including at least one of the blocked primer molecules (334). The circular blocked primer molecule (334) (i.e., a high K_dmolecule, where high K_drelates to binding to RNP2) upon cleavage becomes an unblocked linear primer molecule (344) (a low K_dmolecule, where low K_drelated to binding to RNP2), which has a region (336) complementary to the PBD (332) on the linear template molecule (330) and can bind to the linear template molecule (330).

Once the unblocked linear primer molecule (344) and the linear template molecule (330) are hybridized (i.e., hybridized at the PBD (332) of the linear template molecule (330) and the PBD complement (336) on the unblocked linear primer molecule (344)), 3′→5′ exonuclease activity of the polymerase (338) removes the unhybridized single-stranded DNA at the end of the unblocked primer molecule (344) and the polymerase (338) can copy the linear template molecule (330) to produce a synthesized activating molecule (346) (a complement of the non-target strand, which is a target strand). The synthesized activating molecule (346) is capable of activating RNP2 (302→308). As described above, because the nucleic acid-guided nuclease in the RNP2 (308) complex exhibits (that is, possesses) both cis- and trans-cleavage activity, more blocked primer molecules (334) become unblocked primer molecules (344) triggering activation of more RNP2s (308) and more trans-cleavage activity in a cascade. As stated above in relation to blocked and unblocked nucleic acid molecules (both linear and circular), the unblocked primer molecule has a higher binding affinity for the gRNA in RNP2 than does the blocked primer molecule, although there may be some “leakiness” where some blocked primer molecules are able to interact with the gRNA in RNP2. However, an unblocked primer molecule has a substantially higher likelihood than a blocked primer molecule to hybridize with the gRNA of RNP2.

FIG. 3A at bottom depicts the concurrent activation of reporter moieties. Intact reporter moieties (309) comprise a quencher (310) and a fluorophore (311). As described above in relation to FIG. 1B, the reporter moieties are also subject to trans-cleavage by activated RNP1 (305) and RNP2 (308). The intact reporter moieties (309) become activated reporter moieties (312) when the quencher (310) is separated from the fluorophore (311), and the fluorophore emits a fluorescent signal (313). Signal strength increases rapidly as more blocked primer molecules (334) become unblocked primer molecules (344) generating synthesized activating molecules (346) and triggering activation of more RNP2 (308) complexes and more trans-cleavage activity of the reporter moieties (309). Again, here the reporter moieties are shown as separate molecules from the blocked nucleic acid molecules, but other configurations may be employed and are discussed in relation to FIG. 4. Also, as with the cascade assay embodiment utilizing blocked nucleic acid molecules that are not blocked primers, with the exception of the gRNA in RNP1, the cascade assay components stay the same no matter what target nucleic acid(s) of interest are being detected.

FIG. 3B is a diagram showing the sequence of steps in an exemplary cascade assay involving blocked primer molecules and circular template molecules. The cascade assay of FIG. 3B differs from that depicted in FIG. 3A by the configuration of the template molecule. Where the template molecule in FIG. 3A was linear, in FIG. 3B the template molecule is circular. At left of FIG. 3B is a cascade assay reaction mix comprising 1) RNP1s (301) (only one RNP1 is shown); 2) RNP2s (302); 3) a circular template molecule (352) (non-target strand); 4) a circular blocked primer molecule (334); and 5) a polymerase (338), such as a D29 polymerase. The circular template molecule (352) (non-target strand) comprises a PAM sequence (331) and a primer binding domain (PBD) (332). Blocked primer molecule (334) comprises a cleavable region (335) and a complement to the PBD (332) on the circular template molecule (352).

Upon addition of a sample comprising a target nucleic acid of interest (304) (capable of complexing with the gRNA in RNP1 (301)), the target nucleic acid of interest (304) combines with and activates RNP1 (305) but does not interact with or activate RNP2 (302). Once activated, RNP1 cuts the target nucleic acid of interest (304) via sequence specific cis-cleavage, which activates non-specific trans-cleavage of other nucleic acids present in the reaction mix, including at least one of the blocked primer molecules (334). The circular blocked primer molecule (334), upon cleavage, becomes an unblocked linear primer molecule (344), which has a region (336) complementary to the PBD (332) on the circular template molecule (352) and can hybridize with the circular template molecule (352).

Once the unblocked linear primer molecule (344) and the circular template molecule (352) are hybridized (i.e., hybridized at the PBD (332) of the circular template molecule (352) and the PBD complement (336) on the unblocked linear primer molecule (344)), 3′→5′ exonuclease activity of the polymerase (338) removes the unhybridized single-stranded DNA at the 3′ end of the unblocked primer molecule (344). The polymerase (338) can now use the circular template molecule (352) (non-target strand) to produce concatenated activating nucleic acid molecules (360) (which are concatenated target strands), which will be cleaved by the trans-cleavage activity of activated RNP1. The cleaved regions of the concatenated synthesized activating molecules (360) (target strand) are capable of activating the RNP2 (302→308) complex.

As described above, because the nucleic acid-guided nuclease in RNP2 (308) comprises both cis- and trans-cleavage activity, more blocked primer molecules (334) become unblocked primer molecules (344) triggering activation of more RNP2s (308) and more trans-cleavage activity in a cascade. FIG. 3B at bottom depicts the concurrent activation of reporter moieties. Intact reporter moieties (309) comprise a quencher (310) and a fluorophore (311). As described above in relation to FIG. 1B, the reporter moieties are also subject to trans-cleavage by activated RNP1 (305) and RNP2 (308). The intact reporter moieties (309) become activated reporter moieties (312) when the quencher (310) is separated from the fluorophore (311), and the fluorescent signal (313) is unquenched and can be detected. Signal strength increases rapidly as more blocked primer molecules (334) become unblocked primer molecules (344) generating synthesized activating nucleic acid molecules and triggering activation of more RNP2s (308) and more trans-cleavage activity of the reporter moieties (309). Again, here the reporter moieties are shown as separate molecules from the blocked nucleic acid molecules, but other configurations may be employed and are discussed in relation to FIG. 4. Also note that as with the other embodiments of the cascade assay, in this embodiment, with the exception of the gRNA in RNP1, the cascade assay components stay the same no matter what target nucleic acid(s) of interest are being detected.

The polymerases used in the “blocked primer molecule” embodiments serve to polymerize a reverse complement strand of the template molecule (non-target strand) to generate a synthesized activating molecule (target strand) as described above. In some embodiments, the polymerase is a DNA polymerase, such as a BST, T4, or Therminator polymerase (New England BioLabs Inc., Ipswich Mass., USA). In some embodiments, the polymerase is a Klenow fragment of a DNA polymerase. In some embodiments the polymerase is a DNA polymerase with 5′→3′ DNA polymerase activity and 3′→5′ exonuclease activity, such as a Type I, Type II, or Type III DNA polymerase. In some embodiments, the DNA polymerase, including the Phi29, T7, Q5®, Q5U®, Phusion®, OneTaq®, LongAmp®, Vent®, or Deep Vent® DNA polymerases (New England BioLabs Inc., Ipswich Mass., USA), or any active portion or variant thereof. Also, a 3′ to 5′ exonuclease can be separately used if the polymerase lacks this activity.

FIG. 4 depicts three mechanisms in which a cascade assay reaction can release a signal from a reporter moiety. FIG. 4 at top shows the mechanism discussed in relation to FIGS. 2A, 3A and 3B. In this embodiment, a reporter moiety 409 is a separate molecule from the blocked nucleic acid molecules present in the reaction mix. Reporter moiety (409) comprises a quencher (410) and a fluorophore (411). An activated reporter moiety (412) emits a signal from the fluorophore (411) once it has been physically separated from the quencher (410).

FIG. 4 at center shows a blocked nucleic acid molecule (403), which is also a reporter moiety. In addition to quencher (410) and fluorophore (411), a blocking moiety (407) can be seen (see also blocked nucleic acid molecules 203 in FIG. 2A). Blocked nucleic acid molecule/reporter moiety (403) comprises a quencher (410) and a fluorophore (411). In this embodiment of the cascade assay, when the blocked nucleic acid molecule (403) is unblocked due to trans-cleavage initiated by the target nucleic acid of interest binding to RNP1, the unblocked nucleic acid molecule (406) also becomes an activated reporter moiety with fluorophore (411) separated from quencher (410). Note both the blocking moiety (407) and the quencher (410) are removed. In this embodiment, reporter signal is directly generated as the blocked nucleic acid molecules become unblocked.

FIG. 4 at the bottom shows that cis-cleavage of an unblocked nucleic acid or a synthesized activation molecule at a PAM distal sequence by RNP2 generates a signal. Shown are activated RNP2 (408), unblocked nucleic acid molecule (461), quencher (410), and fluorophore (411) forming an activated RNP2 with the unblocked nucleic acid/reporter moiety intact (460). Cis-cleavage of the unblocked nucleic acid/reporter moiety (461) results in an activated RNP2 with the reporter moiety activated (462), comprising the activated RNP2 (408), the unblocked nucleic acid molecule with the reporter moiety activated (463), quencher (410) and fluorophore (411).

Applications of the Cascade Assay

The present disclosure describes cascade assays for detecting a target nucleic acid of interest in a sample. As described above, the various embodiments of the cascade assay are notable in that, with the exception of the gRNA in RNP1, the cascade assay components stay the same no matter what target nucleic acid(s) of interest are being detected.

Target nucleic acids of interest are derived from samples. Suitable samples for testing include, but are not limited to, any environmental sample, such as air, water, soil, surface, food, clinical sites and products, industrial sites and products, pharmaceuticals, medical devices, nutraceuticals, cosmetics, personal care products, agricultural equipment and sites, and commercial samples, and any biological sample obtained from an organism or a part thereof, such as a plant, animal, or bacteria. In some embodiments, the biological sample is obtained from an animal subject, such as a human subject. A biological sample is any solid or fluid sample obtained from, excreted by or secreted by any living organism, including, without limitation, single celled organisms, such as bacteria, yeast, protozoans, and amoebas among others, multicellular organisms including plants or animals, including samples from a healthy or apparently healthy human subject or a human patient affected by a condition or disease to be diagnosed or investigated, such as an infection with a pathogenic microorganism, such as a pathogenic bacteria or virus. For example, a biological sample can be a biological fluid obtained from, for example, blood, plasma, serum, urine, stool, sputum, mucous, lymph fluid, synovial fluid, bile, ascites, pleural effusion, seroma, saliva, cerebrospinal fluid, aqueous or vitreous humor, or any bodily secretion, a transudate, an exudate (for example, fluid obtained from an abscess or any other site of infection or inflammation), or fluid obtained from a joint (for example, a normal joint or a joint affected by disease, such as rheumatoid arthritis, osteoarthritis, gout or septic arthritis), or a swab of skin or mucosal membrane surface (e.g., a nasal or buccal swab).

In some embodiments, the sample can be a viral or bacterial sample or a biological sample that has been minimally processed, e.g., only treated with a brief lysis step prior to detection. In some embodiments, minimal processing can include thermal lysis at an elevated temperature to release nucleic acids. Suitable methods are contemplated in U.S. Pat. No. 9,493,736, among other references. Common methods for cell lysis involve thermal, chemical, enzymatic, or mechanical treatment of the sample or a combination of those. In some embodiments, minimal processing can include treating the sample with chaotropic salts such as guanidine isothiocyanate or guanidine HCl. Suitable methods are contemplated in U.S. Pat. Nos. 8,809,519, 7,893,251, among other references. In some embodiments, minimal processing may include contacting the sample with reducing agents such as DTT or TCEP and EDTA to inactivate inhibitors and/or other nucleases present in the crude samples. In other embodiments, minimal processing for biofluids may include centrifuging the samples to obtain cell-debris free supernatant before applying the reagents. Suitable methods are contemplated in U.S. Pat. No. 8,809,519, among other references. In still other embodiments, minimal processing may include performing DNA/RNA extraction to get purified nucleic acids before applying CRISPR Cascade reagents.

FIG. 5A shows a lateral flow assay (LFA) device that can be used to detect the cleavage and separation of a signal from a reporter moiety. For example, the reporter moiety may be a single-stranded or double-stranded oligonucleotide with terminal biotin and fluorescein amidite (FAM) modifications; and, as described above, the reporter moiety may also be part of a blocked nucleic acid. The LFA device may include a pad with binding particles, such as gold nanoparticles functionalized with anti-FAM antibodies; a control line with a first binding moiety attached, such as avidin or streptavidin; a test line with a second binding moiety attached, such as antibodies; and an absorption pad. After completion of a cascade assay (see FIGS. 2A, 3A, and 3B), the assay reaction mix is added to the pad containing the binding particles, (e.g., antibody labeled gold nanoparticles). When the target nucleic acid of interest is present, a reporter moiety is cleaved, and when the target nucleic acid of interest is absent, the reporter is not cleaved.

A moiety on the reporter binds to the binding particles and is transported to the control line. When the target nucleic acid of interest is absent, the reporter moiety is not cleaved, and the first binding moiety binds to the reporter moiety, with the binding particles attached. When the target nucleic acid of interest is present, one portion of the cleaved reporter moiety binds to the first binding moiety, and another portion of the cleaved reporter moiety bound to the binding particles via the moiety binds to the second binding moiety. In one example, anti-FAM gold nanoparticles bind to a FAM terminus of a reporter moiety and flow sequentially towards the control line and then to the test line. For reporters that are not trans-cleaved, gold nanoparticles attach to the control line via biotin-streptavidin and result in a dark control line. In a negative test, since the reporter has not been cleaved, all gold conjugates are trapped on control line due to attachment via biotin-streptavidin. A negative test will result in a dark control line with a blank test line. In a positive test, reporter moieties have been trans-cleaved by the cascade assay, thereby separating the biotin terminus from the FAM terminus. For cleaved reporter moieties, nanoparticles are captured at the test line due to anti-FAM antibodies. This positive test results in a dark test line in addition to a dark control line.

In some embodiments, the LFA device is designed for syndromic testing. For example, multiple strips with pooled RNP1s targeting different target nucleic acids of interest may be employed, either as separate devices or in a combined device. As a non-limiting example, a syndromic testing device could include four lateral flow strips, with each strip indicating the presence of at least one out of several generally related (e.g., by genetics or by treatment) pathogens (FIG. 5B). One example of a use for syndromic testing is in respiratory illness. For example, the first lateral flow strip could indicate the presence of at least one of the several strains of influenza that cause the common flu (e.g., influenza A, influenza A/H1, influenza A/H3, influenza A/H1-2009, and influenza B); the second lateral flow strip could indicate the presence of at least one of the multiple strains of respiratory syncytial virus (RSV), such as RSV-A and RSV-B; the third lateral flow strip could indicate the presence of at least one variant of SARS-CoV-2 (e.g., B.1.1.7, B.1.351, P.1, B.1.617.2, BA.1, BA.2, BA.2.12.1, BA.4, and BA.5); and the fourth lateral flow strip could indicate the presence of at least one of other pathogens of interest (e.g., parainfluenza virus 1-4, human metapneumovirus, human rhinovirus, human enterovirus, adenovirus, coronavirus HKU1, coronavirus NL63, coronavirus 229E, coronavirus OC43, MERS, and many more). The results shown in FIG. 5B indicate a positive test for the presence of RSVA and/or RSV B nucleic acid molecules. Also as seen in FIG. 5B, the syndromic testing device could further include a lateral flow strip for a negative control and a lateral flow strip for a positive control.

The components of the cascade assay may be provided in various kits. In one aspect, the kit for detecting a target nucleic acid of interest in a sample includes: first ribonucleoprotein complexes (RNP1s), second ribonucleoprotein complexes (RNP2s), blocked nucleic acid molecules, and reporter moieties. The first complex (RNP1) comprises a first nucleic acid-guided nuclease and a first gRNA, where the first gRNA includes a sequence complementary to the target nucleic acid(s) of interest. Binding of the first complex (RNP1) to the target nucleic acid(s) of interest activates trans-cleavage activity of the first nucleic acid-guided nuclease. The second complex (RNP2) comprises a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest. The blocked nucleic acid molecule comprises a sequence complementary to the second gRNA, where trans-cleavage of the blocked nucleic acid molecule results in an unblocked nucleic acid molecule and the unblocked nucleic acid molecule can bind to the second complex (RNP2), thereby activating the trans-cleavage activity of the second nucleic acid-guided nuclease. Activating trans-cleavage activity in RNP2 results in an exponential increase in unblocked nucleic acid molecules and in active reporter moieties, where reporter moieties are nucleic acid molecules and/or are operably linked to the blocked nucleic acid molecules and produce a detectable signal upon cleavage by RNP2.

In a second aspect, the kit for detecting a target nucleic acid molecule in sample includes: first ribonucleoprotein complexes (RNP1s), second ribonucleoprotein complexes (RNP2s), template molecules, blocked primer molecules, a polymerase, NTPs, and reporter moieties. The first ribonucleoprotein complex (RNP1) comprises a first nucleic acid-guided nuclease and a first gRNA, where the first gRNA includes a sequence complementary to the target nucleic acid of interest and where binding of RNP1 to the target nucleic acid(s) of interest activates trans-cleavage activity of the first nucleic acid-guided nuclease. The second complex (RNP2) comprises a second nucleic acid-guided nuclease and a second gRNA that is not complementary to the target nucleic acid of interest. The template molecules comprise a primer binding domain (PBD) sequence as well as a sequence corresponding to a spacer sequence of the second gRNA. The blocked primer molecules comprise a sequence that is complementary to the PBD on the template nucleic acid molecule and a blocking moiety.

Upon binding to the target nucleic acid of interest, RNP1 becomes active triggering trans-cleavage activity that cuts at least one of the blocked primer molecules to produce at least one unblocked primer molecule. The unblocked primer molecule hybridizes to the PBD of one of the template nucleic acid molecules, is trimmed of excess nucleotides by the 3′-to-5′ exonuclease activity of the polymerase and is then extended by the polymerase and NTPs to form a synthesized activating molecule with a sequence that is complementary to the second gRNA of RNP2. Upon activating RNP2, additional trans-cleavage activity is initiated, cleaving at least one additional blocked primer molecule. Continued cleavage of blocked primer molecules and subsequent activation of more RNP2s proceeds at an exponential rate. A signal is generated upon cleavage of a reporter molecule by active RNP2 complexes; therefore, a change in signal production indicates the presence of the target nucleic acid molecule.

Any of the kits described herein may further include a sample collection device, e.g., a syringe, lancet, nasal swab, or buccal swab for collecting a biological sample from a subject, and/or a sample preparation reagent, e.g., a lysis reagent. Each component of the kit may be in separate container or two or more components may be in the same container. The kit may further include a lateral flow device used for contacting the biological sample with the reaction mixture, where a signal is generated to indicate the presence or absence of the target nucleic acid molecule of interest. In addition, the kit may further include instructions for use and other information.

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention and are not intended to limit the scope of what the inventors regard as their invention, nor are they intended to represent or imply that the experiments below are all of or the only experiments performed. It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific aspects without departing from the spirit or scope of the invention as broadly described. The present aspects are, therefore, to be considered in all respects as illustrative and not restrictive.

Example I: Preparation of Nucleic Acids of Interest

Mechanical lysis: Nucleic acids of interest may be isolated by various methods depending on the cell type and source (e.g., tissue, blood, saliva, environmental sample, etc.). Mechanical lysis is a widely-used cell lysis method and may be used to extract nucleic acids from bacterial, yeast, plant and mammalian cells. Cells are disrupted by agitating a cell suspension with “beads” at high speeds (beads for disrupting various types of cells can be sourced from, e.g., OPS Diagnostics (Lebanon N.J., US) and MP Biomedicals (Irvine, Calif., USA)). Mechanical lysis via beads begins with harvesting cells in a tissue or liquid, where the cells are first centrifuged and pelleted. The supernatant is removed and replaced with a buffer containing detergents as well as lysozyme and protease. The cell suspension is mixed to promote breakdown of the proteins in the cells and the cell suspension then is combined with small beads (e.g., glass, steel, or ceramic beads) that are mixed (e.g., vortexed) with the cell suspension at high speeds. The beads collide with the cells, breaking open the cell membrane with shear forces. After “bead beating”, the cell suspension is centrifuged to pellet the cellular debris and beads, and the supernatant may be purified via a nucleic acid binding column (such as the MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit from ThermoFisher (Waltham, Mass., USA) and others from Qiagen (Hilden Germany), TakaraBio (San Jose, Calif., USA), and Biocomma (Shenzen, China)) to collect the nucleic acids (see the discussion of solid phase extraction below).

Solid phase extraction (SPE): Another method for capturing nucleic acids is through solid phase extraction. SPE involves a liquid and stationary phase, which selectively separate the target analyte (here, nucleic acids) from the liquid in which the cells are suspended based on specific hydrophobic, polar, and/or ionic properties of the target analyte in the liquid and the stationary solid matrix. Silica binding columns and their derivatives are the most commonly used SPE techniques, having a high binding affinity for DNA under alkaline conditions and increased salt concentration; thus, a highly alkaline and concentrated salt buffer is used. The nucleic acid sample is centrifuged through a column with a highly porous and high surface area silica matrix, where binding occurs via the affinity between negatively charged nucleic acids and positively charged silica material. The nucleic acids bind to the silica matrices, while the other cell components and chemicals pass through the matrix without binding. One or more wash steps typically are performed after the initial sample binding (i.e., the nucleic acids to the matrix), to further purify the bound nucleic acids, removing excess chemicals and cellular components non-specifically bound to the silica matrix. Alternative versions of SPE include reverse SPE and ion exchange SPE, and use of glass particles, cellulose matrices, and magnetic beads.

Thermal lysis: Thermal lysis involves heating a sample of mammalian cells, virions, or bacterial cells at high temperatures thereby damaging the cellular membranes by denaturizing the membrane proteins. Denaturizing the membrane proteins results in the release of intracellular DNA. Cells are generally heated above 90° C., however time and temperature may vary depending on sample volume and sample type. Once lysed, typically one or more downstream methods, such as use of nucleic acid binding columns for solid phase extraction as described above, are required to further purify the nucleic acids.

Physical lysis: Common physical lysis methods include sonication and osmotic shock. Sonication involves creating and rupturing of cavities or bubbles to release shockwaves, thereby disintegrating the cellular membranes of the cells. In the sonication process, cells are added into lysis buffer, often containing phenylmethylsulfonyl fluoride, to inhibit proteases. The cell samples are then placed in a water bath and a sonication wand is placed directly into the sample solution. Sonication typically occurs between 20-50 kHz, causing cavities to be formed throughout the solution as a result of the ultrasonic vibrations; subsequent reduction of pressure then causes the collapse of the cavity or bubble resulting in a large amount of mechanical energy being released in the form of a shockwave that propagates through the solution and disintegrates the cellular membrane. The duration of the sonication pulses and number of pulses performed varies depending on cell type and the downstream application. After sonication, the cell suspension typically is centrifuged to pellet the cellular debris and the supernatant containing the nucleic acids may be further purified by solid phase extraction as described above.

Another form of physical lysis is osmotic shock, which is most typically used with mammalian cells. Osmotic shock involves placing cells in DI/distilled water with no salt added. Because the salt concentration is lower in the solution than in the cells, water is forced into the cell causing the cell to burst, thereby rupturing the cellular membrane. The sample is typically purified and extracted by techniques such as e.g., solid phase extraction or other techniques known to those of skill in the art.

Chemical lysis: Chemical lysis involves rupturing cellular and nuclear membranes by disrupting the hydrophobic-hydrophilic interactions in the membrane bilayers via detergents. Salts and buffers (such as, e.g., Tris-HCl pH8) are used to stabilize pH during extraction, and chelating agents (such as ethylenediaminetetraacetic acid (EDTA)) and inhibitors (e.g., Proteinase K) are also added to preserve the integrity of the nucleic acids and protect against degradation. Often, chemical lysis is used with enzymatic disruption methods (see below) for lysing bacterial cell walls. In addition, detergents are used to lyse and break down cellular membranes by solubilizing the lipids and membrane proteins on the surface of cells. The contents of the cells include, in addition to the desired nucleic acids, inner cellular proteins and cellular debris. Enzymes and other inhibitors are added after lysis to inactivate nucleases that may degrade the nucleic acids. Proteinase K is commonly added after lysis, destroying DNase and RNase enzymes capable of degrading the nucleic acids. After treatment with enzymes, the sample is centrifuged, pelleting cellular debris, while the nucleic acids remain in the solution. The nucleic acids may be further purified as described above.

Another form of chemical lysis is the widely-used procedure of phenol-chloroform extraction. Phenol-chloroform extraction involves the ability for nucleic acids to remain soluble in an aqueous solution in an acidic environment, while the proteins and cellular debris can be pelleted down via centrifugation. Phenol and chloroform ensure a clear separation of the aqueous and organic (debris) phases. For DNA, a pH of 7-8 is used, and for RNA, a more acidic pH of 4.5 is used.

Enzymatic lysis: Enzymatic disruption methods are commonly combined with other lysis methods such as those described above to disrupt cellular walls (bacteria and plants) and membranes. Enzymes such as lysozyme, lysostaphin, zymolase, and protease are often used in combination with other techniques such as physical and chemical lysis. For example, one can use cellulase to disrupt plant cell walls, lysosomes to disrupt bacterial cell walls and zymolase to disrupt yeast cell walls.

Example II: RNP Formation

For RNP complex formation, 250 nM of LbCas12a nuclease protein was incubated with 375 nM of a target specific gRNA in 1× Buffer (10 mM Tris-HCl, 100 μg/mL BSA) with 2-15 mM MgCl₂at 25° C. for 20 minutes. The total reaction volume was 2 μL. Other ratios of LbCas12a nuclease to gRNAs were tested, including 1:1, 1:2 and 1:5. The incubation temperature can range from 20° C.-37° C., and the incubation time can range from 10 minutes to 4 hours.

Example III: Blocked Nucleic Acid Molecule Formation

Ramp cooling: For formation of the secondary structure of blocked nucleic acids, 2.5 μM of a blocked nucleic acid molecule (any of Formulas I-IV) was mixed in a T50 buffer (20 mM Tris HCl, 50 mM NaCl) with 10 mM MgCl₂for a total volume of 50 μL. The reaction was heated to 95° C. at 1.6° C./second and incubated at 95° C. for 5 minutes to dehybridize any secondary structures. Thereafter, the reaction was cooled to 37° C. at 0.015° C./second to form the desired secondary structure.

Snap cooling: For formation of the secondary structure of blocked nucleic acids, 2.5 μM of a blocked nucleic acid molecule (any of Formulas I-IV) was mixed in a T50 buffer (20 mM Tris HCl, 50 mM NaCl) with 10 mM MgCl₂for a total volume of 50 μL. The reaction was heated to 95° C. at 1.6° C./second and incubated at 95° C. for 5 minutes to dehybridize any secondary structures. Thereafter, the reaction was cooled to room temperature by removing the heat source to form the desired secondary structure.

Snap cooling on ice: For formation of the secondary structure of blocked nucleic acids, 2.5 μM of a blocked nucleic acid molecule (any of Formulas I-IV) was mixed in a T50 buffer (20 mM Tris HCl, 50 mM NaCl) with 10 mM MgCl₂for a total volume of 50 μL. The reaction was heated to 95° C. at 1.6° C./second and incubated at 95° C. for 5 minutes to dehybridize any secondary structures. Thereafter, the reaction was cooled to room temperature by placing the reaction tube on ice to form the desired secondary structure.

Example IV: Reporter Moiety Formation

The reporter moieties used in the reactions herein were single-stranded DNA oligonucleotides 5-10 bases in length (e.g., with sequences of TTATT, TTTATTT, ATTAT, ATTTATTTA, AAAAA, or AAAAAAAAA) with a fluorophore and a quencher attached on the 5′ and 3′ ends, respectively. In one example using a Cas12a cascade, the fluorophore was FAM-6, and the quencher was IOWA BLACK® (Integrated DNA Technologies, Coralville, Iowa). In another example using a Cas13 cascade, the reporter moieties were single stranded RNA oligonucleotides 5-10 bases in length (e.g., r(U)n, r(UUAUU)n, r(A)n).

Example V: Cascade Assay

9+1 Format (final reaction mix components added at the same time): RNP1 was assembled using the LbCas12a nuclease and a gRNA for the Methicillin resistant Staphylococcus aureus (MRSA) DNA according to the RNP complex formation protocol described in Example II (for this sequence, see Example VIII). Briefly, 250 nM LbCas12a nuclease was assembled with 375 nM of the MRSA-target specific gRNA. Next, RNP2 was formed using the LbCas12a nuclease and a gRNA specific for a selected blocked nucleic acid molecule (Formula I-IV) using 500 nM LbCas12a nuclease assembled with 750 nM of the blocked nucleic acid-specific gRNA incubated in 1×NEB 2.1 Buffer (New England Biolabs, Ipswich, Mass.) with 5 mM MgCl₂at 25° C. for 20-40 minutes. Following incubation, RNP1s were diluted to a concentration of 75 nM LbCas12a: 112.5 nM gRNA. Thereafter, the final reaction was carried out in 1× Buffer, with 500 nM of the ssDNA reporter moiety, 1×ROX dye (Thermo Fisher Scientific, Waltham, Mass.) for passive reference, 2.5 mM MgCl₂, 4 mM NaCl, 15 nM LbCas12a: 22.5 nM gRNA RNP1, 20 nM LbCas12a: 35 nM gRNA RNP2, and 50 nM blocked nucleic acid molecule (any one of Formula I-IV) in a total volume of 9 μL. 1 μL of MRSA DNA target (with samples having as low as three copies and as many as 30000 copies—see FIGS. 6-14) was added to make a final volume of 10 μL. The final reaction was incubated in a thermocycler at 25° C. with fluorescence measurements taken every 1 minute.

2+1+7 Format (RNP1 and MRSA target pre-incubated before addition to final reaction mix): RNP1 was assembled using the LbCas12a nuclease and a gRNA for the MRSA DNA according to RNP formation protocol described in Example II (for this sequence, see Example VIII). Briefly, 250 nM LbCas12a nuclease was assembled with 375 nM of the MRSA-target specific gRNA. Next, RNP2 was formed using the LbCas12a nuclease and a gRNA specific for a selected blocked nucleic acid molecule (Formula I-IV) using 500 nM LbCas12a nuclease assembled with 750 nM of the blocked nucleic acid-specific gRNA incubated in 1×NEB 2.1 Buffer (New England Biolabs, Ipswich, Mass.) with 5 mM MgCl₂at 25° C. for 20-40 minutes. Following incubation, RNP1s were diluted to a concentration of 75 nM LbCas12a: 112.5 nM gRNA. After dilution, the formed RNP1 was mixed with 1 μL of MRSA DNA target and incubated at 20° C.-37° C. for up to 10 minutes to activate RNP1. The final reaction was carried out in 1× Buffer, with 500 nM of the ssDNA reporter moiety, 1×ROX dye (Thermo Fisher Scientific, Waltham, Mass.) for passive reference, 2.5 mM MgCl₂, 4 mM NaCl, the pre-incubated and activated RNP1, 20 nM LbCas12a: 35 nM gRNA RNP2, and 50 nM blocked nucleic acid molecule (any one of Formula I-IV) in a total volume of 9 μL. The final reaction was incubated in a thermocycler at 25° C. with fluorescence measurements taken every 1 minute.

2+1+6+1 Format (RNP1 and MRSA target pre-incubated before addition to final reaction mix and blocked nucleic acid molecule added to final reaction mix last): RNP1 was assembled using the LbCas12a nuclease and a gRNA for the MRSA DNA according to the RNP complex formation protocol described in Example II (for this sequence, see Example VIII). Briefly, 250 nM LbCas12a nuclease was assembled with 375 nM of the MRSA-target specific gRNA. Next, RNP2 was formed using the LbCas12a nuclease and a gRNA specific for a selected blocked nucleic acid molecule (Formula I-IV) using 500 nM LbCas12a nuclease assembled with 750 nM of the blocked nucleic acid-specific gRNA incubated in 1×NEB 2.1 Buffer (New England Biolabs, Ipswich, Mass.) with 5 mM MgCl₂at 25° C. for 20-40 minutes. Following incubation, RNP1s were diluted to a concentration of 75 nM LbCas12a: 112.5 nM gRNA. After dilution, the formed RNP1 was mixed with 1 μL of MRSA DNA target and incubated at 20° C.-37° C. for up to 10 minutes to activate RNP1. The final reaction was carried out in 1× Buffer, with 500 nM of the ssDNA reporter moiety, 1×ROX dye (Thermo Fisher Scientific, Waltham, Mass.) for passive reference, 2.5 mM MgCl₂, 4 mM NaCl, the pre-incubated and activated RNP1, and 20 nM LbCas12a: 35 nM gRNA RNP2 in a total volume of 9 μL. Once the reaction mix was made, 1 μL (50 nM) blocked nucleic acid molecule (any one of Formula I-IV) was added for a total volume of 10 μL. The final reaction was incubated in a thermocycler at 25° C. with fluorescence measurements taken every 1 minute.

Example VI: Detection of SARS-CoV-2 with the Cascade Assay in Under 10 Minutes

To detect the presence of SARS-CoV-2 in a sample and determine the sensitivity of detection with the cascade assay, titration experiments were performed using a SARS-CoV-2 gamma-inactivated virus and a synthesized positive control. To serve as the positive control for the detection system, a plasmid containing a 316 bp SARS-CoV-2 nucleocapsid gene (N-gene) was synthesized by IDT (Integrated DNA Technologies, Coralville, Iowa). The N-gene sequence was as follows.

SARS-CoV-2 N-gene Target Sequence (Positive

Control; SEQ ID NO: 3):

CTCAAGGAACAACATTGCCAAAAGGCTTCTACGCAGAAGGGAGCAGAGG

CGGCAGTCAAGCCTCTTCTCGTTCCTCATCACGTAGTCGCAACAGTTCA

AGAAATTCAACTCCAGGCAGCAGTAGGGGAACTTCTCCTGCTAGAATGG

CTGGCAATGGCGGTGATGCTGCTCTTGCTTTGCTGCTGCTTGACAGATT

GAACCAGCTTGAGAGCAAAATGTCTGGTAAAGGCCAACAACAACAAGGC

CAAACTGTCACTAAGAAATCTGCTGCTGAGGCTTCTAAGAAGCCTCGGC

AAAAACGTACTGCCACTAAAGC

For the detection of SARS-CoV-2, a gamma-inactivated virus was incubated in a buffer at 95° C. for 1 minute in order to lyse and release viral RNA, followed by reverse transcription to convert the viral RNA to cDNA. The reverse transcription primer is designed to reverse transcribe the SARS-CoV-2 N-gene. The reverse transcription primer is as follows.

	Reverse Transcription Primer (SEQ ID NO: 4):
	GTTTGGCCTTGTTGTTGTT

RNP1 was preassembled with a guide RNA (gRNA) sequence designed to target the N-gene of SARS-CoV-2. The guide sequence is as follows.

	Guide Sequence (SEQ ID NO: 5):
	UAAUUUCUACUAAGUGUAGAUUUGAACUGUUGCGACUACGUGAU

RNP2 was preassembled with a gRNA sequence designed to target an unblocked nucleic acid molecule that results from unblocking (i.e., linearlizing) a circularized blocked nucleic acid molecule. A circularized blocked nucleic acid molecule was designed and synthesized. The blocked nucleic acid molecule was as follows.

Blocked nucleic acid molecule (SEQ ID NO: 6):

GTT*AT*TA*AA*TG*AC*TT*CT*CATT

where the * indicate bonds that are phosphorothioate modified. The 5′ and 3′ ends were covalently linked to form a circularized molecule. The SARS-CoV-2 gamma-inactivated virus or positive control with 1700, 170, 17, or 5 total copies of N-gene DNA, or a negative control (0 copies of N-gene), were added to a reaction mixture to begin the cascade assay. The reaction mix contained the preassembled RNP1, preassembled RNP2, a blocked nucleic acid molecule in a buffer (˜pH 8) containing 4 mM MgCl₂and 101 mM NaCl. The buffering conditions were optimized to reduce non-specific nickase activity by the RNP complexes.

The cascade assay reaction proceeded for 20 minutes at 37° C. and fluorescence from the reporter molecule was measured. In all the SARS-CoV-2 gamma-inactivated virus and positive control titrations, a significant change in fluorescence was observed after 10 and 5 minutes, relative to the negative control (see the results in FIGS. 6 and 7). For the results shown in FIG. 6, the presence of the N-gene was detected in 10 minutes or less at 37° C. The data represent 3 independent biological replicates. Data is presented as mean±s.d.****=p<0.0001 (student t-test). For the results shown in FIG. 7, the presence of SARS-CoV-2 was detected in 10 minutes or 5 minutes at 37° C. The data represent 3 independent biological replicates. Data is presented as mean±s.d.****=p<0.0001 (student t-test). The results indicate that the cascade assay can detect as few as 5 SARS-CoV-2 target molecules in 10 minutes or less at room temperature.

Example VII: Detection of MRSA in 5 Minutes with Cascade Assay at 37° C.

To detect the presence of Methicillin resistant Staphylococcus aureus (MRSA) and determine the sensitivity of detection with the cascade assay, titration experiments with a MRSA DNA target nucleic acid of interest were performed. The MRSA DNA sequence (NCBI Reference Sequence NC: 007793.1) is as follows.

SEQ ID NO: 7:
ATGAAAAAGATAAAAATTGTTCCACTTATTTTAATAGTTGTAGTTGTCGGGTTTGGTATATATTTTTATG

CTTCAAAAGATAAAGAAATTAATAATACTATTGATGCAATTGAAGATAAAAATTTCAAACAAGTTTATAA

AGATAGCAGTTATATTTCTAAAAGCGATAATGGTGAAGTAGAAATGACTGAACGTCCGATAAAAATATAT

AATAGTTTAGGCGTTAAAGATATAAACATTCAGGATCGTAAAATAAAAAAAGTATCTAAAAATAAAAAAC

GAGTAGATGCTCAATATAAAATTAAAACAAACTACGGTAACATTGATCGCAACGTTCAATTTAATTTTGT

TAAAGAAGATGGTATGTGGAAGTTAGATTGGGATCATAGCGTCATTATTCCAGGAATGCAGAAAGACCAA

AGCATACATATTGAAAATTTAAAATCAGAACGTGGTAAAATTTTAGACCGAAACAATGTGGAATTGGCCA

ATACAGGAACAGCATATGAGATAGGCATCGTTCCAAAGAATGTATCTAAAAAAGATTATAAAGCAATCGC

TAAAGAACTAAGTATTTCTGAAGACTATATCAAACAACAAATGGATCAAAATTGGGTACAAGATGATACC

TTCGTTCCACTTAAAACCGTTAAAAAAATGGATGAATATTTAAGTGATTTCGCAAAAAAATTTCATCTTA

CAACTAATGAAACAGAAAGTCGTAACTATCCTCTAGGAAAAGCGACTTCACATCTATTAGGTTATGTTGG

TCCCATTAACTCTGAAGAATTAAAACAAAAAGAATATAAAGGCTATAAAGATGATGCAGTTATTGGTAAA

AAGGGACTCGAAAAACTTTACGATAAAAAGCTCCAACATGAAGATGGCTATCGTGTCACAATCGTTGACG

ATAATAGCAATACAATCGCACATACATTAATAGAGAAAAAGAAAAAAGATGGCAAAGATATTCAACTAAC

TATTGATGCTAAAGTTCAAAAGAGTATTTATAACAACATGAAAAATGATTATGGCTCAGGTACTGCTATC

CACCCTCAAACAGGTGAATTATTAGCACTTGTAAGCACACCTTCATATGACGTCTATCCATTTATGTATG

GCATGAGTAACGAAGAATATAATAAATTAACCGAAGATAAAAAAGAACCTCTGCTCAACAAGTTCCAGAT

TACAACTTCACCAGGTTCAACTCAAAAAATATTAACAGCAATGATTGGGTTAAATAACAAAACATTAGAC

GATAAAACAAGTTATAAAATCGATGGTAAAGGTTGGCAAAAAGATAAATCTTGGGGTGGTTACAACGTTA

CAAGATATGAAGTGGTAAATGGTAATATCGACTTAAAACAAGCAATAGAATCATCAGATAACATTTTCTT

TGCTAGAGTAGCACTCGAATTAGGCAGTAAGAAATTTGAAAAAGGCATGAAAAAACTAGGTGTTGGTGAA

GATATACCAAGTGATTATCCATTTTATAATGCTCAAATTTCAAACAAAAATTTAGATAATGAAATATTAT

TAGCTGATTCAGGTTACGGACAAGGTGAAATACTGATTAACCCAGTACAGATCCTTTCAATCTATAGCGC

ATTAGAAAATAATGGCAATATTAACGCACCTCACTTATTAAAAGACACGAAAAACAAAGTTTGGAAGAAA

AATATTATTTCCAAAGAAAATATCAATCTATTAACTGATGGTATGCAACAAGTCGTAAATAAAACACATA

AAGAAGATATTTATAGATCTTATGCAAACTTAATTGGCAAATCCGGTACTGCAGAACTCAAAATGAAACA

AGGAGAAACTGGCAGACAAATTGGGTGGTTTATATCATATGATAAAGATAATCCAAACATGATGATGGCT

ATTAATGTTAAAGATGTACAAGATAAAGGAATGGCTAGCTACAATGCCAAAATCTCAGGTAAAGTGTATG

ATGAGCTATATGAGAACGGTAATAAAAAATACGATATAGATGAATAA

Briefly, an RNP1 was preassembled with a gRNA sequence designed to target MRSA DNA. Specifically, RNP1 was designed to target a 20 bp region of the mecA gene of MRSA: TGTATGGCATGAGTAACGAA (SEQ ID NO: 8). An RNP2 was preassembled with a gRNA sequence designed to target an unblocked nucleic acid molecule that results from unblocking (i.e., linearizing) a circularized blocked nucleic acid molecule. The circularized blocked nucleic acid molecule was designed and synthesized (SEQ ID NO: 6): GTT*AT*TA*AA*TG*AC*TT*CT*CATT, where the * indicate bonds that are phosphorothioate modified. The 5′ and 3′ ends were covalently linked to form a circularized molecule. MRSA DNA (SEQ ID NO: 7) with 3000, 300, 30, or 3 total copies, or a negative control (e.g., 0 copies), were added to a reaction mixture to begin the cascade assay. The reaction mix contained the preassembled RNP1, preassembled RNP2, and a circularized blocked nucleic acid molecule, in a buffer (pH of about 8) containing 4 mM MgCl₂and 101 mM NaCl. The buffering conditions were optimized to reduce non-specific nickase activity by the RNP complexes. The cascade assay proceeded for 10 minutes at 37° C., and fluorescence from the reporter moiety was measured. In all titrations, a significant change in fluorescence was observed after 10 and 5 minutes, relative to the negative control (see the results in FIG. 8). The cascade assay was initiated to identify the presence of MRSA in 10 minutes or 5 minutes at 37° C. Data represent 3 independent biological replicates. Data is presented as mean±s.d.****=p<0.0001 (student t-test). The results indicate that the cascade assay can detect as few as 3 MRSA target molecules in only 5 minutes when at 37° C.

Example VIII: Detection of MRSA in Under 10 Minutes with a Cascade Assay at 25° C.

To detect the presence of MRSA and determine the sensitivity of detection with the cascade assay, titration experiments with MRSA DNA (SEQ ID NO: 7) were performed.

Briefly, an RNP1 was preassembled with a guide RNA (gRNA) sequence designed to target MRSA DNA. Specifically, RNP1 was designed to target the following 20 bp sequence in the mecA gene of MRSA: TGTATGGCATGAGTAACGAA (SEQ ID NO: 8). An RNP2 was preassembled with a gRNA sequence designed to target an unblocked nucleic acid molecule that results from unblocking (i.e., linearizing) a circularized blocked nucleic acid molecule. A circularized blocked nucleic acid molecule was designed and synthesized (SEQ ID NO: 6): GTT*AT*TA*AA*TG*AC*TT*CT*CATT, where the * indicate bonds that are phosphorothioate modified. The 5′ and 3′ ends were covalently linked to form a circularized molecule.

MRSA DNA (SEQ ID NO: 7) with 30000, 3000, 300, 30, or 3 total copies, or a negative control (e.g., 0 copies), was added to a reaction mixture to begin the cascade assay. The reaction mix contained the preassembled RNP1, preassembled RNP2, the circularized blocked nucleic acid molecule in a buffer (˜pH 8) containing 4 mM MgCl₂and 101 mM NaCl. The buffering conditions were optimized to reduce non-specific nickase activity by the RNP complexes. The cascade reaction proceeded for 20 minutes at 25° C., and fluorescence by the reporter molecule was measured. In all titrations, a significant change in fluorescence was observed after 10 and 5 minutes, relative to the negative control (see the results in FIG. 9), indicating that the cascade assay can detect as few as 3 MRSA target molecules in 10 minutes or less while at room temperature. The data represent 3 independent biological replicates and is presented as mean±s.d.****=p<0.0001 (student t-test).

Example IX: Optimized Detection of MRSA in 1 Minute with the Cascade Assay at 25° C.

RNP1 was preassembled with a gRNA sequence designed to target MRSA DNA (SEQ ID NO: 7). Specifically, RNP1 was designed to target the following 20 bp sequence in the mecA gene of MRSA: TGTATGGCATGAGTAACGAA (SEQ ID NO: 8). RNP2 was preassembled with a gRNA sequence designed to target an unblocked nucleic acid molecule that results from unblocking a blocked nucleic acid molecule. Five different double stranded and linear blocked nucleic acid molecules were designed, synthesized, and tested: molecule C5, molecule C6, molecule C7, molecule C8, and molecule C9. The nucleotide sequences of molecules C5-C9 are as follows.

C5 (SEQ ID NO: 9):

GTTATTGAGAATTATTGTCATATTATTCTAATATTATTAAGGCTTATT

CACTGTTATTATTATAATTATTAAGCTTATT

C6 (SEQ ID NO: 10):

GTTATTGAGAAGTTATTATCATCTATTATTAATAAGTTATTGCCACTA

TTATTGTTATAATTATTAAGCTTATT

C7 (SEQ ID NO: 11):

GTTATTGAGAAGTATTATTCATCTAATTATTATAAGGCCTTATTACTG

TTATTATTAATAAGCTTATT

C8 (SEQ ID NO: 12):

GTTATTGAGAAGTCTTATTATCTAATATTATTAGGCCACTGTTATTAT

TATAATAAGCTTATT

C9 (SEQ ID NO: 13):

GTTATTGAGAAGTCATTATTATCTAATAAGTTATTGCCACTGTTATTA

TTATAATAAGCTTATT

Three copies of MRSA DNA (SEQ ID NO: 7) or a negative control (e.g., 0 copies) were added to a reaction mix to begin the cascade assay. The reaction mix contained the preassembled RNP1, preassembled RNP2, and one of the five blocked nucleic acid molecules in a buffer (˜pH 8) containing 4 mM MgCl₂and 71 mM NaCl. These buffering conditions were optimized to reduce non-specific nickase activity by the RNP complexes. Each cascade assay proceeded for 10-20 minutes at 25° C., and fluorescence by the reporter molecule was measured for each cascade assay containing C5 (see the results shown in FIG. 10, where the presence of just 3 MRSA targets was detected in 5 minutes or less at 25° C. The data represent 9 independent biological replicates and is presented as mean±s.d.****=p<0.0001 (student t-test), molecule C6 (see the results shown in FIG. 11, where the presence of just 3 MRSA targets was detected in 5 minutes or less at 25° C. The data represent 6 independent biological replicates and is presented as mean±s.d.****=p<0.0001 (student t-test)), molecule C7 (see the results shown in FIG. 12, where the presence of just 3 MRSA targets was detected in 5 minutes or less at 25° C. Data represent 6 independent biological replicates and is presented as mean±s.d.****=p<0.0001 (student t-test)), molecule C8 (see the results shown in FIG. 13, where the presence of just 3 MRSA targets was detected in 5 minutes or less at 25° C. Data represent 6 independent biological replicates and is presented as mean±s.d.****=p<0.0001 (student t-test)), and molecule C9 (see the results shown in FIG. 14, where the presence of just 3 MRSA targets was detected in 10 minutes or less at 25° C. Data represent 6 independent biological replicates and data is presented as mean±s.d.****=p<0.0001 (student t-test)). A significant change in fluorescence is observed after 1 minute and after 5 minutes, relative to the negative control, indicating that the cascade assay can be optimized to detect as few as 3 MRSA target molecules in as little as 1 minute while at room temperature.

While certain embodiments have been described, these embodiments have been presented by way of example only and are not intended to limit the scope of the present disclosures. Indeed, the novel methods, apparatuses, modules, instruments and systems described herein can be embodied in a variety of other forms; furthermore, various omissions, substitutions and changes in the form of the methods, apparatuses, modules, instruments and systems described herein can be made without departing from the spirit of the present disclosures. The accompanying claims and their equivalents are intended to cover such forms or modifications as would fall within the scope and spirit of the present disclosures.

Claims

We claim:

1. A reaction mixture for a CRISPR nuclease cascade assay comprising:

a first ribonucleoprotein (RNP) (RNP1) complex comprising a first CRISPR nuclease and a first guide RNA (gRNA); wherein the first gRNA comprises a sequence complementary to a target nucleic acid of interest, and wherein the first CRISPR nuclease nuclease exhibits both cis-cleavage activity and trans-cleavage activity;

a second ribonucleoprotein (RNP2) complex comprising a second CRISPR nuclease and a second gRNA that is not complementary to the target nucleic acid of interest; wherein the second CRISPR nuclease exhibits both CRISPR nuclease; and

a plurality of blocked nucleic acid molecules comprising a sequence complementary to the second gRNA, wherein the blocked nucleic acid molecules do not bind to the RNP1 complex or the RNP2 complex.

2. The reaction mixture of claim 1, wherein the first and/or second CRISPR nuclease is a Cas3, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas14, Cas12h, Cas12i, Cas12j, Cas13a, Cas13b nuclease.

3. The reaction mixture of claim 1, wherein the first CRISPR nuclease is a different CRISPR nuclease than the second CRISPR nuclease.

4. The reaction mixture of claim 1, wherein the first and/or second CRISPR nuclease is a Type V or Type VI CRISPR nuclease.

5. The reaction mixture of claim 1, wherein the first and/or second CRISPR nuclease comprises a RuvC nuclease domain or a RuvC-like nuclease domain and lacks an HNH nuclease domain.

6. The reaction mixture of claim 1, wherein the blocked nucleic acid molecules comprise a structure represented by any one of Formulas I-IV, wherein Formulas I-IV comprise in the 5′-to-3′ direction:

(a)A-(B-L)_J-C-M-T-D (Formula I);

wherein A is 0-15 nucleotides in length;

B is 4-12 nucleotides in length;

L is 3-25 nucleotides in length;

J is an integer between 1 and 10;

C is 4-15 nucleotides in length;

M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)_J-C and T-D are separate nucleic acid strands;

T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; and

D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A;

(b)D-T-T′-C-(L-B)_J-A (Formula II);

wherein D is 0-10 nucleotides in length;

T-T′ is 17-135 nucleotides in length;

T′ is 1-10 nucleotides in length and does not hybridize with T;

C is 4-15 nucleotides in length and comprises at least 50% sequence complementarity to T;

L is 3-25 nucleotides in length and does not hybridize with T;

B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;

J is an integer between 1 and 10;

A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;

(c)T-D-M-A-(B-L)_J-C (Formula III);

wherein T is 17-135 nucleotides in length;

D is 0-10 nucleotides in length;

M is 1-25 nucleotides in length or is absent, wherein if M is absent then T-D and A-(B-L)_J-C are separate nucleic acid strands;

A is 0-15 nucleotides in length and comprises at least 50% sequence complementarity to D;

B is 4-12 nucleotides in length and comprises at least 50% sequence complementarity to T;

L is 3-25 nucleotides in length;

J is an integer between 1 and 10; and

C is 4-15 nucleotides in length; or

(d)T-D-M-A-L_p-C (Formula IV);

wherein T is 17-31 nucleotides in length (e.g., 17-100, 17-50, or 17-25);

D is 0-15 nucleotides in length;

M is 1-25 nucleotides in length;

A is 0-15 nucleotides in length and comprises a sequence complementary to D; and

L is 3-25 nucleotides in length;

p is 0 or 1;

C is 4-15 nucleotides in length and comprises a sequence complementary to T.

7. The reaction mixture of claim 6, wherein:

(a) T of Formula I comprises at least 80% sequence complementarity to B and C;

(b) D of Formula I comprises at least 80% sequence complementarity to A;

(d) B of Formula II comprises at least 80% sequence complementarity to T;

(e) A of Formula II comprises at least 80% sequence complementarity to D;

(f) A of Formula III comprises at least 80% sequence complementarity to D;

(g) B of Formula III comprises at least 80% sequence complementarity to T;

(h) A of Formula IV comprises at least 80% sequence complementarity to D; and/or

(i) C of Formula IV comprises at least 80% sequence complementarity to T.

8. The reaction mixture of claim 1, wherein the blocked nucleic acid molecules comprise a first sequence complementary to the second gRNA and a second sequence not complementary to the second gRNA, wherein the second sequence at least partially hybridizes to the first sequence resulting in at least one loop.

9. The reaction mixture of claim 1, wherein the reaction mixture comprises about 1 fM to about 10 μM of the RNP1.

10. The reaction mixture of claim 1, wherein the reaction mixture comprises about 1 fM to about 1 mM of the RNP2.

11. The reaction mixture of claim 1, wherein the reaction mixture comprises at least two different RNP1s, wherein different RNP1s comprise different gRNA sequences.

12. The reaction mixture of claim 11, wherein the reaction mixture comprises 2 to 10000 different RNP1s.

13. The reaction mixture of claim 12, wherein the reaction mixture comprises 2 to 1000 different RNP1s.

14. The reaction mixture of claim 13, wherein the reaction mixture comprises 2 to 100 different RNP1s.

15. The reaction mixture of claim 14, wherein the reaction mixture comprises 2 to 10 different RNP1 complexes.

16. The reaction mixture of claim 1, wherein the blocked nucleic acid molecules include the sequence of any one of SEQ ID NOs: 14-1421.

17. The reaction mixture of claim 1, wherein the blocked nucleic acid molecules are circular.

18. The reaction mixture of claim 1, wherein the blocked nucleic acid molecules are linear.

19. The reaction mixture of claim 1, wherein a K_dof the blocked nucleic acid molecules to the RNP2 is about 10⁵-fold greater or more than the K_dof unblocked nucleic acid molecules.

20. The reaction mixture of claim 1, wherein the RNP2 complex recognizes a PAM sequence.

21. The reaction mixture of claim 1, wherein the RNP2 complex does not recognize a PAM sequence.

22. The reaction mixture of claim 1, wherein the target nucleic acid of interest is of bacterial, viral, fungal, mammalian or plant origin.

23. The reaction mixture of claim 1, further comprising a reporter moiety: wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule and is operably linked to the blocked nucleic acid molecule that produces a detectable signal upon cleavage by RNP1 and/or RNP2; or wherein the reporter moiety comprises a DNA, RNA or chimeric nucleic acid molecule and is not operably linked to the blocked nucleic acid molecule and produces a detectable signal upon cleavage by RNP1 and/or RNP2.

24. The reaction mixture of claim 23, wherein the detectable signal is produced within about 1-10 minutes upon binding of the target nucleic acid of interest to RNP1.

25. The reaction mixture of claim 24, wherein the detectable signal is a fluorescent, chemiluminescent, radioactive, colorimetric or other optical signal.

26. The reaction mixture of claim 24, wherein the reporter moiety comprises a modified nucleoside or nucleotide.

27. The reaction mixture of claim 26, wherein the modified nucleoside or nucleotide comprises a locked nucleic acid (LNA), peptide nucleic acid (PNA), 2′-O-methyl (2′-O-Me) modified nucleoside, 2′-fluoro (2′-F) modified nucleoside, and/or a phosphorothioate (PS) bond.

28. The reaction mixture of claim 1, wherein the blocked nucleic acid molecule is a blocked primer molecule.

Resources